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Reactive oxygen species (ROS) play an important role in the development of many 
diseases. Common assays to test the ability of hydrophobic compounds to prevent oxidative 
stress are radical scavenging assays and cell studies. However, these radical assays often 
do not accurately reflect biological outcomes, and the use of different cell lines limits the 
ability to directly compare compound efficacy (Chapter 1). Results from DNA damage 
prevention assays can directly compare antioxidant efficacy, but these assays have been 
limited to water-soluble compounds. Chapter 2 discusses the first assay that quantifiably 
evaluates the ability of hydrophobic compounds to prevent metal-mediated DNA damage 
inhibition via gel electrophoresis. This assay allows biologically relevant evaluation of 
compounds for their effectiveness under consistent conditions. The glutathione peroxidase 
mimic ebselen and its derivatives prevent copper-mediated DNA damage (IC50 values 280-
450 µM), but do not significantly inhibit iron-mediated DNA damage. In combination with 
radical scavenging assays, these biologically relevant assays enable identification of 
structure-function relationships for hydrophobic antioxidant compounds and drugs. 
Studies presented in Chapter 3 investigate the effect of metal binding on drug 
properties. Fluconazole (FLC) binds both iron and copper, and stabilizes Cu+ and Fe2+ over 
Cu2+ and Fe3+, respectively, as measured by cyclic voltammetry. Using gel electrophoresis 
assays, the effects of FLC on copper- and iron-mediated DNA damage were determined. 
FLC does not cause DNA damage by itself, but addition of FLC lowers the concentration 
of Fe2+ or Cu+ needed to cause 50% DNA damage (EC50) by 50 and 40 %, respectively, 
increasing reactive oxygen species production. 
  iii 
The studies described in Chapter 4 investigate the antioxidant capabilities of a series 
of plant-derived, procyanidin-rich condensed tannins (CTs) with different structural 
features for their ability to inhibit copper (IC50 162.5 ± 0.3 µM to 27% DNA damage 
inhibition at the highest concentration) and iron-mediated (IC50 0.75 ± 0.01 to 4.96 ± 0.01 
µM) DNA damage. The activity of CTs are compared to six commercially available 
polyphenolic compounds. This is the first study to investigate structure-activity 
relationships for CTs and their abilities to prevent metal-mediated DNA damage. 
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+ H2O2; lane 5-14: p + Fe
2+ + H2O2 + 0.001, 0.01, 0.1, 0.5, 1, 2.5, 5, 
10, 25, and 50 mg/L H. lupulus, respectively; C) lane 3: p + 200 mg/L 
T. inflorescentia + H2O2, lane 4: p + Fe
2+ (2 µM) + H2O2; lane 5-14: 
p + Fe2+ + H2O2 + 0.001, 0.01, 0.1, 0.5, 1, 2.5, 5, 10, 25, and 50 
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SHOULD AND CAN THE ORAC ANTIOXIDANT ASSAY BE REPLACED? 
 
1.1 Introduction 
 Why Do We Care About Antioxidants? Reactive oxygen species (ROS), such as 
superoxide (O2
2-) and hydroxyl radical (•OH), and reactive nitrogen species (RNS), such 
as ONOO- and NO•,1–6 control a variety of physiological responses such as changes in gene 
expression, apoptosis, and proliferation.7 ROS and RNS play an important role in the 
development of many diseases,6,8,9 including atherosclerosis,10 neurodegenerative 
diseases,6,11–15 inflammation,6,15,16 cancer,17–19 and aging.1,3,20–23 A diverse array of 
antioxidants, including polyphenols, vitamins C and E, and carotenoids, can prevent 
damage caused by ROS.24–28 Therefore, researchers have attempted to quantify and 
compare the ability of antioxidants to prevent ROS damage and to understand the 
mechanisms by which they prevent this damage.  
 Currently, there is no accepted ‘‘total antioxidant parameter’’ as a nutritional index 
available for the labeling of food and biological fluids due to the lack of standardized 
quantitation methods,29 and many reviews have been published about various issues and 
opinions about antioxidant measurement.30–38 Frankel and Meyer38 point out the difficulties 
with using one-dimensional methods to evaluate multifunctional food and biological 
antioxidants. The authors suggest a suitable protocol should fulfill several factors; (a) have 
a biologically relevant substrate, (b) be tested under various oxidation conditions, (c) 
measure initial and secondary oxidation products, (d) compare antioxidants at the same 
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molar concentrations of active components, and (e) quantify antioxidants on the basis of 
induction period, percent inhibition, rates of hydroperoxide formation or decomposition, 
or IC50 (concentration to inhibit 50% damage) values. The many assays for measuring 
antioxidant efficacy are different in terms of substrates, probes, reaction conditions, 
quantitation methods, solvents, and radical sources. Thus, it is extremely challenging to 
compare results from different assays.38 In addition, new assays claiming to measure 
antioxidant capacity are continually being introduced.39,40 
This Chapter does not discuss all antioxidant assays in their complexity and 
variations. Instead, the intent of this review is to illustrate the diversity and complexity of 
the topic and to highlight aspects that are often neglected, such as biological relevance and 
difficulty in comparison between different assays. Where possible, review articles are 
referenced for further reading about common antioxidant assays and their limitations.  
 The History of The Oxygen Radical Absorbance Capacity Assay. The oxygen 
radical absorbance capacity (ORAC) assay has found broad application for measuring the 
antioxidant capacity of botanical41 and biological36 samples. In 2007, the United States 
Department of Agriculture (USDA) released the first database of antioxidant activity for 
277 selected foods followed by 326 additional entries in 2010. The USDA published these 
tables to compare various foods and food additives using a standardized method so that 
nutraceutical companies could use them to educate consumers about the comparative 
antioxidant benefits of products.42.46 In 2012, the USDA withdrew all of their ORAC tables 
for two reasons: 1) the routine misuse by food and dietary supplement companies to 
promote products, and 2) the in vitro ORAC data for antioxidant capacity of foods did not 
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predict in vivo effects, coupled with mixed results in clinical trials to test the benefits of 
dietary antioxidants.43  
 The ORAC method does not use a biologically relevant radical, and does not 
measure prevention of ROS or RNS generation.42 However, the number of publications 
using ORAC as method for antioxidant measurement is steadily increasing every year 
(2003: 16; 2012: 182; 2019: 249 new publications).44 This assay uses a peroxyl radical 
generator, 2,2‘-azobis(2-amidinopropane) dihydrochloride (AAPH; Figure 1.1) and 
measures the decrease in fluorescence due to oxidative degradation at 510 and 700 nm. 
Radical scavengers protect the fluorescent molecule from reacting with the peroxyl radical. 
 
Scheme 1.1. Thermal decomposition to obtain the AAPH radical used in the ORAC assay. 
 
Özyürek et al.29 discuss the importance of terminology when comparing 
antioxidants, since some assays measure antioxidant activity and others antioxidant 
capacity. Antioxidant activity typically describes the kinetics of quenching reactive species 
and is usually expressed as reaction rates or scavenging percentages per unit time, whereas 
antioxidant capacity is the thermodynamic conversion efficiency of reactive species by 
antioxidants, such as the number of moles of reactive species scavenged by one mole of 
antioxidant during a fixed time period. Both are important factors in measuring antioxidant 
efficacy. Antioxidant assays can be classified with respect to their approaches: type of ROS 














Antioxidant assays are often grouped by their general mechanism (Figure 1.2), such 
as hydrogen atom transfer (HAT; Reaction 1) and single electron-transfer (SET; Reaction 
2), where AH represents the antioxidant in these reactions and M represents an electron 
donor, for example a metal. HAT assays are usually competitive and measure antioxidant 
activity, whereas SET assays are usually noncompetitive, evaluate total antioxidant 
capacity, and involve a redox reaction with the probe.30,45  
ROO• + AH  →  ROOH + A•       (1) 
Mn+ + e- (from AH)  →  AH• + M(n-1)      (2) 
 In the competitive HAT assays, the oxidant reacts with a target species, leading to 
changes in its spectroscopic properties that are measured by changes in absorbance, 
fluorescence, or luminescence. Antioxidants typically compete against another molecule, 
such as fluorescein, for the oxidant. Thus, less fluorescein is oxidized by the ROS in the 
presence of an antioxidant, and quantitation is derived from the kinetic curves obtained.45 
HAT assays can involve photochemically unstable radicals or incomplete trapping of 
radicals by the antioxidant, resulting in an underestimation of antioxidant activity.  
 SET-based assays measure the capacity of an antioxidant to reduce an oxidant 
resulting in a color or fluorescence change.30,32 SET assays are quantified by the degree of 
the color change, which is proportional to antioxidant concentration.30 These assays assume 
a correlation of antioxidant capacity with reducing capacity.30 This mechanistic picture is 
complicated by the fact that antioxidants can react through multiple mechanisms rather 
than through only one predominant mechanism.46 Therefore, the division of antioxidant 
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activity into two major mechanistic classes of assays may result in neglecting to consider 
multiple possible antioxidant mechanisms that may also be dose-dependent. 
Metals Are Important But Neglected. Hydroxyl radical (•OH) is generated by the 
oxidation of primarily iron and copper in vivo and in vitro (Reaction 3).47 Iron-mediated 
formation of •OH from hydrogen peroxide (H2O2) is the primary cause of DNA damage 
and cell death under oxidative stress conditions in prokaryotes48 and eukaryotes, including 
humans.49–51 The reduced metal ions can be regenerated by cellular reductants, making 
hydroxyl radical generation catalytic in cells.51,52 Oxidative DNA damage occurs in two 
ways: damage to the phosphate backbone resulting in strand breaks and oxidation of the 
nucleotide bases. Both types of  DNA damage can be quantified.53–58 
 Fe2+/Cu+  +  H2O2  → Fe3+/Cu2+  +  •OH  +  OH-  (3) 
 Copper and iron play important roles in various diseases, including Alzheimer’s 
and Parkinson’s diseases, among others.6,11–15,59 The hydroxyl radical is likely the final 
facilitator of most radical induced tissue damage.60,61 Almost all ROS give rise to hydroxyl 
radical formation, and the hydroxyl radical is extremely short-lived, reacting with almost 
every type of molecule found in living cells including sugars, amino acids, lipids, and 
nucleotides.60 Although hydroxyl radical formation can occur in several ways, the most 
important mechanism in vivo is through transition-metal-catalyzed decomposition of 
superoxide and hydrogen peroxide.59 
Iron-mediated DNA damage is the most investigated, since it is the underlying 
cause of many diseases.16,18,23-25,29-35,47 Non-protein-bound Fe2+ concentrations are around 
10 M in E. coli and humans.63 Under oxidative stress conditions, these concentrations can 
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increase to 80–320 µM in E. coli,47,52,62,63 and Linn et al.48,64,65 have shown that iron-
mediated DNA damage is the underlying cause of cell death of E. coli under oxidative 
stress. Iron coordinates to DNA in vivo resulting in the production of the hydroxyl radical 
in close proximity.48  
Copper concentrations in human serum can range from 10 to 25 mM47,66,67 but 
increase to 0.1 mM under several metabolic processes.47,68 DNA damage can be detected 
through backbone breakage, base oxidation, inter- and intra-strand crosslinking, and DNA–
protein crosslinking.47 Cu2+ and has been shown to coordinate to the DNA double helix 
and promote double-strand breakage through the Fenton-like reaction (Reaction 3).69–71 
Halliwell et al.72,73 emphasized that oxidative DNA damage is an important biomarker for 
ROS damage. DNA is one of the most important biomolecules and target of ROS and there 
are numerous mechanisms to counteract DNA damage.72,74  
Duthie et al.75 have described the ability of antioxidants to prevent oxidation 
through different mechanisms: 1) transition metal coordination to prevent radical 
formation, 2) reducing high concentrations of O2
•-, and 3) scavenging radicals (Figure 1.3). 
Since antioxidants can prevent metal-DNA damage through several mechanisms, it is 
important to measure direct DNA damage instead of individual mechanisms to gain a 
complete picture of antioxidant activity. 
The Issue with Trolox. A common standard to measure antioxidant activity is 6-
hydroxy-2, 5, 7, 8-tetranethylchroman-2-carboxylic acid (Trolox), a water soluble Vitamin 
E derivative.76 It was first reported by Cort in 197577,78 and was quickly adopted as a 




Figure 1.3. Antioxidants can prevent metal-mediated DNA damage through different mechanisms. 
 
 
it using the Trolox equivalent (TE) metric. Trolox is a known radical scavenger, but the 
exact mechanism of its activity is not fully understood.82  
 One of the primary issues with using Trolox as a standard, which is not commonly 
discussed, is that comparing antioxidants to a compound that can only scavenge radicals 
results in the neglect of other mechanisms by which antioxidants may prevent damage. For 
example, glutathione (GSH), a naturally occurring antioxidant with intracellular 
concentrations of up to 10 mM,83 plays an important role in metal homeostasis and can 
prevent oxidative DNA damage by metal coordination.84 Perron et al.24 correlated the pKa 
of the most acidic phenolic hydrogen for polyphenols versus their iron-mediated DNA 
damage prevention ability. These results established iron binding as the mechanism of the 
observed antioxidant activity. In addition, Vacek et al.85 highlighted the importance of 
copper-chelation for the DNA damaging ability of the semi-synthetic flav-onolignan 7-O-





1.2 Assays Measuring Antioxidant Radical Scavenging  
Oxygen Radical Absorbance Capacity Assay. The oxygen radical absorbance 
capacity (ORAC) assay combines two different factors, inhibition time and degree of 
inhibition. Initially, the intensity of the fluorescent molecule β-phycoerythrin is measured. 
Peroxyl radicals, generated through thermal decomposition, react with β-phycoerythrin, 
resulting in a decrease in fluorescence. Trolox (1.0 μM/L) is used as a standard for this 
assay, and antioxidant activity is expressed in Trolox equivalents (TE)/g. In theory, 
antioxidants react with the peroxyl radical, preventing the expected fluorescence decrease 
(Scheme 1.1).76  
Use of β-phycoerythrin has some shortcomings, including variability in its 
reactivity with peroxyl radicals, photobleaching, and interactions with polyphenols by non-
specific binding. These issues resulted in the testing of alternatives such as 3’,6’-
dihydroxyspiro[isobensofuran-1[3H],9’[9H]-xanthen]-3-one and dichlorofluirescein.76 
The most established fluorescent molecule is fluorescein since it is cheap and can be used 
with little interference from tested antioxidants.42  
The ORAC assay was first introduced by Cao et al.86 in 1993 and quickly became 
very popular due to its ease of use after Cao and Prior’s modifications.30,87,88 In 2003, the 
USDA rewarded the collaborating Brunswick and Prior a Small Business Innovation 
Research (SBIR) grant to develop ORAC assays for singlet oxygen, hydroperoxide, and 
superoxide anion.42 This panel of ORAC tests was hoped to provide a comprehensive 
antioxidant profile with applications across nutritional and human health markets. Due to 
the extended development of ORAC assays, standardized protocols for various solvent 
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systems and sample origins exist. Advantages of these ORAC assays are therefore 
flexibility in solvent choice, either aqueous or organic as well as ease of measurement.89,90 
Disadvantages of ORAC assay, including the use of non-biological relevant radical, the 
lack of measuring ROS or RNS generation, and misuse by food and dietary supplement 
companies, have been discussed previously in the History of The Oxygen Radical 
Absorbance Capacity Assay section. 
Hydroxyl Radical Averting Capacity (HORAC) Assay. The hydroxyl radical 
averting capacity (HORAC) assay is based on oxidation of fluorescein by hydroxyl radical 
via HAT. Hydroxyl radical is generated by treating H2O2 with Co
2+ (Reaction 4), as first 
reported by Ou et al.89 In this assay, samples such as food items, extracts, or individual 
compounds, are dissolved in methanol and diluted with phosphate buffer (pH 7.4), and the 
antioxidant binds Co2+ to prevent hydroxyl radical formation. Antioxidant effectiveness is 
based on the inhibition of fluorescein oxidation by hydroxyl radical through a HAT 
mechanism. Although the quantification is similar to the ORAC assay, there is no 
correlation between the results of the two assays.89 
Fluorescein + Co2+ + H2O2 → oxidized fluorescein   (4) 
2,2-Diphenyl-1-picrylhydrazyl radical assay. The 2,2-diphenyl-1-picrylhydrazyl 
radical (DPPH) assay was developed by Blois91 in 1958, and it is one of the most common  
antioxidant assays. Sanchez-Moreno et al.92 suggested that the DPPH assay was an easy 
and accurate method for measuring the antioxidant capacity of fruit and vegetable juices 
or extracts. DPPH radical is a very stable, nitrogen-based radical, and it is commercially 
available. DPPH is reduced by receiving a hydrogen atom from an antioxidant to form the 
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corresponding hydrazine.93 This assay measures decolorization through radical quenching 
of the violet DPPH at 515 nm. DPPH assays are commonly carried out in methanol or a 
methanol/water mixture,94,95 and results are measured after a defined time period, typically 
30 minutes.94 
DPPH is sensitive to oxygen, some Lewis bases, and solvents.96 In addition, DPPH 
has very limited aqueous solubility, and the interference of antioxidant absorbances with 
DPPH absorbances can present a problem for quantitative analysis.34 An advantage of the 
DPPH assay is that the reaction time can be adjusted based on the reactivity and size of the 
antioxidant.97 Several reviews further discuss the pitfalls of this assay, including 
reproducibility among different laboratories; limited stability if the solution is not prepared 
relatively fresh, resulting in issues with long-duration experiments; its low solubility in 
aqueous solutions; and interference caused by amino acids, peptides, or proteins due to the 
ability of DPPH to deprotonate them.79,80,98 
 2,2’-Azinobis(3-ethyl-benzothiazoline-6-sulfonic acid assay. The 2,2’-azinobis(3-
ethyl-benzothiazoline-6-sulfonic acid (ABTS) assay, also sometimes called the Trolox 
equivalent antioxidant capacity (TEAC) assay, is a discoloration assay used for lipophilic 
and hydrophilic antioxidants first introduced by Re et al.99 The pre-formed radical cation 
of 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid, ABTS•+) is generated by ABTS 
oxidation with potassium persulfate, and it is reduced in the presence of hydrogen-donating 
antioxidants in ethanol or phosphate buffer.99 Antioxidant activity is measured by the 
depletion of the colored ABTS•+, measured at 734 nm.99 Antioxidant activity is expressed 
as the concentration of antioxidants giving the same percentage change in absorbance as 
 12 
 
1mM Trolox resulting in the unit Trolox-equivalent antioxidant capacity (TEAC/mg).37 
ABTS assay results correlate better with the ORAC assay results than DPPH assay 
results.100 In addition, the ABTS radical has multiple wavelengths that allow analysis with 
less interference than DPPH. The ABTS radical (unlike DPPH) is soluble in water, 
allowing for the testing of both hydrophobic and hydrophilic compounds. The ABTS 
radical is only stable for several minutes at room temperature, significantly impacting 
reproducibility of results.101  
 Thiobarbituric-Acid-Reactive-Substance Assay. The thiobarbituric-acid-reactive-
substance assay (TBARS) has been used for the estimation of lipid peroxidation since the 
early 1950s. It is considered an index of lipid peroxidation.102 Malondialdehyde (MDA) is 
produced as a side product by autooxidation or reaction with ROS and enzymatic 
degradation of polyunsaturated fatty acids in cells. The reactive aldehyde, MDA causes 
toxic stress in cells as it reacts with proteins and DNA. In the TBARS assay, MDA reacts 
with two equivalents of thiobarbituric acid (TBA) by an acid-catalyzed, nucleophilic-
addition reaction, resulting in a pink color that can be measured at 532 nm.102–104 This 
method is sensitive to low levels of MDA in cells, but it may overestimate the amount of 
cellular MDA,102,105 since cellular carbohydrates and phenylpropanoid-type pigments can 
interfere with TBARS results. This interference can become a significant issue, since 
different plants and cells have different carbohydrate concentrations and their 
concentrations can vary depending on previously induced stress.102,104,106–108 The 
advantages of the TBARS assay is its simplicity, its inexpensiveness, and its ability to be 
used in high throughput assays and processed with minimal sample manipulation. 
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 Enhanced Chemiluminescence Assay. The enhanced chemiluminescence (ECL) 
assay, first introduced by Hirayama et al.,109 is based on the measurement of enhanced 
luminescence of the luminol radical compared to luminol, so the reaction is dependent on 
the constant production of luminol-based radicals. In the original assay, the hydroxyl 
radical was generated by the Fenton reaction (Reaction 3, using H2O2, Fe
2+
, and luminol in 
a borate buffer (pH 7.4).109 More common currently is the use of horse radish peroxidase 
(HRP)-catalyzed oxidation of the chemiluminescent luminol by hydrogen peroxide.110 
Antioxidants scavenge the luminol radical, resulting in a temporary loss of emission at 425 
nm.110,111 Emission resumes after the antioxidant is consumed, and antioxidant 
effectiveness is obtained from comparison to standard calibration curves and measures time 
of depressed light emission versus the concentration of the antioxidant in µmol/L.111,112 
Once again, Trolox is commonly used as a standard.111 Advantages of the ECL assay 
include the ability to use it for high-throughput screening due to its rapid measurement 
time, typically 40 to 45 minutes.112,113 The assay can be performed using organic or 
aqueous solvents, but direct comparisons between different assays performed in different 
solvent systems is difficult.  
 
1.3. Assays Measuring the Metal Reducing Power of Antioxidants 
The Ferric Reduction Antioxidant Power Assay. The ferric reduction antioxidant 
power (FRAP) assay was first introduced by Benzie and Strain114 in 1996  for the 
evaluation of the antioxidant capacity of human plasma and was later extended for other 
uses.76 A variety of samples can be analyzed using this method, including fruits, juices, 
 14 
 
tissue samples, plasma, blood, and nutritional supplements. Antioxidant activity is 
evaluated from reduction of the FeIII(TPTZ)2Cl3 (TPTZ = 2,4,6-tri(2-pyridyl)-s-triazine) 
complex to the Fe2+ complex in acetate buffer (pH 3.6). The increasing blue color of the 
Fe2+ complex can be measured at 593 nm with an extinction factor of 22,230 M-1cm-1. 
FRAP values can be obtained by the comparison of the absorbance change in the test 
mixture with those obtained from a calibration curve derived from increasing 
concentrations of Fe2+. The reference for antioxidant activity in this assay is most 
commonly Trolox and sometimes ascorbic acid or uric acid, with units typically expressed 
as Trolox equivalents (mg/100 g).  
The reduction potential of the Fe3+ salt to Fe2+ (~0.70 V) is comparable to ABTS•- 
in the Trolox equivalent antioxidant capacity (TEAC) assay (0.68 V). The difference 
between the FRAP and TEAC assays is the pH of the reaction; the TEAC assay is 
performed at a neutral pH, whereas FRAP is performed at a pH of 3.6. This is one of the 
biggest disadvantages of FRAP, since it is not performed at a physiologically relevant pH. 
The reaction is also non-specific, there can be possible iron chelation interference, and it is 
not suitable for slowly reactive polyphenol compounds. In addition, it cannot evaluate the 
antioxidant activity of species that act by hydrogen transfer, such as many natural occurring 
thiols (including glutathione or proteins).76 
The advantages of the FRAP and TEAC assays are their simplicity, since no special 
or expensive equipment is necessary, reagents are simple to prepare, and it is reproducible 
and fast (30 min or less) with a straightforward procedure that can be automated, semi-
automated or performed manually.114 
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The Cupric Reducing Antioxidant Capacity Assay. The cupric reducing antioxidant 
capacity (CUPRAC) assay is similar to the FRAP assay, since it is based on measuring an 
antioxidant’s ability to reduce copper(II)-neocuproine (Cu(II)-Nc) or copper(II)- 
bathocuproine in ammonium acetate buffer (pH 7).29 This assay was first introduced in 
2004 by Apak et al.115 and is an electron transfer assay. Cu2+ reduction is quantified by 
decreasing absorbances at 490 and 450 nm, respectively,29,76 with the degree of color 
directly correlated to the antioxidant concentration.29 The reaction is complete after 30 min 
and therefore fairly fast, similar to the FRAP and TEAC assays. Antioxidant capacity is 
reported in Trolox equivalents, defined as the reducing potency of a 1 mM Trolox 
solution.29 Unlike FRAP, CUPRAC can measure thiols such as glutathione. 
The Folin-Ciocateu Total Phenolic Assay. The Folin-Ciocateu (FC) method was 
originally developed for protein determination by taking advantage of the Folin reagent’s 
reactivity with the tyrosine residues in proteins.116 Singleton et al.30,117 adapted this assay 
to determine the polyphenol content in wine. This assay oxidizes phenol compounds 
though a semioquinone radicals into quinones117 in alkaline solution (pH 10) using the 
Folin reagent, molybdotungstophosphate heteropolyanion (3H2O-P2O5-13WO3-5MoO3-
10H2O). The resulting reduced Folin reagent has a yellow color with an absorbance 
maximum of 765 nm.118 Advantages of the FC assay are its simplicity, since it does not 
require specialized equipment, and its long wavelength for measuring activity that 
minimizes antioxidant interference.118 Reducing agents, such as ascorbic acid or certain 
amino acids, interfere with FC analyses and can result in an overestimation of phenolic 
content in the sample.118 
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1.4 Are cellular assays better than in vitro assays?  
The results of in vitro antioxidant assays, as described previously, often do not 
correlate with biological relevance due to solvent, radical source, or other issues. An 
alternative would be to assess antioxidant activity in cells, but this approach comes with an 
alternate set of concerns. For example, different cell types differ in oxidative stress 
responses, repair mechanisms, and other features that affect antioxidant behavior, making 
comparisons between cell lines extremely unreliable.119–123 Even if one cell line were to be 
selected as an exemplar, it is not clear what selection criteria would be most relevant.124 
Additionally, cells are complex systems, and even cells of the same type can differ in levels 
of glutathione, superoxide dismutase, glutathione peroxidase, and/or DNA repair enzymes 
depending on culturing conditions and the nature of the assays, differences that would alter 
the experimental results.120,121,123,125 Another challenge is establishing antioxidants cell 
permeability and therefore intracellular concentrations. Because cells take time to culture 
and assay, typically significantly more time than is required for in vitro assays, this hinders 
high-throughput screening. In addition, the cell culturing process can increase oxidative 
stress, resulting in the alteration of results.124 And lastly, the question of how to assess the 
damage caused by cellular oxidative stress is critical.72,74,126 Commonly used cellular 
assays of oxidative stress typically measure one mechanism for antioxidant activity and 
unrelated cellular conditions can alter the results. For example, the TBARS assay measures 
lipid peroxidation and, as previously discussed, the results of this assay can be influenced 
by cellular carbohydrate levels. Thus, measuring only antioxidant prevention of cell death 
using this assay are sometimes unreliable and could neglect oxidative stress that results in 
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DNA mutations rather than lipid peroxidation.  An advantage of cellular assays is that they 
account for absorption, intracellular distribution, metabolism, and excretion.127 The 
assessment of each contributor can be time intensive and difficult for high throughput 
screening, making cellular assays typically not the first choice in antioxidant evaluation. 
 This Chapter provides an overview of the vast number of antioxidant assays. The 
ORAC assay was viewed as one of the most promising of a wide variety of antioxidant 
assays prior to the USDA withdrawing ORAC assay results in 2012. Since then, no assay 
has been identified as a suitable replacement for the ORAC assay due to the variety of 
different parameters each assay encompasses, such as radical source, solvent, measurement 
technique, and mechanisms assessed, as described in this Chapter. In addition, each assay 
has different sensitivities to antioxidant interference, oxygen, light, and other issues that 
need to be accounted for when comparing assay results. All of these variances result in 
different advantages, disadvantages, and limitations of each assay. There are several 
reviews127–131 about antioxidants in clinical trials128,129,132 discussing these challenges. 
Since there are still knowledge gaps on the mechanisms of bioavailability, biotransformation, 
and action of antioxidant supplements, it is a current challenge to choose the most 
appropriate assay to obtain meaningful and comparable results.131 In addition, the number 
of antioxidants tested to date, the use of pharmacological and not dietary doses may 
produce harmful effects, and insufficient duration of the clinical trials also has made large 






 The assessment and ranking of antioxidant activity is truly complex. Most assays 
focus on one possible mechanism (e.g., SET or HAT) or use organic solvents and radicals 
that are not biologically relevant. These issues resulted in the USDA’s withdrawal of the 
prominent ORAC assay in 2012, an assay that has not been replaced. All these issues 
highlight that it is an utopic thought one assay could assess all the different aspects of 
antioxidant activity. The best approach for testing and comparing antioxidants is to 
selectively test the antioxidants for targeted purposes and carefully consider the limitations 
of each method. 
 
1.6 Dissertation overview 
 In addition to the work presented in this dissertation, I have contributed to several 
other manuscripts and publications.132-137 I conducted EPR spectroscopy experiments to 
verify the proposed reaction mechanism of Cu2+ with methimazole (MMI). I was the first 
to provide proof of thiyl radical formation upon MMI reduction of Cu2+ to Cu+.133 I also 
conducted DNA damage assays with a [Ru(MMI)6]Cl3 that showed the improved 
antioxidant properties of the complex compared to MMI in preventing iron-mediated DNA 
damage.134 Additionally, I performed copper- and iron-DNA damage assays for 
penicillamine to correlate the resulting IC50 values to the corresponding stability constants 
of selected thiol-and selone-containing amino acids,135 and I have also performed similar 
DNA damage assays to evaluate the ability of tinidazole complexes to induce DNA 
damage.136 In collaboration with Dr. Craig Goodman, I developed a protocol using H9c2, 
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RASC, and RAOSMC cell lines to evaluate polyphenol toxicity and ability to prevent cell 
death und regular and high iron-conditions.137 Furthermore, I expanded our understanding 
of thione- and selone-containing imidazoles by highlighting the importance of aromaticity, 
denticity, and the effects of various electron-donating and -withdrawing substituents.138  
 In this dissertation, Chapter 1 reviews the issues arising from in vitro antioxidant 
evaluation techniques. Although a significant number of reviews explain and compare the 
various methods for evaluating antioxidant ability, this Chapter focuses on discussing these 
techniques in light of replacing the ORAC standard for antioxidant activity after the USDA 
withdrew it in 2012. Chapter 1 also provides an overview of the issues surrounding 
antioxidant evaluation including the biological relevance of these assays. 
 Chapter 2 discusses development of the first antioxidant assay that enables the 
evaluation of hydrophobic compounds to prevent metal-mediated DNA damage. Most 
current antioxidant assays only focus on a specific antioxidant mechanism, such as radical 
scavenging or the ability to reduce copper and iron. Both classes of assays commonly use 
non-biologically relevant radicals and organic solvents. This new hydrophobic gel 
electrophoresis assay allows the evaluation of copper- and iron-mediated DNA damage of 
hydrophobic compounds under biologically relevant conditions.  
 In this work, we demonstrate that copper and iron produce different damaging 
species upon reaction with H2O2 that are therefore differently affected by increasing 
ethanol concentrations. EPR spectra show that high-ethanol concentrations completely 
scavenge iron-generated hydroxyl radical, whereas the damaging species produced by 
copper and H2O2 is longer-lived and not readily scavenged. A variety of iron-binding 
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polyphenol antioxidants were tested for their ability to prevent iron-mediated DNA damage 
under high-ethanol conditions, and their IC50 values correlate well with those obtained 
under low-ethanol conditions, indicating the significance of metal coordination in 
preventing iron-mediated DNA damage under these conditions.  
 This new assay enabled evaluation of hydrophobic ebselen analogs and provides 
insight into their antioxidant mechanisms. This is the first assay that enables the 
quantifiable evaluation of metal-mediated DNA damage prevention of hydrophobic 
compounds under biologically relevant conditions and allows for the direct comparison of 
a variety of antioxidants to enable development of structure-function relationships. 
 The work presented in Chapter 3 investigates the role of fluconazole (FLC) in the 
production of ROS by copper and iron.139 Electrochemical studies demonstrate that FLC-
metal binding favors Cu+ and Fe2+ over Cu2+ and Fe3+, respectively, and mass spectrometry 
studies reveal FLC-metal coordination ratios of only 2:1 with copper and iron. Plasmid 
DNA damage studies show that FLC causes no DNA damage by itself or in combination 
with H2O2 or ascorbate, but, in the presence of hydrogen peroxide, FLC significantly 
enhances the ability of copper and iron to cause DNA damage. Research to date has 
primarily focused on ergosterol depletion by FLC that results in the disruption of the cell 
membrane of C. neoformans and causes growth inhibition. However, the results in this 
Chapter indicate that the biological mechanism of action for FLC is more complex and 
likely involves metal ions. Since the FLC resistance of C. neoformans is increasing, 
exploring FLC-metal interactions may provide a pathway to enhance DNA damage to the 
pathogen and reduce the development of resistant strains. 
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In Chapter 4, four different condensed tannins (CTs) from V. macrocarpon, H. 
lupulus, V. vinifera seed, and T. inflorescentia were tested for their ability to prevent metal-
mediated DNA damage. V. macrocarpon CTs are the most effective at inhibiting both 
copper- and iron-mediated DNA damage. Although H. lupulus, V. vinifera seed, and T. 
inflorescentia CTs prevent little-to-no copper-mediated DNA damage, they prevent 
significantly more iron-mediated DNA damage at low micromolar concentrations. Only H. 
lupulus and T. inflorescentia CTs promote iron-mediated DNA damage at very low (0.1 
and 1 mg/L) concentrations in addition to antioxidant activity at higher concentrations, the 
first report of this dual activity with iron. CTs with A-type linkages, such as in V. 
macrocarpon may more effectively inhibit copper- and iron-mediated DNA damage than 
CTs with B-type linkages. In addition, higher percentages of catechin compared to 
epicatechin subunits and higher percentages of galloylation may also reduce CT 
antioxidant activity. This is the first study to investigate the ability of CTs with several 
different structural characteristics for prevention metal-mediated DNA damage. Although 
further study is required to firmly establish structure-activity trends among a variety of 
CTs, these results demonstrate the significant effects of CT structural features on 
antioxidant efficacy.  
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DEVELOPMENT OF A NEW ASSAY TO EVALUATE ANTIOXIDANT ACTIVITY 




The term “oxidative stress” is commonly used to describe the increased production 
that can be caused, for example, by inflammation or the decreased elimination of reactive 
oxygen species (ROS), such as superoxide (O2
•-) and hydroxyl radical (•OH).1–4 ROS 
control various vital physiological responses such as changes in gene expression, apoptosis, 
and cell proliferation.5 ROS also play an important role in the development of many 
diseases,6,7 such as atherosclerosis,8 neural degenerative diseases,9–13 inflammation,13,14 
cancer,15–17 and aging.1,3,18–21  
Molecular oxygen in the cell is converted to O2
•- and H2O2 by direct oxidation of 
flavoproteins, and Halliwell et al.22–25 have demonstrated that transition metals play an 
essential role in ROS production.26–28 Iron reacts with hydrogen peroxide to produce the 
hydroxyl radical29 (Reaction 1) that attacks the DNA at a deoxyribose sugar moiety,30 
abstracting a hydrogen atom at the 4’ position.  Hydroxyl radical also oxidizes lipids, small 
molecules, and proteins. The oxidized Fe3+ or Cu2+ can be regenerated by ascorbic acid 
reduction23 or reaction with the reduced form of nicotinamide adenine dinucleotide 
(NADH).2,31 H2O2 can be produced catalytically as well as nonenzymatically through the 
proportionation of superoxide,32 and from natural cellular respiration.33 
 33 
 
Fe2+/Cu+ + H2O2 → Fe3+/Cu2+ + ⁻OH + ﮲OH [1] 
Duthie et al.33 have described the ability of antioxidants to prevent oxidation using 
three different mechanisms: 1) coordination to transition metals catalysts to prevent 
initiating radical formation, 2) decreasing localized O2
•- concentrations to reduce oxidation 
reactions, and 3) preventing the initiation reactions by scavenging free radicals that can 
abstract H from molecules. Common in vitro assays testing antioxidant activity primarily 
focus on their radical scavenging ability. Some of the most common radicals used in these 
assays include 2,2’-diphenyl-1-picryl-hydrazyl (DPPH)34–36 or 2,2’azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid (ABTS; Figure 2.1).36,37 Both DPPH and ABTS form 
stable organic radicals, very different from most ROS, especially hydroxyl radical.  In 
addition, these radical scavenging assays are typically performed in organic solvents.37–39 
Thus, the primary measures of antioxidant ability to scavenge radicals are not very 
biologically relevant and often do not accurately reflect antioxidant prevention of DNA 
damage.37,40 
Other assays evaluate the ability of antioxidants to reduce Fe3+ or Cu2+, including 
the ferric reduction antioxidant power (FRAP) assay41 or the cupric reducing antioxidant 
capacity (CUPRAC) assay.42  These assays only asses one possible mechanism by which 
antioxidants can prevent damage. In addition, FRAP assays are conducted at a pH of 3.6, 
a non-biological pH, whereas CUPRAP assays are conducted at biological pH 7. Since 
typical radical scavenging and metal reduction assays are not wholly biologically relevant 





Figure 2.1. Structures of A) the radicals DPPH and ABTS commonly used in antioxidant assays, B) Trolox 
and Edaravone, known radical scavengers, C) various selones and pyridine derivatives, and D) ebselen and 
ebsulfur derivatives.  
 
establish and compare antioxidant ability.43–45 However, the use of different cell lines for 
these assays limits the ability to compare results, and antioxidant efficacy and toxicity 
issues limit the ability to screen many compounds.46–48 In addition, all these assays generate 
different distinct values as they are based on different underlying mechanisms and 
processes for antioxidant activity  
After the development of the ORAC assay for singlet oxygen, peroxynitrite, 
hydroxyl radical, and superoxide radical anion in 199349 and subsequent modifications for 
use in different solvent systems.50–53 Development of standard protocols for these ORAC 
assays, making them straightforward, adaptable to many different sample types, and able 
to be run in both aqueous and organic solvent systems.54,55 In 2007, the first ORAC assay 
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database of 277 selected foods or food additives was released by the United States 
Department of Agriculture (USDA), followed by 326 additional entries in 2010. The 
USDA published these tables to compare various foods and food additives using a 
standardized method so that nutraceutical companies could use them to educate consumers 
about the comparative antioxidant benefits of products.53,46 In 2012, the USDA withdrew 
all their ORAC tables for two reasons: 1) the routine misuse by food and dietary 
supplement companies to promote products, and 2) the fact that in vitro ORAC data for 
antioxidant capacity of foods did not predict in vivo effects, coupled with mixed results in 
clinical trials testing the benefits of dietary antioxidants.56,43,49  
Due to the lack of correlations between ORAC results and observed biological effects, 
in 2012, the USDA discontinued the use of this assay and even entirely deleted the ORAC 
database from their website.36,57,58 They stated the lack of understanding surrounding 
antioxidant metabolic pathways and mechanisms of action in addition to the lack of 
correlation between the measured antioxidant activities and biological effects as a reason 
for this decision.36,57 Due to these challenges, no other standard assay or method of 
evaluating and comparing antioxidant activity has been put into place since 2012. 
In cells, apoptosis occurs when cellular damage exceeds cellular capabilities to 
repair it. Mitochondrial dysfunction, respiratory chain inhibition, loss of inner 
mitochondrial membrane potential, and increased mitochondrial membrane permeability 
are all types of ROS damage that result in apoptosis.59 DNA fragmentation is also  
associated with late stage apoptosis.59,60 Oxidative-stress-induced apoptosis may represent 
an antimutagenic and carcinogenic defense mechanism to eradicate cells with unrepairable 
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DNA damage.60 Therefore, investigating DNA damage prevention through antioxidants is 
an important aspect to be studied.61 Often, antioxidants are studied with radical scavenging 
assays, such as DPPH or ABTS assays, and their results are directly converted to the ability 
of the compound to prevent DNA damage without direct measurements using DNA.62 
 Results from DNA damage prevention assays can directly compare antioxidant 
efficacy, but these assays are limited to testing water-soluble compounds.63–68 Sies et al.69 
tried to evaluate peroxynitrite-induced DNA damage prevention of the hydrophobic 
antioxidant ebselen, but quantification of the results was problematic because the 
scavenging of methanol was not sufficiently accounted for, only one concentration of 
Ebselen was tested, and adequate control lanes of the compound itself are missing. The 
assay presented in this work mimics the cellular environment by measuring metal-mediated 
DNA damage caused by the hydroxyl radical, the same mechanisms that cause DNA 
damage and cell death.70–75 In addition, DNA damage prevention is quantifiable and the 
limitation of water-solubility is reduced. This new assay enables the testing and comparison 
of water-insoluble compounds such as ebselen and Edaravone, among others, as described 
in this work. 
 
2.2 Results and Discussion 
These more hydrophobic DNA gel electrophoresis assays determine the ability of 
compounds to prevent copper- or iron-mediated DNA damage by hydroxyl radical 
(Reaction 1) under biologically relevant conditions.76–79 The pH and NaCl concentrations 
are adjusted to biological relevant conditions80 and ethanol is used to mimic organic radical 
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scavengers in the cell. Copper concentrations in human serum can range from 10 to 25 
mM81–83 but increase to 0.1 mM under several metabolic processes.82,84 DNA damage such 
as backbone breakage, base oxidation, inter- and intra-strand crosslinking, and DNA–
protein crosslinking, can be detected.82 In this assay, Cu+ coordinates DNA and promotes 
single-strand breakage by the Fenton-like reaction (Reaction 1),85–87 and damaged and 
undamaged DNA is separated by gel electrophoresis. Halliwell et al.23,61 emphasized that 
oxidative DNA damage is an important biomarker for cellular ROS damage, and DNA is 
one of the most important biomolecules and target of ROS damage.61,88  
In these assays, iron or copper and hydrogen peroxide are used in concentrations 
similar to those found in cells. E. coli grown in standard media have concentrations of 
labile iron iron that it is not bound in proteins and can participate in radical generation 
between 15-30 μM, depending on growth conditions.30,89 The supercoiled (undamaged) 
and nicked (damaged) plasmid DNA is separated using gel electrophoresis, allowing a 
quantitative analysis of antioxidant activity. 
Effects of increased ethanol concentrations. Linn et al.70,90–93 studied the effect of 
ethanol on DNA damage caused by the Fenton reaction (Reaction 1). In the presence of 
hydrogen peroxide, they determined three modes of DNA damage by iron-generated 
hydroxyl radical: Mode I damage is caused by loosely DNA-bound Fe2+ and is moderately 
reduced by ethanol scavenging (Reaction 2); Mode II damage results from tightly DNA-
base-coordinated Fe2+ and is very resistant to ethanol scavenging; and Mode III damage 
results from labile Fe2+ in solution, which is readily scavenged by ethanol. The ethanyl, 
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like other alkyl radicals, can lead directly or indirectly to the production of DNA-derived 
radicals and form DNA-8-alylguanine adducts.94–97  
 
[2] 
Therefore, in DNA gel electrophoresis assays similar to the one introduced in this 
Chapter, Perron et al.,98 who themselves refined the gel electrophoresis assay developed 
by Henle et al.,92 used ethanol (10 mM) to mimic naturally occurring organic compounds 
in cells that can act as radical scavengers. Ethanol is not a common additive in plasmid 
DNA gel-electrophoresis studies: less than 10 reports of ethanol or methanol addition in 
these types of assays exist,69,92,99–101 and none examine antioxidant prevention of DNA 
damage. Sies et al.69 used methanol only to dissolve hydrophobic compounds, and did not 
thoroughly investigate the effect of methanol’s radical scavenging ability on DNA damage. 
To make DNA damage prevention studies with more hydrophobic compounds 
possible in these new DNA damage assays, the ethanol concentration is increased from 10 
mM to 1.7 M. The hydrophobic antioxidant compounds are dissolved in 100% ethanol and 
1 µL of this stock solution is added to a total volume of 10 µL, resulting in the ethanol 
concentration of 1.7 M. This 1700-fold increase in ethanol has no significant effect on 
copper-mediated DNA damage by Cu+ (6 µM with 50 µM H2O2; pH 7), with 94 ± 4 % and 
93 ± 4 % DNA damage at 1.7 M and 10 mM ethanol, respectively.  
In contrast, iron-mediated DNA damage prevention by Fe2+ dependent upon ethanol 
concentration. Under low-ethanol (10 mM) conditions, 2 µM Fe2+ in the presence of 
hydrogen peroxide results in 92 ± 3% DNA damage, but under high-ethanol (1.7 M) 
conditions (both at pH 6 to prevent iron precipitation102), no DNA damage is observed at 
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this Fe2+ concentration. At constant H2O2 concentration, increasing DNA damage with 
increasing Fe2+ concentration is observed at 10 mM and 1.7 M ethanol, respectively (Figure 
2.2), but in all cases, more Fe2+ is required to damage the same percentage of DNA under 
low- and high-ethanol conditions. For these hydrophobic gel assays under high-ethanol 
conditions, a concentration of 15 µM Fe2+ was chosen because of its high percentage of 
DNA damage (~90%), similar to the DNA damage percentage under low-ethanol 
conditions with 2 µM Fe2+. This direct correlation between increased Fe2+ concentrations 
and increased DNA damage (Figure 2.2) at different ethanol concentrations has not been 
previously examined. This difference between the effects of ethanol on copper- and iron-
mediated DNA damage is likely due to the metals producing different damaging species. 
Fe2+ reacts with H2O2 to produce hydroxyl radical,
103,104 as has been thoroughly established 
in vitro103,105 and in cells.106–110  The DNA-damaging species produced by Cu+ has been 
extensively studied, and many suggest generation of hydroxyl radical from the reaction of  
 
Figure 2.2: Dose-response curves for iron-mediated DNA damage with 10 mM (diamonds) and 1.7 M 





24,111–116 Ingraham et al.117 was one of the first to suggest that hydroxyl radical 
is not the primary radical formed, followed by many studies supporting his 
hypothesis,8,67,117–122 although the exact identity of the oxidizing species has not been 
determined. It is clear, however, that compared to Fe2+ in the presence of hydrogen 
peroxide, Cu+ forms a more stable oxidant that is much less susceptible to radical 
scavengers such as ethanol.123,124  
 Electron paramagnetic spectroscopy. EPR experiments were conducted to further 
explore the influence of ethanol on copper- and iron-generated radical species. These 
studies were carried out at room temperature in the presence of the spin trap 5,5-dimethyl-
1-pyrroline-N-oxide (DMPO) to observe the radicals produced. High ethanol 
concentrations (1.7 M) completely prevent formation of the DMPO-OH adduct with Fe2+ 
(300 µM) and H2O2. When the concentration of ethanol is reduced to 425 mM, the DMPO-
OH signal starts to appear (Figure 2.7A), indicating that ethanol directly prevents hydroxyl 
radical generation. 
With Cu+ under similar conditions, the DMPO-OH adduct is observed without 
ethanol addition. With ethanol, both DMPO-OH and DMPO-ethanyl adducts are observed 
(Figure 2.3), consistent with immediate hydroxyl radical formation and subsequent ethanol 
scavenging of this radical.125–129 These results highlight that Cu+ and H2O2 form an 
oxidizing agent less readily scavenged by ethanol than the oxidizing agent formed by Fe2+ 
and H2O2.
124 This is the first study of DMPO-OH radical generation by copper and iron 






Figure 2.3. EPR spectra of A) Fe2+, H2O2, and DMPO in MES buffer (10 mM, pH 6) with 1.7 M ethanol 
after 1) 5 min and 2) 30 min, with 425 mM ethanol after 3) 5 min and 4) 45 min, and without ethanol after 
5) 5 min and 6) 45 min (due to signal overload spectra without ethanol were collected with lower receiver 
gain of 103 versus 105 for all other spectra), and B) Cu2+ ascorbate, H2O2, and DMPO in MOPS buffer (10 
mM, pH 7) with 1.7 M ethanol after 1) 5 min and 2) 40 min and without ethanol after 3) 5 min and 4) 45 min. 
 
Correlating antioxidant behavior in high- and low-ethanol DNA damage 
prevention assays. To evaluate the impact high-ethanol concentrations have on antioxidant 
prevention of iron-mediated DNA damage, a set of six polyphenols (Figure 2.4) were tested 
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for their ability to prevent DNA damage under high- and low-ethanol conditions. 
Polyphenol antioxidant activity has been extensively studied, and polyphenol compounds 
are well-known iron chelators76,98,130 and radical scavengers,131–134 making them ideal for 
a comparison study. 
 




Figure 2.5. Gel electrophoresis images showing tannic acid (TA) prevention of iron-mediated DNA damage. 
MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2; lane 3: p + 20 µM TA + 
H2O2 + 1.7 M ethanol; lane 4: p + Fe2+ (2 µM) + H2O2 + ethanol (10 mM); lane 5: p + Fe2+ (15 µM) + H2O2 
+ ethanol (1.7 M); lanes 6-12: Fe2+ (15 µM) + H2O2 + ethanol (1.7 M) + TA (0.1, 1, 2.5, 5, 7.5, 10, and 20 
µM , respectively).  
 
These gel assays were conducted under low- and high-ethanol conditions with 
either Fe2+ (2 and 15 M for low-ethanol and high-ethanol conditions, respectively) with 
hydrogen peroxide (50 M). Addition of polyphenol compounds prevent iron-mediated 
DNA damage as shown in the gel images for tannic acid in Figure 2.5. The DNA bands in  
Lane 3 indicate that TA does not cause DNA damage in the presence of H2O2, but Fe
2+ and 
H2O2 cause over 90% damage (Figure 2.5, lane 4). The same amount of DNA damage 
occurs with Fe2+ (15 µM) and H2O2 with 1.7 M ethanol (Figure 2.5, lane 5). Increasing TA 
concentrations up to 20 µM (Figure 2.5, lanes 6-12) prevent this iron-mediated DNA 
damage. The plasmid DNA band intensities from these studies were quantified, and the 
resulting data were fit with a dose-response curve to determine the tannic acid 
concentration required to inhibit 50% DNA damage (IC50 value; Figure 2.6A); the IC50 
value for TA prevention of iron-mediated DNA damage with 1.7 M ethanol is 2.27 ± 0.01 
μM (Table 2.1). Due to the susceptibility of iron-generated hydroxyl radical to ethanol 
scavenging, iron concentrations are 7.5 times higher in the high-ethanol (15 µM Fe2+) than 
in the low-ethanol (2 µM Fe2+) assay conditions. It is therefore consistent that the 
polyphenol IC50 values for prevention of iron-mediated DNA damage under high-ethanol 
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conditions (2.27-1432 µM) are higher than those determined under low-ethanol conditions 




Figure 2.6.  IC50 plots for prevention of iron-mediated DNA damage in the presence of 10 mM and 1.7 M 




Table 2.1. IC50 values for polyphenol prevention of iron-mediated DNA damage under high (1.7 M) and low 
(10 mM) ethanol conditions and polyphenol scavenging of DPPH. 
Compound 
Fe2+ IC50 [µM] 
high ethanol 




TA 2.27 ± 0.01 0.3 ± 0.1a 1.00 ± 0.01 
GA 82.0 ± 0.2 15.2 ± 0.1b 10.44 ± 0.02 
PCA 281 ± 1 34.7 ± 0.3b  124.2 ± 0.1 
EGC 723 ± 2 11.6 ± 0.2b  3.38 ± 0.01 
EGCG 14.0 ± 0.1 1.10 ± 0.01b  3.40 ± 0.01 
EC 1432 ± 3 58.9 ± 0.5b  28.97 ± 0.02 
aIC50 values from reference 135.   bIC50 values from reference 98.   
To determine whether a correlation exists between the polyphenol IC50 values from the 
low- and high-ethanol DNA assays, the log IC50 values were plotted together (Figure 2.7), 
resulting in a linear fit with a high R2 value of 0.872. The catechol or gallol groups of these 
polyphenol compounds coordinate iron, and Perron et al.76,98 established that, under low-
ethanol conditions, the polyphenol IC50 values can be predicted by their first phenolic pKa, 
highlighting the importance of iron binding for their antioxidant activity. Since 
polyphenols exhibit a range of antioxidant and prooxidant behavior in DNA damage assays 
with copper under low-ethanol conditions,76 similar DNA damage prevention correlations 
under high- and low-ethanol conditions were not explored for copper. 
 
Figure 2.7 Correlation of polyphenol IC50 values for prevention of DNA damage under high and low 




Metal-binding to prevent DNA damage.  DNA is one of the most important 
biomolecules and a target of damage be ROS, and there are numerous mechanisms to 
counteract DNA damage.61,88 Halliwell et al.23,61 emphasized that oxidative DNA damage 
is an important biomarker for ROS damage. As a result, antioxidant behavior often is 
studied using radical scavenging assays (such as DPPH or ABTS assays), and these results 
are then sometimes translated to the ability of the antioxidants to prevent DNA damage 
without preforming direct DNA damage measurements.62 Linn et al.70,71,136 demonstrated 
that iron-mediated DNA damage is the underlying cause of cell death of E. coli under 
oxidative stress, and others have shown similar behavior in eukaryotic cells, including 
human cells. 70,71,136 This damage arises because Fe2+ coordinates to DNA in vivo resulting 
hydroxyl radical production in close proximity to the DNA and subsequent oxidative 
damage.71 Antioxidant-metal coordination plays an important role in preventing metal-
mediated DNA damage,63,76,135,137 since the antioxidant can bind the metal ion where 
hydroxyl radical is generated and prevent its release.  Thus, directly measuring antioxidant 
prevention of DNA damage is an important and distinct aspect of understanding 
antioxidant behavior.61 
To study and compare the effect of metal chelation on DNA damage under high-
and low-ethanol conditions, four compounds that systematically differ in their metal-
coordination properties were tested under 10 mM and 1.7 M ethanol conditions. N,N’-
dimethylimazole selone (dmise) is an imidazole selone well-studied for its ability to 
coordinate copper and iron through selenium,138–140 and 2,2′-bipyridine (bipy) is also an 
extremely well-studied nitrogen chelating ligand for iron and copper (Figure 2.1C).141,142 
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These two metal-binding motifs are combined in (2-mercapto-1-methylimidazolyl)-
pyridine selone (sepyMe), a bidentate ligand that can coordinate through the selone Se and 
the pyridine nitrogen atoms.143 Ethyl-bis(imidazole) selone (ebis) is also a bidentate ligand, 
binding metals through both selenium atoms.138 Bidentate ligands coordinate more strongly 
to metal ions than monodentate ligands with similar coordination sites. 
Since the polyphenols showed the importance of metal interaction for the observed 
DNA damage prevention, we used these five compounds to compare different antioxidant 
characteristics such as denticity and different metal coordination sites to explore this role. 
Pyridine and bipy and borderline bases and are expected to coordinate more strongly to 
borderline Fe2+ than to soft Cu+. Selones, one the other hand, are soft bases and therefore 
coordinate better to Cu+ than Fe2+. In addition, bidentate ligands, such as bipy and ebis, 
should coordinate more strongly to metals than their monodentate analogs. If metal 
coordination plays a significant role in this DNA damage prevention assay, these trends 
should be reflected in the IC50 values obtained.  
Increasing ethanol concentrations increases the copper-mediated DNA damage IC50 
value of dmise from ~240 to 312.8 ± 0.7 µM (Table 2.2). With iron-mediated DNA 
damage, the dmise IC50 value increases from 3.68 ± 0.01 to 658 ± 2 µM, respectively, a 
179-fold difference (Table 2.2). For ebis, IC50 values for copper-mediated DNA damage 
decrease somewhat with increasing ethanol concentration: 8.20 ± 0.02 and 13.09 ± 0.03 
µM, respectively, for high- and low-ethanol conditions. Similar to dmise, the ebis IC50 
value for iron-mediated DNA damage prevention increases more dramatically with 
increasing ethanol concentrations (IC50 values of 3.2 ± 0.9 and 140.5 ± 0.3 µM, 
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Table 2.2. IC50 values for metal-mediated DNA damage prevention and DPPH scavenging of selones and ebselen and ebsulfur derivatives (NP = IC50 
value not obtained due to solubility issues, NA = IC50 value not tested).  
a)
 
Estimated IC50; no fit could be obtained due to concentration limitations. b) IC50 values from reference 143. 
 
Compound 
Cu+ IC50 [µM] 
high ethanol 
Cu+ IC50 [µM]  
low ethanol 
Fe2+ IC50 [µM] 
high ethanol 




Dmise 312.8 ± 0.7 ~240a,b 658 ± 2 3.68 ± 0.01b 199.7 ± 0.1 
Ebis 8.20 ± 0.02 13.09 ± 0.03b 140.5 ± 0.3 3.2 ± 0.9b 1.12 ± 0.01 
SepyMe - 11.85 ± 0.01b 603 ± 1 44.7 ± 0.1b 107.4 ± 0.1 
Bipy 
2.56 ± 0.01 NP 22.18 ± 0.04 NP 
no scavenging  
0.1 – 1000 µM 
Pyridine 
NA NA 
no inhibition  
1-2000 µM 
NA 
No scavenging  
0.1 – 1000 µM 
Ebselen 
280.7 ± 0.8 NP 
no inhibition  
1-400 µM 
NP 
no scavenging  
0.1 – 500 µM 
Ebselen-N-acetic acid 581 ± 4 NP no inhibition 1-700 µM NP NA 
Ebselen-7-carboxylic acid 213.3 ± 0.6 NP 235.3 ± 0.6 NP NA 
Ebselen-7-carboxylic acid methyl ester 51.2 ± 0.1 NP no inhibition 1-700 µM NP NA 
Ebsulfur-acetic acid no inhibition 1-700 µM NP no inhibition 1-700 µM NP NA 
Ebsulfur-7-carboxylic acid methyl ester no inhibition 1-400 µM NP no inhibition 1-400 µM NP NA 
Edaravone 
no inhibition  
1-1000 µM 
NP no inhibition 1-1000 µM NP ~3.08a 
Trolox 
no inhibition  
1-1000 µM 
no inhibition  
1-1000 µM 
no inhibition 1-1000 µM 728.5 ± 2.4 6.82 ± 0.01 
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respectively). This increase in IC50 values for iron- compared to copper-mediated DNA 
damage prevention is consistent with the expected trend that favors selenium-copper over 
selenium-iron coordination.  In addition, IC50 values for the bidentate ebis compared to the 
monodentate dmise are 38- and 18-fold higher for prevention of copper-mediated DNA 
damage under high and low ethanol concentrations, respectively, and 5-fold higher for 
prevention of iron-mediated DNA damage under high ethanol concentrations.  
 The same denticity trends hold true for monodentate and bidentate nitrogen donor 
ligands: pyridine does not exhibit any iron-mediated DNA damage prevention (1 – 2000 
µM), but bipy has IC50 values of 2.56 ± 0.01 and of 22.18 ± 0.04 µM for copper- and iron- 
mediated DNA damage prevention at high-ethanol concentrations (no low-ethanol IC50 
values can be obtained  due to the poor water solubility of bipy. For the mixed-donor, 
bidentate selone sepyMe, IC50 values are 44.7 ± 0.1 and 603 ± 1 µM for iron-mediated DNA 
damage prevention under low- and high-ethanol conditions, respectively. The IC50 value 
for sepyMe is smaller than that determined for dmise, indicating that addition of the pyridine 
substituent increases iron-mediated DNA-damage prevention, consistent with metal-
binding being a mechanistic factor in these high-ethanol DNA damage assays.  
Since bipy, sepyMe, dmise, and ebis are established metal chelators,138,144,145 a well-
known radical scavenger Edaravone, a substituted 2-pyrazolin-5-one (Figure 2.1B), was 
tested to establish the importance of metal coordination in this assay. Edaravone was 
approved by the Federal Drug Administration (FDA) in 2017 as the first drug for the 
treatment of amyotrophic lateral sclerosis (ALS),146–149 a fatal degenerative disease that 
affects the motor neurons connecting the brain and spinal cord, leading to paralysis and 
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death.150 ALS results from mutations in the gene encoding the ubiquitous antioxidant 
enzyme Cu,Zn-superoxide dismutase (SOD1). This enzyme scavenges superoxide radical, 
decomposing it into oxygen and hydrogen peroxide, to maintain cellular redox 
balance.151,152  SOD1 is also a major copper-binding protein that regulates cellular copper 
homeostasis,152,153and SOD1 mutations may cause disruption of copper homeostasis and 
increased copper levels in the spinal cord.153 In addition, Homma et al.148 observed that 
Edaravone effectively prevents ferroptosis in Hepa 1–6 cells, a process triggered by iron-
generated hydroxyl radical (Reaction 1) that results in lipid peroxidation and cell death.148 
 The exact mechanism of action of Edaravone in the treatment of ALS is unknown, 
but it is thought to be a radical scavenger in vivo,150 and Edaravone is soluble in acetic acid, 
methanol, or ethanol, but poorly soluble in water.150 In contrast, Trolox (Figure 2.1B), is a 
fairly water-soluble vitamin E derivative that is also a well-studied radical scavenger.154–
157 It is commonly used as a standard against which antioxidant activity is compared in 
ROS scavenging assays, expressed as Trolox equivalents (TE).51 Because of the established 
radical scavenging abilities of Trolox and Edaravone, we wanted to compare results of our 
high-ethanol DNA gel electrophoresis assays to those of the DPPH radical scavenging 
assay for these compounds. Antioxidants such as Edaravone and Trolox that do not 
coordinate metals but act as radical scavengers should not prevent metal-mediated DNA 
damage under high-ethanol conditions. 
In these assays, Edaravone does not prevent copper- or iron-mediated DNA damage 
but scavenges DPPH with an IC50 value of 3.08 µM (Table 2.2), consistent with other 
studies.158–160 Trolox also does not prevent copper- or iron-mediated DNA damage under 
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high-ethanol conditions, but it does have a very high IC50 value of 728 µM for iron-
mediated DNA damage under low-ethanol conditions. These results highlight a 
shortcoming with the use of Trolox as a gold standard for antioxidant assays: comparing 
every antioxidant to a compound that can only scavenge radicals likely results in the 
neglect of other potential antioxidant mechanisms. As highlighted by the use of known 
metal chelators, metal chelation plays an important role in antioxidant prevention of metal-
mediated DNA damage under high-ethanol conditions.  
Examining DNA damage prevention abilities for hydrophobic compounds. 
Hydrophobic antioxidants have a lot of potential, especially in the area of 
neuropharmaceuticals, where biodistribution of drugs is limited by the blood-brain barrier 
(BBB) that prevents transit of >98% of small molecules.161 Water-soluble drugs can be 
structurally modified to become lipid-soluble drugs that can cross the BBB, but issues arise 
with in vitro screening since current models vary greatly in cost, technical demands, and 
intended applications.161,162   
The hydrophobic antioxidant drug ebselen is another example of how an assay to 
evaluate hydrophobic compounds for their abilities to prevent biologically relevant DNA 
damage could greatly benefit development of more potent antioxidant drugs. Ebselen 
(Figure 2.1D) was developed in the early 1980s by Helmut Sies et al.163 as a glutathione 
peroxidase (GPx) mimic to prevent oxidative damage by hydrogen peroxide, 
measurements performed in organic solvents due to ebselen’s insolubility in water.164–167 
Ebselen also prevents oxidative stress in cultured cells as well as in Se-deficient mice, an 
effect independent of endogenous GPx expression.168 In the 1980s and 1990s, ebselen was 
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examined in clinical trials for treatment of brain ischemia during stroke, and approved in 
Japan for this purpose,169 but in the U.S., it failed in clinical trials for treatment of asthma, 
atherosclerosis, cerebral infarction, myocardial ischemia, peptic ulcer, and rheumatic 
disorder due to insufficient efficacy compared to placebo and concerns regarding its 
toxicity.14,111 Ebselen is currently in Phase II clinical trials for hearing loss and tinnitus and 
in phase I/II trials for Meniere’s disease, tobramycin-induced ototoxicity, chemotherapy-
induced hearing loss, and as a treatment for bipolar disorder.166,170,171  
Despite its setbacks in clinical trials, ebselen continues to be the standard for 
measuring small-molecule GPx-like activity, and it is a well-established ROS 
scavenger,172–175 although its biological mechanisms are not firmly established. One major 
issue preventing more biologically relevant studies of the antioxidant activity of ebselen 
and ebselen derivatives is its very limited water solubility (13.6µg/mL or 50 µM). Our 
high-ethanol DNA damage prevention assay is capable of testing DNA damage even for 
hydrophobic compounds such as ebselen with water-solubilities of as little as 25 µM. 
Sies et al.69 tested the ability of ebselen to inhibit peroxynitrite-induced DNA 
damage in a 1% methanol system (0.2 M). Since methanol scavenges radicals similarly to 
ethanol,69,176 the DNA damage control lane exhibited only 25% damage in this study. 
Although it was reported that 50 µM ebselen inhibits 43% of DNA damage caused by 
peroxynitrite (100 µM),69 this translates to prevention of only 14% DNA damage. Due to 
this small difference in DNA damage inhibition, and since the experiment was only 
performed once, not in triplicate, it is not clear that the observed inhibition is significantly 




Figure 2.8. Gel electrophoresis images showing ebselen prevention of copper- and iron-mediated DNA 
damage. MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 and A) lane 3: p + 
400 µM ebselen + H2O2 + 1.7 M ethanol; lane 4: p + Cu2+ (6 µM) + ascorbate (7.5 µM) + H2O2 + ethanol 
(10 mM); lane 5: p + Cu2+ (6 µM) + ascorbate (7.5 µM) + H2O2 + ethanol (1.7 M); lanes 6-13: Cu2+ (6 µM) 
+ ascorbate (7.5 µM) + H2O2 + ethanol (1.7 M) + ebselen (1, 10, 50, 100, 200, 300, and 400 µM , 
respectively). B) lane 3: p + 400 µM ebselen + H2O2 + 1.7 M ethanol; lane 4: p + Fe2+ (2 µM) + H2O2 + 
ethanol (10 mM); lane 5: p + Fe2+ (15 µM) + H2O2 + ethanol (1.7 M); lanes 6-12: Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) + ebselen (1, 10, 50, 100, 200, 300, and 400 µM, respectively). 
 
In contrast, we tested ebselen for prevention of copper-mediated DNA damage in 
our high-ethanol assay. As shown in Figure 2.8A, Cu+/H2O2 causes over 86 ± 4% DNA 
damage (Figure 2.8A, lane 5; 1.25 equiv ascorbate is added to reduce Cu2+ to the DNA-
damaging Cu+ 23), comparable to DNA damage prevention observed under low-ethanol 
conditions 85 ± 2%, lane 4). A similar amount of DNA damage occurs under high- (on 
average 90 ± 5%) and low- (on average 89 ± 3%) ethanol conditions in the presence of Fe2+ 
and H2O2 (Figure 2.8B, lanes 4 and 5). 
Ebselen alone does not cause DNA damage in the presence of H2O2 (lane 3), but 
increasing ebselen concentrations up to 400 µM (Figures 2.8A and B, lanes 6-13) prevents 
copper-mediated DNA damage. Even under these more hydrophobic conditions, the upper 
concentration range is limited by ebselen’s solubility in aqueous 1.7 M ethanol solution. 




Figure 2.9. Dose-response curve for ebselen prevention of copper-mediated DNA damage under high-
ethanol conditions. 
 
These gel data were fit with a dose-response curve (Figure 2.9), and the IC50 value 
for ebselen prevention of copper-mediated DNA damage is 280.7 ± 0.8 μM. Due to 
ebselen’s limited water solubility, our method is the first to determine an IC50 value for its 
ability to prevent DNA damage, a biologically relevant endpoint. Although it is an 
excellent radical scavenger (Table 2.2), ebselen shows only modest ability to prevent 
metal-mediated DNA damage, a primary cause of cell death under oxidative stress 
conditions.70,71,90,92,93,177 
The ability to test hydrophobic compounds such as ebselen for their ability to 
prevent metal-mediated DNA damage opens up a new area of antioxidant investigations, 
including development of more effective ebselen derivatives to prevent this DNA damage. 
Ebselen derivatives178 were selected for testing using our high-ethanol DNA damage 
prevention studies based on the presence of structural features that might enhance metal 
coordination.  Similar to ebselen itself, these ebselen derivatives were examined for their 
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ability to prevent metal-mediated DNA damage under high-ethanol conditions, the first 
study to examine the ability of ebselen derivatives to prevent DNA damage. 
Similar to ebselen, all the tested ebselen derivatives more effectively prevent 
copper-mediated DNA damage than iron-mediated damage, with only ebselen-7-
carboxylic acid (Figure 2.1) able to prevent iron-mediated DNA damage (IC50 of 235.3 ± 
0.6 µM; Table 2.2). In addition, the selenium-containing ebeselen derivatives are more 
effective than their sulfur analogs, highlighting the importance of selenium for antioxidant 
activity of these compounds. This is unsurprising, since ebsulfur is a less-effective GPx 
mimic compared to ebselen.101 
 Carboxylic acid moieties are known metal coordination sites,179,180 and addition of 
a carboxylate group to ebselen to form ebselen-7-carboxylic acid lowers the IC50 value for 
copper-mediated DNA damage prevention from 280.7 ± 0.8 to 213.3 ± 0.6 µM. The methyl 
ester of this compound is the most effective at preventing copper-mediated DNA damage, 
with an over-four-fold increase in activity compared to ebselen-7-carboxylic acid. Moving 
the carboxylate group to the para-position of the phenyl ring in ebselen-N-acetic acid 
decreases its ability to prevent copper-mediated DNA damage relative to ebselen. 
 Ebselen-7-carboxylic acid is also the only ebselen derivative that prevents iron-
mediated DNA damage, likely due to the potential chelating site of the carboxylate oxygen 
and the selenium.  Blocking this carboxylate oxygen with a methyl group in ebselen-7-
carboxylic acid methyl ester, prevents all activity, further suggesting that antioxidant 
activity ebselen-7-carboxylic acid results from iron binding at this site. Ebselen and its 
derivatives more effectively prevent copper- over iron-mediated DNA damage, a results 
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that likely arises because of the soft selenium more strongly interacting with the soft Cu+ 
than the borderline Fe2+, although adding a hard oxygen donor near the selenium site with 
the potential for bidentate binding makes ebselen-7-carboxylic acid nearly equivalent in its 
ability to prevent copper- and irom-mediated DNA damage. 
 We have demonstrated that this DNA damage prevention assay permits assessment 
of hydrophobic compounds that cannot otherwise be investigated using DNA damage 
methods, including Edaravone, ebselen, and ebselen derivatives. Since we are examining 
DNA damage prevention directly, this assay is more biologically relevant than typical 
radical scavenging assays, and avoids the need to dubiously extend radical scavenging 
results to the more complex system of DNA damage prevention. This more hydrophobic 
DNA damage prevention assay is a significant step forward that will allow development of 
more effective hydrophobic antioxidants for the treatment and prevention of diseases 
caused by oxidative stress.  
 
2.3 Conclusions 
Most antioxidant assays only focus on specific antioxidant mechanism, such as 
radical scavenging or the reduction potential of copper and iron. Both classes of assays 
commonly use long-lived radicals, organic solvents, or other non-biologically relevant 
conditions. This resulted in the USDA distancing itself from ORAC results in 2012. In 
addition, DNA damage assays have been limited to hydrophobic compounds, and DPPH 
and ABTS assays, among others, have been translated into DNA damage prevention results 
without actually testing the compounds directly with DNA. We present the first gel 
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electrophoresis assay that allows the evaluation of copper- and iron-mediated DNA damage 
of hydrophobic compounds under biologically relevant conditions.  
Iron-mediated DNA damage is more susceptible to increased ethanol 
concentrations than copper. This is reflected in the decade-long discussion of the actual 
oxidizing species produced by the Fenton- and Fenton-like reactions. This study 
demonstrates the differential susceptibility of the Fenton and Fenton-like reaction to 
ethanol through EPR spectroscopy experiments. Metal interactions play a major role in this 
assay, highlighted by the trends observed for polyphenol prevention of iron-mediated DNA 
damage, since iron binding is an establishe antioxidant mechanism for these compounds. 
In addition, the importance of metal coordination was also demonstrated by examining the 
IC50 value trends of a group of ligands with nitrogen- and selone moieties for prevention 
of copper- and iron-mediated DNA damage. Edaravone and Trolox, radical scavengers that 
do not coordinate to metals, show no activity in this assay. Although Edaravone is used to 
treat ALS that has been associated with elevated copper concentrations, our results suggest 
that Edaravone’s mechanism of action likely does not involve significant copper 
interaction.  
For the first time, this assay allowed biologically relevant DNA damage prevention 
testing for ebselen and ebselen derivatives. Ebselen prevents only copper-mediated DNA 
damage, but addition of a carboxylate group to form a potential metal chelating site allows 
ebselen-7-carboxylic acid to prevent both copper- andiron-mediated DNA damage.  By 
testing a variety of potential antioxidants using this hydrophobic DNA damage assay, we 
showed that this new assay can be used to evaluate and compare new classes of compounds, 
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such as drugs that might cross the BBB, and can give insight into mechanisms for 
antioxidant behavior. This assay could potentially be used for the screening of new drugs 
to slow the process of Alzheimer’s, Parkinson’s and other diseases caused by oxidative 
stress. 
 
2.4 Experimental Methods 
Materials. Water was deionized (diH2O) using a Nano Pure DIamond Ultrapure 
H2O system (Barnstead International). 3-(N-morpholino)propanesulfonic acid (MOPS; 
Sigma), 2-(N-morpholino)ethanesulfonic acid (MES; BDH), NaCl (99.999% Alfa Aesar), 
CuSO4 (Fisher), FeSO4 (Acros), H2O2 (Fisher), DMPO (Cayman Chemicals), ascorbic acid 
(Alfa Aesar), DPPH (Alfa Aesar), Edaravone (Acros), Trolox (Acros), methanol (Sigma-
Aldrich), pyridine (Alfa Aesar), bipy (Chem-Implex), GA (Acros), EC (Sigma), TA (Sigma 
Aldrich), PCA (Frontier Scientific), EGC (TCI), EGCG (Enzo), agarose (Sigma), Chelex 
(Sigma), and ebselen (Acros) were used as received. The ebselen derivatives (Figure 1D) 
were provided by Dr. Daniel Whitehead and Dr. Heeren Gordhan in the Department of 
Chemistry at Clemson University. 
EPR spectroscopy. To prepare EPR samples, Cu(SO4)2∙3H2O (300 µM), ascorbic 
acid (375 µM), and H2O2 (2.5 mM), and indicated ethanol concentrations was added to an 
aqueous solution of MOPS (pH 7, 10 mM). DMPO (30 mM) was added to all the samples 
as a spin trap. Iron-containing samples were prepared with FeSO4 (300 µM), H2O2 (2.5 
mM) and DMPO (30 mM) with indicated ethanol concentrations in MES (pH 6, 10 mM). 
Deionized water was added to a final volume of 500 µL. EPR spectra were measured on a 
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Bruker EMX spectrometer at room temperature in a quartz flat cell. Spectra centered at 
3431.24 G were acquired with a sweep width of 100 G. The modulation amplitude was 
2.00 G with time and conversion constants of 81.92 s, and microwave power and frequency 
were 1.99 mW and 9.756 GHz, respectively.  
DPPH assay. DPPH solutions (1.2 mg in 30 mL methanol, 100 µM) were prepared 
fresh before each experiment: 0.5 mL of sample with indicated concentrations in methanol 
were combined with 1 mL of DPPH solution (100 µM) with a final concentration of 67 µM 
DPPH in methanol. The samples were incubated for 30 min in the dark, and spectra were 
taken at 515 nm on a Thermo Electron Corporation BioMate3 UV-visible spectrometer. 
Percentages of DPPH scavenging were calculated using the equation %DPPH scavenged 
= ((A-A0)/(AT-A0))*100, where A is the absorbance of the incubated sample and DPPH, 
A0 is the absorbance of DPPH in methanol, and AT is the absorbance of DPPH incubated 
with 50 µM Trolox. 
Plasmid DNA transfection, amplification, and purification. Plasmid DNA (pBSSK) 
was purified from DH1 E. coli competent cells using a ZyppyTM Plasmid Miniprep Kit 
(400 count, Zymo Research). Tris-EDTA buffer (pH 8.01) was used to elute the plasmid 
DNA from the spin columns. Plasmid was dialyzed against 130 mM NaCl for 24 h at 4°C 
to ensure all Tris-EDTA buffer and metal contaminates were removed, and plasmid 
concentration was determined by UV-vis spectroscopy at a wavelength of 260 nm. 
Absorbance ratios of A250/A260   0.95 and A260/A280  1.8 were determined for DNA used 
in all experiments. Plasmid purity was determined through digestion of plasmid (0.1 pmol) 
with Sac 1 and KpN1 in a mixture of NEB buffer and bovine serum albumin at 37°C for 
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90 min. Digested plasmids were compared to an undigested plasmid sample and a 1 kb 
molecular weight marker using gel electrophoresis. 
DNA damage gel electrophoresis experiments. Samples were prepped at room 
temperature by adding MOPS (10 mM, pH 7.0) or MES (10 mM, pH 6), NaCl (130 mM) 
and enough Deionized water to have a final volume of 10 µL at the end. In a cold room at 
4 ºC, the compounds were dissolves in ethanol (100% proof), added to the indicated lanes 
and mixed. This step was performed below room temperature to minimize ethanol 
evaporation and reduce deviation between experiments. After the mixture warmed up to 
room temperature, the indicated concentrations of CuSO4∙5H2O, ascorbate (7.5 µM, to 
reduce Cu2+ to Cu+), and indicated compound were combined in an acid-washed (1 M HCl 
for ~ 1 h) microcentrifuge tubes and allowed to stand for 5 min at room temperature. 
Plasmid (pBSSK, 0.1 pmol in 130 mmol NaCl) was then added to the reaction mixtures 
and they were allowed to stand for 5 min at room temperature. H2O2 (50 µM) was added 
and allowed to react at room temperature for 30 min. EDTA (50 µM) was added after 30 
min to quench the reactions. For the Fe2+ DNA damage experiments, the indicated 
concentrations of FeSO4∙7H2O and MES (10 mM, pH 6.0) were used, and no ascorbate 
was added. All concentrations are final concentrations in a 10 µM volume.  
Samples were loaded into a 1% agarose gel in a TAE running buffer (50); damaged 
and undamaged plasmid was separated by electrophoresis (140 V for 60 min). Gels were 
stained using ethidium bromide and imaged using UV light. The amounts of nicked 
(damaged) and circular (undamaged) were analyzed using UViProMW (Jencons Scientific 
Inc., 2007). Intensity of circular plasmid was multiplied by 1.24, due to the lower binding 
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affinity of ethidium bromide to supercoiled plasmid.63,181 Intensities of the nicked and 
supercoiled bands were normalized for each lane so that % nicked + % supercoiled = 100%. 
All percentages were corrected for residual nicked DNA prior to calculation. Results were 
obtained in triplicate for all experiments, and standard deviations are represented as error 
bars. The plots of percent DNA damage versus log concentration of copper or iron were fit 
to a variable-slope sigmoidal dose-response curve using SigmaPlot (v. 11.0, Systat 
Software, Inc.).  
IC50 Determination. Plots of percent inhibition of DNA damage versus log 
concentration of the indicated compound were fit to a variable slope sigmoidal dose-
response curve using SigmaPlot, version 11 (Systat Software, Inc.). IC50 value errors were 
calculated from error propagation of the gel electrophoresis measurements. Statistical 
significance was determined by calculating p values at 95% confidence (p < 0.05 indicates 
significance) as described by Perkowski et al.182 Data from DNA damage assays are 
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Figure 2.10. Gel image of iron-mediated DNA damage prevention by EC, GA, PCA, EGC, and EGCG. For 
all gel images MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 (50 μM); A) 
lane 3: p + H2O2 + EC (2000 μM); lane 4: p + Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + Fe2+ (15 
μM) + H2O2 + ethanol (1.7 M); lanes 6-14: p + H2O2 + FeSO4 (15 μM) +EC (1, 10, 50, 100, 250, 500, 750, 
1000, and 2000 μM, respectively); B) lane 3: p + H2O2 + GA (1000 μM); lane 4: p + Fe2+ (2 μM) + H2O2 + 
ethanol (10 mM); lane 5: p + Fe2+ (15 μM) + H2O2 + ethanol (1.7 M); lanes 6-14: p + H2O2 + FeSO4 (15 μM) 
+GA (1, 10, 50, 75, 100, 250, 500, 750, and 1000 μM, respectively); C) lane 3: p + H2O2 + PCA (2000 μM); 
lane 4: p + Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + Fe2+ (15 μM) + H2O2 + ethanol (1.7 M); lanes 
6-14: p + H2O2 + FeSO4 (15 μM) +PCA (1, 10, 50, 100, 250, 500, 750, 1000, and 2000 μM, respectively); 
D) lane 3: p + H2O2 + EGC (2000 μM); lane 4: p + Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + Fe2+ 
(15 μM) + H2O2 + ethanol (1.7 M); lanes 6-14: p + H2O2 + FeSO4 (15 μM) + EGC (1, 10, 50, 100, 250, 500, 
750, 1000, and 2000 μM, respectively); E) lane 3: p + H2O2 + EGCC (500 μM); lane 4: p + Fe2+ (2 μM) + 
H2O2 + ethanol (10 mM); lane 5: p + Fe2+ (15 μM) + H2O2 + ethanol (1.7 M); lanes 6-14: p + H2O2 + FeSO4 





Figure 2.11. Gel image of copper- and iron-mediated DNA damage prevention by Trolox. For all gel images 
MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2. (50 μM); A) lane 3: p + 
H2O2 + Trolox (2000 μM); lane 4: p +Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); lanes 5-
13: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) +Trolox (0.1, 1, 5, 10, 50, 100, 500, 1000, and 2000 μM, 
respectively); B) lane 3: p + H2O2 + Trolox (1000 μM); lane 4: p +Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 
+ ethanol (10 mM); lane 5: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (1.7 M); lanes 6-13: p + 
H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) +Trolox (0.1, 1, 5, 10, 50, 100, 500, and 1000 μM, respectively); 
C) lane 3: p + H2O2 + Trolox (2000 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + Fe2+ 
(15 μM) + H2O2 + ethanol (1.7 M); lanes 6-10: p + H2O2 + Fe2+ (15 μM) +Trolox (10, 50, 100, 500, and 1000 
μM, respectively); D) lane 3:p + H2O2 + Trolox (2000 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 







Figure 2.12. Gel image of iron-mediated DNA damage prevention by dmise, ebis, bipy, pyridine, sepyMe, 
and Edaravone. For all gel images MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p 
+ H2O2. (50 μM); A) lane 3: p + H2O2 + dmise (4000 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 
mM); lane 5: p + H2O2 + Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-15: p + H2O2 + Fe2+ (15 μM) +dmise (0.5, 
1, 10, 50, 100, 400, 1000, 2000, and 4000 μM, respectively); B) lane 3: p + H2O2 + ebis (400 μM); lane 4: p 
+Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-14: p 
+ H2O2 + Fe2+ (15 μM) +ebis (0.1, 0.5, 1, 5, 10, 50, 100, 200 and 400 μM, respectively); C) lane 3: p + H2O2 
+ bipy (1000 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Fe2+ (15 μM) + 
ethanol (1.7 M); lanes 6-12: p + H2O2 + Fe2+ (15 μM) +bipy (0.5, 1, 10, 50, 100, 400, and 1000 μM, 
respectively); D) lane 3: p + H2O2 + pyridine (2000 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); 
lane 5: p + H2O2 + Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-14: p + H2O2 + Fe2+ (15 μM) +pyridine (1, 10, 
50, 100, 250, 500, 750, 1000, and 2000 μM, respectively); E) lane 3: p + H2O2 + sepyMe (2000 μM); lane 4: 
p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-14: 
p + H2O2 + Fe2+ (15 μM) + sepyMe (1, 10, 50, 100, 250, 500, 750, 1000 and 2000 μM, respectively); F) lane 
3: p + H2O2 + Edaravone (1000 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + 
Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-14: p + H2O2 + Fe2+ (15 μM) + Edaravone (0.1, 1, 5, 10, 50, 100, 




Figure 2.13. Gel image of copper-mediated DNA damage prevention by dmise, ebis, bipy, and Edaravone. 
For all gel images MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2. (50 μM); 
A) lane 3: p + H2O2 + dmise (4000 μM); lane 4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 
mM); lane 5: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ethanol (1.7 M); lanes 6-14: p + H2O2 + Cu2+ 
(6 μM) + ascorbate (7.5 μM) +dmise (1, 10, 50, 100, 400, 750, 1000, 2000, and 4000 μM, respectively); B) 
lane 3: p + H2O2 + ebis (100 μM); lane 4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); 
lane 5: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ethanol (1.7 M); lanes 6-11: p + H2O2 + Cu2+ (6 μM) 
+ ascorbate (7.5 μM) +ebis (0.5, 1, 5, 10, 50, and 100 μM, respectively); C) lane 3: p + H2O2 + bipy (1000 
μM); lane 4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Cu2+ (6 
μM) + ascorbate (7.5 μM) + ethanol (1.7 M); lanes 6-14: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) +bipy 
(0.5, 1, 5, 10, 50, 100, 500, and 1000 μM, respectively); D) lane 3: p + H2O2 + Edaravone (1000 μM); lane 
4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Cu2+ (6 μM) + 
ascorbate (7.5 μM) + ethanol (1.7 M); lanes 6-13: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + Edaravone 





Figure 2.14. Gel image of iron-mediated DNA damage prevention by ebselen-N-acetic acid, ebselen-7-
carboxylic acid, ebsulfur-N-acetic acid, and ebsulfur-7-carboxylic acid methyl ester. For all gel images MW: 
1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2. (50 μM); A) lane 3: p + H2O2 + 
ebselen-N-acetic acid (700 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Fe2+ 
(15 μM) + ethanol (1.7 M); lanes 6-15: p + H2O2 + Fe2+ (15 μM) + ebselen-N-acetic acid (1, 10, 50, 100, 200, 
300, 400, 500, 600, and 700 µM, respectively); B) lane 3: p + H2O2 + ebselen-7-carboxylic acid (700 μM); 
lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Fe2+ (15 μM) + ethanol (1.7 M); lanes 
6-14: p + H2O2 + Fe2+ (15 μM) + ebselen-7-carboxylic acid (1, 10, 50, 100, 200, 300, 400, 500, 600, and 700 
µM, respectively); C) lane 3: p + H2O2 + ebsulfur-N-acetic acid (400 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + 
ethanol (10 mM); lane 5: p + H2O2 + Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-12: p + H2O2 + Fe2+ (15 μM) 
+ ebsulfur-N-acetic acid (1, 50, 100, 200, 300, and 400 µM, respectively); D) lane 3: p + H2O2 + ebsulfur-7-
carboxylic acid methyl ester (400 μM); lane 4: p +Fe2+ (2 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 
+ Fe2+ (15 μM) + ethanol (1.7 M); lanes 6-13: p + H2O2 + Fe2+ (15 μM) + ebsulfur-7-carboxylic acid methyl 








Figure 2.15. Gel image of copper-mediated DNA damage prevention ebselen-N-acetic acid, ebselen-7-
carboxylic acid, ebsulfur-7-carboxylic acid methyl ester, ebsulfur-N-acetic acid, ebsulfur-7-carboxylic acid 
methyl ester. For all gel images MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + 
H2O2. (50 μM); A) lane 3: p + H2O2 + ebselen-N-acetic acid (700 μM); lane 4: p + Cu2+ (6 μM) + ascorbate 
(7.5 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ethanol (1.7 
M); lanes 7-13: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) +ebselen-N-acetic acid (1, 10, 50, 100, 200, 
300, 400, 500, 600, and 700 μM, respectively); B) lane 3: p + H2O2 + ebselen-7-carboxylic acid (700 μM); 
lane 4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Cu2+ (6 μM) + 
ascorbate (7.5 μM) + ethanol (1.7 M); lanes 7-16: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) ebselen-7-
carboxylic acid (1, 10, 50, 100, 200, 300, 400, 500, 600 and 700 µM, respectively); C) lane 3: p + H2O2 + 
ebsulfur-7-carboxylic acid methyl ester (700 μM); lane 4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + 
ethanol (10 mM); lane 5: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ethanol (1.7 M); lanes 7-15: p + 
H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ebsulfur-7-carboxylic acid methyl ester (1, 10, 50, 100, 200, 
300, 400, 500, 600 and 700 µM, respectively); D) lane 3: p + H2O2 + ebsulfur-N-acetic acid (400 μM); lane 
4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); lane 5: p + H2O2 + Cu2+ (6 μM) + 
ascorbate (7.5 μM) + ethanol (1.7 M); lanes 7-13: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ebsulfur-
N-acetic acid (1, 50, 100, 200, 300 and 400 µM, respectively); E) lane 3: p + H2O2 + ebsulfur-7-carboxylic 
acid methyl ester (400 μM); lane 4: p + Cu2+ (6 μM) + ascorbate (7.5 μM) + H2O2 + ethanol (10 mM); lane 
5: p + H2O2 + Cu2+ (6 μM) + ascorbate (7.5 μM) + ethanol (1.7 M); lanes 7-13: p + H2O2 + Cu2+ (6 μM) + 





Figure 2.16.  Dose-response curves for iron-mediated DNA damage prevention under high-ethanol (1.7 M) 
conditions for A) tannic acid, B) protocatechuic acid, C) gallic acid, D) epicatechin, E) epigallocatechin 





Figure 2.17. Dose-response curves for A) copper-mediated DNA damage prevention by Trolox under high-
ethanol conditions (1.7 M), B) iron-mediated DNA damage prevention by Trolox and 1.7 M ethanol, C) 
copper-mediated DNA damage with Trolox and 10 mM ethanol, and D) iron-mediated DNA damage with 





Figure 2.18. Dose-response curves for iron-mediated DNA damage prevention under ethanol (1.7 M) 






Figure 2.19. Dose-response curves for copper-mediated DNA damage prevention under ethanol (1.7 M) 





Figure 2.20. Dose-response curves for iron-mediated DNA damage prevention under high-ethanol (1.7 M) 
conditions for A) ebselen, B) ebselen-N-acetic acid, C) ebsulfur-7-carboxylic acid, and D) ebulfur-7-






Figure 2.21. Dose-response curves for copper-mediated DNA damage prevention under high-ethanol 
conditions (1.7 M) for A) ebselen B) ebselen-N-acetic acid C) ebsulfur-N-acetic acid, D) ebsulfur-7-













% Damage p Value 
1: plasmid DNA (p) - 99.99 ± 0.02 0.01 - - 
2: p + H2O2 (50 µM) - 99.99 ± 0.02 0.01 - - 
3: p + EC+ H2O2 + ethanol (1.7 M) 2000 99.82 ± 0.31 0.18 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol (10 
mM) 
- 20.01 ± 4.89 
79.99 
- - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol (1.7 
M) 
- 4.19 ± 0.12 
95.81 
0 - 
6: p + Fe2+ (15 µM) + H2O2 + EC + ethanol 
(1.7 M) 
1 4.28 ± 1.44 
95.72 
0.09 ± 1.44 0.924 
7: 10 2.83 ± 2.36 97.17 -1.41 ± 2.36 0.409 
8:  50 1.05 ± 1.22 98.95 -3.28 ± 1.22 0.043 
9:  100 1.12 ± 1.09 98.88 -3.21 ± 1.09 0.036 
10:  250 4.09 ± 4.51 95.91 -0.10 ± 4.51 0.973 
11:  500 22.20 ± 3.01 77.80 18.80 ± 3.01 0.008 
12: 750 20.80 ± 5.99 79.20 17.34 ± 5.99 0.036 
13: 1000 37.41 ± 2.82 62.59 34.67 ± 2.82 0.002 
14:  2000 68.99 ± 1.20 31.01 67.63 ± 1.20 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage p Value 
1: plasmid DNA (p) - 100 ± 0.00 - - 
2: p + H2O2 (50 µM) - 100 ± 0.00 - - 
3: p + GA+ H2O2 + ethanol (1.7 M) 1000 100 ± 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol (10 mM) - 20.01 ± 4.89 79.99 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol (1.7 M) - 14.55 ± 2.04 85.45 0 - 
6: p + Fe2+ (15 µM) + H2O2 + GA + ethanol 
(1.7 M) 
1 10.99 ± 3.16 
89.01 
-4.01 ± 3.13 0.157 
7: 10 11.11 ± 6.31 88.89 -3.90 ± 6.29 0.395 
8:  50 36.36 ± 0.15 63.64 25.63 ± 0.15 < 0.001 
9:  75 57.51 ± 2.41 42.49 50.33 ± 2.42 < 0.001 
10:  100 66.59 ± 4.24 33.41 60.92 ± 4.25 < 0.001 
11:  250 82.06 ± 4.43 17.94 79.04 ± 4.45 < 0.001 
12: 500 93.36 ± 3.24 6.64 92.21 ±3.24 < 0.001 
13: 750 98.73 ± 1.96 1.27 98.52 ± 1.94 < 0.001 
14:  1000 98.57 ± 0.36 1.43 98.29 ± 0.35 < 0.001 












% Damage p Value 
1: plasmid DNA (p) - 100 ± 0 0.00 - - 
2: p + H2O2 (50 µM) - 100 ± 0 0.00 - - 
3: p + PCA+ H2O2 + ethanol (1.7 M) 2000 100 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol (10 mM) - 20.01 ± 4.89 79.99 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol (1.7 M) - 12.94 ± 2.12 87.06 0 - 
6: p + Fe2+ (15 µM) + H2O2 + PCA + ethanol 
(1.7 M) 
1 11.56 ± 3.68 
88.44 
-1.58 ± 3.68 0.535 
7: 10 7.63 ± 4.56 92.37 -6.10 ± 4.56 0.146 
8:  50 20.51 ± 2.37 79.49 8.70 ± 2.37 0.239 
9:  100 42.17 ± 3.99 57.83 33.58 ± 3.99 0.005 
10:  250 48.37 ± 2.01 51.63 40.70 ± 2.01 < 0.001 
11:  500 68.40 ± 1.18 31.60 63.70 ± 1.18 < 0.001 
12: 750 73.01 ± 5.30 26.99 69.00 ± 5.30 < 0.001 
13: 1000 76.50 ±3.01 23.50 73.01 ± 3.01 < 0.001 
14:  2000 79.46 ± 4.95 20.54 76.40 ± 4.95 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage p Value 
1: plasmid DNA (p)  100 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  100 ± 0 0.00 - - 
3: p + TA+ H2O2 + ethanol (1.7 M) 20 99.99 ± 0.02 0.01 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol (10 
mM) 
 10.61 ± 4.89 80.39 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol (1.7 
M) 
 13.53 ± 3.15 86.47 0 - 
6: p + Fe2+ (15 µM) + H2O2 + TA + ethanol 
(1.7 M) 
0.1 9.42 ± 1.69 90.58 -3.05 ± 1.69 0.089 
7: 1 27.56 ± 3.84 72.44 17.60 ± 3.84 0.015 
8:  2.5 57.11 ± 5.54 42.89 51.20 ± 5.54 0.004 
9:  5 97.41 ± 1.50 2.59 97.06 ± 1.50 < 0.001 
10:  7.5 99.76 ± 0.41 0.24 99.73 ± 0.41 < 0.001 
11:  10 100 ± 0 0.00 100 ± 0 < 0.001 
12: 20 100 ± 0 0.00 100 ± 0 < 0.001 












% Damage p Value 
1: plasmid DNA (p)  100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  0.00 ± 0 0.00 - - 
3: p + EGC+ H2O2 + ethanol (1.7 M) 2000 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
 20.94 ± 8.87 79.06 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
 5.44 ± 2.92 94.56 0 - 
6: p + Fe2+ (15 µM) + H2O2 + EGC + 
ethanol (1.7 M) 
1 4.43 ± 2.31 95.57 -0.69 ± 2.28 0.652 
7: 10 0.33 ± 0.40 99.67 -5.40 ± 0.40 0.002 
8:  50 2.02 ± 2.91 97.98 -3.61 ± 2.91 0.165 
9:  100 6.20 ± 4.03 93.80 0.81 ± 4.03 0.761 
10:  250 15.19 ± 5.65 84.81 10.31 ± 5.65 0.087 
11:  500 37.53 ± 5.93 62.47 33.94 ± 5.93 0.010 
12: 750 46.66 ± 1.78 53.34 43.59 ± 1.78 < 0.001 
13: 1000 73.59 ± 3.25 26.41 72.08 ± 3.25 < 0.001 
14:  2000 92.84 ± 1.66 7.16 92.43 ± 1.66 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage p Value 
1: plasmid DNA (p)  100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  99.96 ± 0.06 0.04 - - 
3: p + EGCG+ H2O2 + ethanol (1.7 M) 500 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
 12.86 ± 3.56 87.14 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
 13.25 ± 3.96 86.75 0 - 
6: p + Fe2+ (15 µM) + H2O2 + EGCG 
+ ethanol (1.7 M) 0.1 
18.26 ± 4.61 81.74 5.83 ± 4.61 0.160 
7: 1 11.57 ± 4.01 88.43 -1.89 ± 4.01 0.500 
8:  5 3.15 ± 4.10 96.85 -11.59 ± 4.10 0.038 
9:  10 43.98 ± 3.02 56.02 35.47 ± 3.02 0.002 
10:  25 82.10 ± 5.48 17.90 79.41 ± 5.48 0.002 
11:  50 84.80 ± 2.23 15.20 82.53 ± 2.23 < 0.001 
12: 100 98.79 ± 0.91 1.21 98.65 ± 0.91 < 0.001 
13: 250 99.98 ± 0.1 0.02 100.03 ± 0.01 < 0.001 
14:  500 99.96 ± 0.7 0.04 100.00 ± 0.07 < 0.001 












% Damage p Value 
1: plasmid DNA (p)  99.99 ± 0.02 0.01 - - 
2: p + H2O2 (50 µM)  99.98 ± 0.04 0.02 - - 
3: p + sepyMe+ H2O2 + ethanol (1.7 M) 2000 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
 23.49 ± 3.90 76.51 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
 4.53 ± 2.26 95.47 0 - 
6: p + Fe2+ (15 µM) + H2O2 + sepyMe 
+ ethanol (1.7 M) 
1 6.40 ± 2.57 93.60 1.97 ± 2.57 0.316 
7: 10 10.56 ± 2.18 89.44 6.33 ± 2.19 0.038 
8:  50 13.60 ± 3.90 86.40 9.51 ± 3.90 0.052 
9:  100 23.63 ± 2.37 76.37 20.01 ± 2.37 0.005 
10:  250 23.86 ± 1.75 76.14 20.25 ± 1.75 0.005 
11:  500 42.51 ± 1.48 57.49 39.79 ± 1.48 < 0.001 
12: 750 61.65 ± 2.75 38.35 59.84 ± 2.75 < 0.001 
13: 1000 69.15 ± 3.33 30.85 67.70 ± 3.33 < 0.001 
14:  2000 77.31 ± 1.42 22.69 76.24 ± 1.42 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
Table 2.10. Gel electrophoresis results for pyridine DNA damage assays with Fe2+, and 50 µM H2O2.a 





% Damage p Value 
1: plasmid DNA (p)  100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  100.00 ± 0 0.00 - - 
3: p + pyr+ H2O2 + ethanol (1.7 M) 2000 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + 
ethanol (10 mM) 
 6.46 ± 5.17 93.54 - - 
5: p + Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) 
 2.45± 1.63 97.55 0 - 
6: p + Fe2+ (15 µM) + H2O2 + pyr + 
ethanol (1.7 M) 
1 1.57 ± 1.39 98.43 -0.90 ± 1.39 0.379 
7: 10 1.13 ± 1.05 98.87 -1.35 ± 1.05 0.156 
8:  50 3.11 ±3.53 96.89 0.68 ± 3.53 0.770 
9:  100 0.94 ± 0.65 99.06 -1.55 ± 0.65 0.054 
10:  250 1.46 ± 2.53 98.54 -1.02 ± 2.53 0.557 
11:  500 0.30 ± 0.52 99.70 -2.21 ± 0.52 0.018 
12: 750 1.84 ± 0.11 98.16 -0.63 ± 0.11 0.010 
13: 1000 1.41 ± 1.33 98.59 -1.07 ± 1.33 0.298 
14:  2000 0.34 ± 0.33 99.66 -2.16 ± 0.33 0.008 




Table 2.11. Gel electrophoresis results for bipy DNA damage assays with Fe2+, and 50 µM H2O2.a 





% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 99.37 ± 1.08 0.6 - - 
3: p + bipy+ H2O2 + ethanol (1.7 M) 1000 100 ± 0 0 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
0 16.96 ± 5.20 83.04 - - 
5: p + Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) 
0 30.45 ± 6.49 69.55 0 - 
6: p + Fe2+ (15 µM) + H2O2 + bipy + 
ethanol (1.7 M) 
0.5 27.46 ± 4.92 72.54 -2.79 ± 4.92 0.427 
7: 1 23.17 ± 4.82 76.83 -8.92 ± 4.89 0.085 
8:  10 26.94 ± 0.15 73.06 -3.51 ± 0.15 0.001 
9:  50 98.49 ± 2.62 1.51 99.40 ± 2.60 <0.001 
10:  100 100 ± 0 0 101.55 ± 0 <0.001 
11:  400 100 ± 0 0 101.55 ± 0 <0.001 
12: 1000 100 ± 0 0 101.55 ±0 <0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
Table 2.12. Gel electrophoresis results for bipy DNA damage assays with Cu+, and 50 µM H2O2.a 





% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0.00 - - 
3: p + bipy+ H2O2 + ethanol (1.7 M) 1000 100 ± 0 0.00 - - 
4: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) H2O2 + ethanol (10 mM) 
0 12.30 ± 3.47 87.70 - - 
5: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (1.7 M) 
0 21.20 ± 2.62 78.80 0 - 
6: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + bipy + ethanol (1.7 
M) 
0.5 23.57 ± 1.19 76.43 3.00 ± 1.44 0.069 
7: 1 35.81 ± 1.70 64.19 18.53 ± 2.07 0.004 
8:  5 77.89 ± 2.55 22.11 71.95 ± 3.12 < 0.001 
9:  10 87.37 ± 2.37 12.63 83.97 ± 2.90 < 0.001 
10:  50 98.08 ± 1.27 1.92 97.55 ± 1.55 < 0.001 
11:  100 99.04 ± 0.44 0.96 98.77 ± 0.55 < 0.001 
12: 500 98.25 ± 0.75 1.65 97.93 ± 0.91 < 0.001 
13: 1000 95.41 ± 1.33 4.59 94.16 ± 1.66 < 0.001 












% Damage p Value 
1: plasmid DNA (p) 0 100.0 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100.0 ± 0 0.0 - - 
3: p + dmise+ H2O2 + ethanol (1.7 M) 4000 100.0 ± 0 0.0 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
0 13.7 ± 4.8 86.3 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
0 36.9 ± 4.6 63.1 0 - 
6: p + Fe2+ (15 µM) + H2O2 + dmise + 
ethanol (1.7 M) 
0.5 44.3 ± 4.7 55.7 11.7 ± 4.7 0.050 
7: 1 50.6 ± 3.8 49.4 21.7 ± 3.8 0.010 
8:  10 58.3 ± 2.9 41.7 33.9 ± 2.9 0.002 
9:  50 53.8 ± 3.4 46.2 26.7 ± 3.4 0.005 
10:  100 55.1 ± 5.2 44.9 28.7 ± 5.2 0.011 
11:  400 63.2 ± 5.8 36.8 41.6 ± 5.9 0.007 
12: 1000 72.1 ± 5.8 27.9 55.8 ± 5.9 0.004 
13: 2000 76.7 ± 4.4 23.3 63.1 ± 4.3 0.002 
14: 4000 77.0 ± 7.6 23.0 63.5 ± 7.6 0.005 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage p Value 
1: plasmid DNA (p) 0 99.98 ± 0.03 0.02 - - 
2: p + H2O2 (50 µM) 0 99.97 ± 0.04 0.03 - - 
3: p + dmise+ H2O2 + ethanol (1.7 M) 4000 99.94 ± 0.11 0.06 - - 
4: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) H2O2 + ethanol (10 mM) 
0 15.97 ± 3.01 84.03 - - 
5: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (1.7 M) 
0 20.65 ± 5.37 79.35 0 - 
6: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + dmise + ethanol (1.7 
M) 
1 32.39 ± 4.59 64.71 18.51 ± 4.59 0.020 
7: 10 44.79 ± 0.42 55.21 30.44 ± 0.42 < 0.001 
8:  50 53.10 ± 4.02 46.90 40.99 ± 4.02 0.003 
9:  100 65.28 ± 4.57 34.72 56.32 ± 4.53 0.002 
10:  400 59.66 ± 5.55 40.34 49.22 ± 5.60 0.004 
11:  750 67.02 ± 3.43 32.98 62.71 ± 2.40 < 0.001 
12: 1000 67.44 ± 4.72 32.56 59.01 ± 4.70 < 0.001 
13: 2000 76.52 ± 5.18 23.48 70.48 ± 5.19 0.002 
14: 4000 88.06 ± 5.55 11.94 85.01 ± 5.55 0.001 




Table 2.15. Gel electrophoresis results for ebis DNA damage assays with Fe2+, and 50 µM H2O2.a 





% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0.0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0.0 - - 
3: p + ebis+ H2O2 + ethanol (1.7 M) 400 100 ± 0 0.0 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
0 9.6 ± 5.4 90.4 - - 
5: p + Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) 
0 31.0 ± 0.7 69.0 0 - 
6: p + Fe2+ (15 µM) + H2O2 + ebis + 
ethanol (1.7 M) 
0.1 29.1 ± 2.4 70.9 -2.8 ± 2.4 0.181 
7: 0.5 35.8 ± 5.6 64.2 6.9 ± 5.6 0.166 
8:  1 34.6 ± 0.8 65.4 5.2 ± 0.8 0.008 
9:  5 37.6 ± 2.7 62.4 9.6 ± 2.7 0.025 
10:  10 38.5 ±5.0 61.5 11.0 ± 5.0 0.062 
11:  50 50.9 ± 1.8 49.1 28.8 ± 1.8 0.001 
12: 100 66.4 ± 2.8 33.6 51.4 ± 2.8 <0.001 
13: 200 66.2 ± 2.6 33.8 51.0 ± 2.6 <0.001 
14: 400 73.5 ±3.9 26.5 61.6 ± 3.9 <0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
Table 2.16. Gel electrophoresis results for ebis DNA damage assays with Cu+, and 50 µM H2O2.a 





% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.95 ± 0.04 0.05 - - 
3: p + ebis+ H2O2 + ethanol (1.7 M) 100 100 ± 0.01 0.00 - - 
4: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) H2O2 + ethanol (10 mM) 
0 26.51 ± 3.74 73.49 - - 
5: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (1.7 M) 
0 14.54± 1.95 85.46 - - 
6: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + ebis + ethanol (1.7 M) 
0.5 23.77 ± 4.09 76.23 7.89 ± 1.99 0.021 
7: 1 32.45 ± 1.63 67.55 21.04 ± 1.60 0.002 
8:  5 37.61 ± 2.70 62.39 27.04 ± 2.69 0.003 
9:  10 67.78 ± 6.82 32.22 62.34 ± 6.83 0.004 
10:  50 99.81 ± 0.23 0.19 99.82 ± 0.26 < 0.001 
11:  100 99.62 ± 0.41 0.38 99.63 ± 0.38 < 0.001 













% Damage p Value 
1: plasmid DNA (p)  100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  99.69 ± 0.53 0.31 - - 
3: p + Trolox+ H2O2 + ethanol (1.7 M) 1000 99.90 ± 0.10 0.10 
- - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
 
9.55 ± 0.42 90.45 
- - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
 
22.74 ± 6.79 77.26 
0 - 
6: p + Fe2+ (15 µM) + H2O2 + Trolox 
+ ethanol (1.7 M) 
10 
12.79 ± 4.11 87.21 
3.51 ± 4.11 0.277 
7: 50 0.96 ± 1.25 99.04 -9.61 ± 1.25 0.006 
8:  100 0.13 ± 0.23 99.87 -10.52 ± 0.23 < 0.001 
9:  500 0.00 ± 0.01 100.00 -10.67 ± 0.01 < 0.001 
10: 1000 0.00 ± 0.01 100.00 -10.67 ± 0.01 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 









% Damage p Value 
1: plasmid DNA (p)  100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  100.00 ± 0 0.00 - - 
3: p + Trolox+ H2O2 + ethanol (10 mM) 2000 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
 12.30 ± 3.47 87.70 0 - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(10 mM) 
0.1 21.20 ± 2.62 78.80 0.21 ± 4.51 0.943 
6:  1 23.57 ±1.19 76.43 -6.62 ± 4.87 0.143 
7: 5 35.81 ± 1.70 64.19 -0.26 ± 0.69 0.581 
8:  10 77.89 ± 2.55 22.11 3.74 ± 1.49 0.049 
9:  50 87.37 ± 2.37 12.63 7.08 ± 5.82 0.170 
10:  100 98.08 ± 1.27 1.92 23.47 ± 5.75 0.019 
11:  500 99.04 ± 0.44 0.96 33.33± 5.16 0.008 
12: 1000 98.35 ± 0.75 1.65 66.27 ± 7.88 0.005 
13: 2000 95.41 ± 1.33 4.59 99.90± 0.12 < 0.001 













% Damage p Value 
1: plasmid DNA (p)  100.00 ±0 0.00 - - 
2: p + H2O2 (50 µM)  100.00 ± 0 0.00 - - 
3: p + Trolox+ H2O2 + ethanol (1.7 M) 1000 99.07 ± 1.61 0.93 - - 
4: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (10 mM) 
 7.73 ± 4.47 92.27 
- - 
5: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (1.7 M) 
 22.74 ± 6.79 77.26 0 
- 
6: p + Cu2+ (6 µM) + ascorbate (7.5 
µM) + H2O2 + Trolox + ethanol (1.7 M) 
0.1 15.62 ± 1.41 84.38 -4.87 ± 1.81 0.043 
7: 1 6.15 ± 2.86 93.85 -17.09 ± 2.86 0.009 
8:  5 0.18 ± 0.29 99.82 -24.26 ± 0.35 < 0.001 
9:  10 0.00 ± 0.01 100.00 -24.76 ± 0.01 < 0.001 
10:  50 0.01 ± 0.02 99.99 -24.74 ± 0.02 < 0.001 
11:  100 2.65 ± 4.60 97.35 -21.45 ± 4.60 < 0.001 
12: 500 0.38 ± 0.67 99.62 -24.28 ± 0.66 < 0.001 
13: 1000 0.35 ±0.61 99.65 -24.32 ± 0.61 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
Table2.20. Gel electrophoresis results for Trolox DNA damage assays with Cu+, and 50 µM H2O2 and 10 
mM ethanol.a 





% Damage p Value 
1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.99 ± 0.02 0.01 - - 
3: p + Trolox+ H2O2 + ethanol (10 
mM) 
2000 99.98 ± 0.02 0.02 - - 
4: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (10 
mM) 
0 4.33 ± 0.73 95.67 0 - 
5: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (10 
mM) 
0.1 5.69 ± 2.27 94.31 1.45 ± 2.27 0.384 
6:  1 2.94 ± 2.00 97.06 -1.44 ± 2.00 0.339 
7: 5 1.11 ± 0.92 98.89 -3.35 ± 0.92 0.024 
8:  10 0.21 ± 0.36 99.79 -4.29 ± 0.36 0.002 
9:  50 0.00 ± 0 100.00 -4.51 ± 0 < 0.001 
10:  100 0.02 ± 0.03 99.98 -4.49 ± 0.03 < 0.001 
11:  500 0.99 ± 1.72 99.01 -3.47 ± 1.72 0.073 
12: 1000 0.26 ± 0.39 99.74 -4.23 ± 0.39 0.003 
13: 2000 0.00 ± 0 100.00 -4.51 ± 0 < 0.001 












% Damage p Value 
1: plasmid DNA (p)  100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM)  100.00 ± 0 0.00 - - 
3: p + Edaravone+ H2O2 + ethanol 
(1.7 M) 
1000 100.00 ±0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 + 
ethanol (10 mM) 
 15.35 ±1.31 84.65 - - 
5: p + Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) 
 10.00 ± 4.12 90.00 0 - 
6: p + Fe2+ (15 µM) + H2O2 + 
Edaravone + ethanol (1.7 M) 
0.1 14.26 ± 3.11 85.74 -1.29 ± 3.81 0.616 
7: 1 11.13 ± 1.64 88.87 -4.99 ± 2.01 0.050 
8:  5 6.43 ± 0.56 93.57 -10.54 ± 0.68 0.001 
9:  10 6.04 ± 3.86 93.96 -11.00 ± 4.72 0.056 
10:  50 7.43 ± 5.20 92.57 -9.36± 6.36 0.126 
11:  100 7.42 ± 4.87 92.58 -9.37 ± 5.97 0.114 
12: 500 5.71 ± 2.86 94.29 -11.39 ± 3.50 0.030 
13: 1000 14.70 ±0.30 85.30 -0.77 ± 0.37 0.069 
aData are reported as the average of three trials with calculated standard deviations shown. 








% Damage p Value 
1: plasmid DNA (p)  99.97 ± 0.05 0.03 - - 
2: p + H2O2 (50 µM)  100.00 ±0 0.00 - - 
3: p + Edaravone+ H2O2 + ethanol 
(1.7 M) 
1000 99.98 ±0.03 0.02 - - 
4: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (10 
mM) 
 2.75 ± 1.41 97.25 - - 
5: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (1.7 M) 
 6.01 ±3.28 93.99 0 - 
6: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM)+ H2O2 + Edaravone + 
ethanol (1.7 M) 
0.1 5.25 ± 2.57 94.75 0.23 ± 2.57 0.891 
7: 1 11.35 ± 4.06 88.65 6.66 ± 4.06 0.105 
8:  5 3.37 ± 1.91 96.63 -1.74 ± 1.91 0.255 
9:  10 6.68 ± 1.74 93.32 1.74 ±1.74 0.225 
10:  50 4.81 ± 2.77 95.19 -0.23 ± 2.77 0.899 
11:  100 2.87 ± 2.33 97.13 -2.28 ± 2.33 0.232 
12: 500 3.50 ± 3.68 96.50 -1.61 ± 3.68 0.528 
13: 1000 14.18 ± 2.35 85.82 9.17 ± 2.64 0.894 













% Damage p Value 
1: plasmid DNA (p) 0 100.0 ± 0 0.0 - - 
2: p + H2O2 (50 µM) 0 98.7 ± 2.2 1.3 - - 
3: p + Ebselen + H2O2 + ethanol 
(1.7 M) 
400 100.0 ± 0 0.0 - - 
4: p + Fe2+ (2 µM) + H2O2 + 
ethanol (10 mM) 
0 7.6 ± 2.3 92.4 - - 
5: p + Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) 
0 25.1 ± 3.0 74.9 0 - 
6: p + Fe2+ (15 µM) + H2O2 + 
Ebselen + ethanol (1.7 M) 
1 27.0 ± 2.6 73.0 4.3 ± 2.7 0.110 
7: 5 30.7 ± 1.2 69.3 9.2 ± 1.3 0.007 
8:  10 28.6 ± 5.5 71.4 6.4 ± 5.5 0.181 
9:  50 26.8 ± 3.5 73.2 3.9 ± 3.5 0.193 
10:  100 26.4 ± 2.8 73.6 3.5 ± 2.9 0.172 
11:  200 31.4 ± 3.2 68.6 10.0 ± 3.2 0.032 
12: 400 28.4 ± 4.5 71.6 6.0 ± 4.5 0.147 
aData are reported as the average of three trials with calculated standard deviations shown. 








% Damage p Value 
1: plasmid DNA (p) 0 99.8 ± 0.2 0.2 -  
2: p + H2O2 (50 µM) 0 98.9 ± 0.8 1.1 - - 
3: p + ebselen + H2O2 + ethanol 
(1.7 M) 
400 98.8 ± 1.6 1.2 - - 
4: p + Cu2+ (2 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (10 
mM) 
0 14.9 ± 1.9 85.1 - - 
5: p + Cu2+ (2 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (1.7 M) 
0 13.7 ± 3.6 86.3 0 - 
6: p Cu2+ (2 µM) + ascorbate (7.5 
µM) + ebselen + ethanol (1.7 M) 
1 12.1 ± 2.4 87.9 -0.5 ± 2.4 0.753 
7: 10 13.1 ± 4.8 86.9 0.7 ± 4.8 0.824 
8:  50 18.1 ± 2.0 81.9 6.4 ± 2.0 0.310 
9:  100 34.4 ± 3.4 65.6 25.3 ± 3.5 0.006 
10:  200 50.0 ± 3.5 50.0 43.3 ± 3.5 0.002 
11 300 56.5 ± 4.4 43.5 50.9 ± 4.5 0.003 
12:  400 58.6 ± 8.5 41.4 53.4 ± 8.5 0.008 















% Damage p Value 
1: plasmid DNA (p) 0 100.0 ± 0 0.0 - - 
2: p + H2O2 (50 µM) 0 99.9 ± 0.1 0.1 - - 
3: p + ebselen-N-acetic acid + H2O2 + 
ethanol (1.7 M) 
700 100.0 ± 0 0.0 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
0 18.8 ± 3.1 81.2 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
0 29.3 ± 2.9 70.7 0 - 
6: p + Fe2+ (15 µM) + H2O2 + ebselen-
N-acetic acid + ethanol (1.7 M) 
1 31.1 ± 2.5 68.9 2.7 ± 2.5 0.202 
7: 10 34.8 ± 4.5 65.2 7.9 ± 4.4 0.090 
8:  50 32.8 ± 3.7 67.2 5.6 ± 4.2 0.147 
9:  100 34.1 ± 3.8 65.9 6.9 ± 3.9 0.092 
10:  200 26.4 ± 2.8 73.6 -4.0 ± 2.9 0.139 
11:  300 28.7 ± 3.6 71.3 -0.8 ± 3.6 0.385 
12: 400 24.9 ± 1.7 75.1 -6.1 ± 1.7 0.025 
13: 500 22.8 ± 1.1 77.2 -9.0 ± 1.1 0.005 
14: 600 26.8 ± 2.2 73.2 -3.4 ± 2.2 0.116 
15: 700 32.2 ± 5.6 67.8 4.2 ± 5.6 0.324 
aData are reported as the average of three trials with calculated standard deviations shown. 










% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + ebselen-N-acetic acid + 
H2O2 + ethanol (1.7 M) 
700 100 ± 0 0 - - 
4: p + Cu2+ (2 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (10 
mM) 
0 13.50 ± 1.11 86.50 - - 
5: p + Cu2+ (2 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (1.7 M) 
0 12.22 ± 4.94 87.78 0 - 
6: p Cu2+ (2 µM) + ascorbate (7.5 
µM) + ebselen-N-acetic acid + 
ethanol (1.7 M) 
10 16.36 ± 1.03 83.64 4.72 ± 1.07 0.017 
7: 100 16.75 ± 2.11 83.25 5.14 ± 2.12 0.052 
8:  200 33.29 ± 3.20 66.71 24.91 ± 3.18 0.005 
9:  300 33.59 ± 3.44 66.41 24.36 ± 3.44 0.007 
10:  500 54.05 ± 2.33 45.95 47.67 ± 2.30 0.002 
11:  700 60.01 ± 1.12 39.99 54.43 ± 1.10 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
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Table 2.27. Gel electrophoresis results for ebselen-7-carboxylic acid DNA damage assays with Fe2+, and 









% Damage p Value 
1: plasmid DNA (p) 0 99.96 ± 0.06 0.04 - - 
2: p + H2O2 (50 µM) 0 98.01 ± 1.8 1.99 - - 
3: p + ebselen-7-carboxylic acid + 
H2O2 + ethanol (1.7 M) 
700 100 ± 0 0 - - 
4: p + Fe2+ (2 µM) + H2O2 + 
ethanol (10 mM) 
700 100 ± 0 0 - - 
5: p + Fe2+ (15 µM) + H2O2 + 
ethanol (1.7 M) 
0 15.85 ± 3.45 84.15 - - 
6: p + Fe2+ (15 µM) + H2O2 + 
ebselen-7-carboxylic acid + 
ethanol (1.7 M) 
0 23.44 ± 4.05 76.56 0 - 
7: 1 21.31 ± 1.70 78.69 -0.20 ± 2.10 0.884 
8:  10 21.65 ± 4.28 78.35 0.28 ± 5.26 0.935 
9:  50 23.44 ± 3.19 76.56 2.63 ± 3.91 0.364 
10:  100 39.14 ± 0.25 60.86 23.14 ± 0.31 < 0.001 
11:  200 56.42 ± 3.76 43.58 45.69 ± 4.62 0.003 
12: 300 60.76 ± 5.03 39.24 51.53 ± 6.18 0.005 
13: 400 84.10 ± 1.71 15.90 81.83 ± 2.08 < 0.001 
14: 500 95.42 ± 1.47 4.58 96.63 ± 1.81 < 0.001 
15 600 95.71 ± 3.04 4.29 96.98 ± 3.74 < 0.001 
16: 700 97.38 ± 2.00 2.62 99.20 ± 2.42 < 0.001 




Table 2.28. Gel electrophoresis results for ebselen-7-carboxylic acid methyl ester DNA damage assays 










% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0.00 - - 
3: p + ebselen-7-carboxylic acid 
methyl ester + H2O2 + ethanol (1.7 M) 
400 99.76 ± 0.42 0.24 - - 
4: p + Fe2+ (2 µM) + H2O2 + ethanol 
(10 mM) 
400 100 ± 0 0.00 - - 
5: p + Fe2+ (15 µM) + H2O2 + ethanol 
(1.7 M) 
0 11.00 ± 1.70 89.00 - - 
6: p + Fe2+ (15 µM) + H2O2 + ebselen-
7-carboxylic acid methyl ester + 
ethanol (1.7 M) 
0 18.51 ± 5.45 81.49 0 - 
7: 1 15.46 ± 2.96 84.54 -3.73 ± 2.99 0.163 
8: 10 3.75 ± 2.88 96.25 -18.13± 2.90 0.008 
9: 50 7.75 ± 3.47 92.25 -13.18 ± 3.50 0.023 
10: 100 13.78 ± 1.95 86.22 -5.78 ± 1.93 0.035 
11: 200 7.88 ± 3.82 92.12 -13.06 ± 3.84 0.028 
12: 300 12.10 ± 3.46 87.90 -7.87 ± 3.48 0.059 
13: 400 10.96 ± 2.10 89.04 -9.26 ± 2.12 0.017 




Table 2.29. Gel electrophoresis results for ebsulfur-7-carboxylic acid DNA damage assays with Cu+, and 









% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0.00 - - 
3: p + ebselen-7-carboxylic acid 
methyl ester + H2O2 + ethanol (1.7 M) 
700 99.77 ± 0.29 0.23 - - 
4: p + Cu2+ (2 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (10 mM) 
0 8.52 ± 5.60 91.48 - - 
5: p + Cu2+ (2 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (1.7 M) 
0 11.17 ± 3.58 88.83 0 - 
6: p Cu2+ (2 µM) + ascorbate (7.5 
µM) + ebselen-7-carboxylic acid 
methyl ester + ethanol (1.7 M) 
0.001 13.42 ±3.25 86.58 2.54 ± 3.25 0.309 
7: 0.1 15.19 ± 1.76 84.81 4.53 ± 1.73 0.045 
8:  1 20.82 ± 3.63 79.18 10.84 ± 3.61 0.035 
9:  10 16.31 ± 3.93 83.69 5.81 ± 3.91 0.124 
10:  100 62.96 ± 1.27 37.04 58.31 ± 1.27 < 0.001 
11: 300 67.58 ± 1.91 32.42 63.52 ± 1.93 0.001 
12: 500 67.36 ± 5.03 32.64 63.22 ± 5.04 0.002 
13: 700 71.20 ± 3.88 28.80 67.58 ± 3.84 0.001 




Table 2.30. Gel electrophoresis results for ebsulfur-7-carboxylic acid DNA damage assays with Cu+, and 









% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0 ± 0 - - 
2: p + H2O2 (50 µM) 0  100 ± 0 0 ± 0 - - 
3: p + ebsulfur-7-carboxylic acid + 
H2O2 + ethanol (1.7 M) 
700  100 ± 0 0 ± 0 - - 
4: p + Cu2+ (2 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (10 
mM) 
700  2.03 ± 1.40 97.97 - - 
5: p + Cu2+ (2 µM) + ascorbate 
(7.5 µM) + H2O2 + ethanol (1.7 M) 
0 1.78 ± 1.80 98.22 0 - 
6: p Cu2+ (2 µM) + ascorbate (7.5 
µM) + ebsulfur-7-carboxylic acid 
+ ethanol (1.7 M) 
1 4.43 ± 2.33 95.57 2.70 ± 2.37 0.187 
7: 10 1.65 ± 0.96 98.35 -0.51 ± 0.97 0.459 
8:  50 3.95 ± 0.90 96.05 2.23 ± 0.87 0.047 
9:  100 6.42 ± 0.89 93.58 4.71 ± 0.85 0.011 
10:  200 6.19 ± 1.74 93.81 4.50 ± 1.74 0.011 
11: 300 7.56 ± 3.78 92.44 5.89 ± 3.81 0.116 
12: 400 8.62 ± 3.94 91.38 6.98 ± 3.96 0.093 
13: 500 3.06 ± 2.62 96.94 1.31 ± 2.64 0.481 
14: 600 3.95 ± 2.37 96.05 2.20 ± 2.41 0.255 
15: 700 7.45 ± 2.33 92.55 5.79 ± 2.31 0.049 




Table 2.31. Gel electrophoresis results for ebsulfur-7-carboxylic acid methyl ester DNA damage assays 









% Damage p Value 
1: plasmid DNA (p) 0 99.99 ± 0.02 0.01 - - 
2: p + H2O2 (50 µM) 0 99.98± 0.03 0.02 - - 
3: p + ebsulfur-7- carboxylic acid 
methyl ester + H2O2 + ethanol (1.7 M) 
400 99.96 ± 0.04 0.04 - - 
4: p + Cu2+ (2 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (10 mM) 
400 99.96 ±0.07 0.04 - - 
5: p + Cu2+ (2 µM) + ascorbate (7.5 
µM) + H2O2 + ethanol (1.7 M) 
0 1.11 ± 1.09 97.78 - - 
6: p Cu2+ (2 µM) + ascorbate (7.5 µM) 
+ ebsulfur-7- carboxylic acid methyl 
ester + ethanol (1.7 M) 
0 4.42 ± 1.97 95.58 0 - 
7: 1 2.22 ± 1.63 97.78 -2.27 ± 1.63 0.137 
8:  10 4.69 ± 3.98 95.31 0.31 ± 3.98 0.905 
9:  50 2.88 ± 0.47 97.12 -1.60 ± 0.45 0.025 
10:  100 3.67 ± 1.71 96.33 -0.77 ± 1.68 0.511 
11: 200 2.51 ± 2.42 97.49 -1.95 ± 2.42 0.298 
12: 300 0.78 ± 0.40 99.22 -3.80 ± 0.38 0.003 
13:  400 2.01 ± 0.89 97.99 -2.51 ± 0.92 0.042 





Table 2.32. DPPH scavenging assay results for EC.a 
[EC], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.2 4.71 ± 1.23 0.022 
2 9.81 ± 0.70 0.002 
10 27.20 ± 1.04 < 0.001 
20 40.03 ± 0.86 < 0.001 
40 60.20 ± 0.12 < 0.001 
100 76.67 ± 1.65 < 0.001 
250 95.09 ± 0.06 < 0.001 
500 98.70 ± 0.06 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure 2.22. Dose-response plot for EC in the DPPH-scavenging assay. Error bars are smaller than the 





Table 2.33. DPPH scavenging assay results for GA.a 
[GA], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.01 -2.02 ± 5.30 0.577 
0.1 2.31 ± 5.51 0.543 
1 12.51 ± 0.76 0.001 
5 38.02 ± 1.01 < 0.001 
10 50.54 ± 1.71  < 0.001 
20 63.68 ± 0.40 < 0.001 
50 73.98 ± 0.23 < 0.001 
100 82.31 ± 1.19 < 0.001 
250 96.57 ± 0.38 < 0.001 
500 98.84 ± 0.06 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
Figure 2.23. Dose-response plot for GA in the DPPH-scavenging assay.   
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Table 2.34. DPPH scavenging assay results for PCA.a 
[PCA], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.1 4.86 ± 1.37 0.025 
1 7.95 ± 1.83 0.017 
5 14.75 ± 0.23 < 0.001 
10 22.17 ± 0.89 < 0.001 
15 27.35 ± 0.55 < 0.001 
25 30.21 ± 0.56 < 0.001 
1000 55.18 ± 1.05 < 0.001 
2000 65.28 ± 0.05 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure 2.24. Dose-response plot for PCA in the DPPH-scavenging assay. Error bars are smaller than the 




Table 2.35. DPPH scavenging assay results for TA.a 
[TA], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.001 18.52 ± 0.06 < 0.001 
0.01 51.39 ± 0.06 < 0.001 
0.1 77.41 ± 0.80 < 0.001 
1 91.76 ± 0.17 < 0.001 
10 98.98 ± 0.15 < 0.001 
25 99.54 ± 0.06 < 0.001 
50 99.72 ± 0.06 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 





Table 2.36. DPPH scavenging assay results for EGCG.a 
[EGCG], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.01 4.09 ± 0.01 < 0.001 
0.1 4.01 ± 0.05 < 0.001 
1 61.28 ± 0.01 < 0.001 
5 79.75 ± 0.01 < 0.001 
20 98.89 ± 0.01 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure2.26. Dose-response plot for EGCG in the DPPH-scavenging assay. Error bars are smaller than the 




Table 2.37. DPPH scavenging assay results for sepyMe.a 
[sepyMe], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.01 9.25 ± 0.40 < 0.001 
1 10.53 ± 0.26 < 0.001 
10 33.99 ± 0.32 < 0.001 
25 43.70 ± 0.75 < 0.001 
50 49.02 ± 0.20 < 0.001 
100 53.70 ± 0.36 < 0.001 




Figure 2.27. Dose-response plot for sepyMe in the DPPH-scavenging assay. Error bars are smaller than the 




Table 2.38. DPPH scavenging assay results for pyridine.a 
[pyridine], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.1 4.57 ± 0.40 0.003 
1 2.09 ± 2.28 0.253 
10 0.53 ± 1.02 0.463 
50 -1.67 ± 1.36 0.015 
100 -0.75 ± 0.61 0.167 
500 0.18 ± 0.40 0.517 
1000 9.37 ± 0.06 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
Figure 2.28. Dose-response plot for pyridine in the DPPH-scavenging assay. Error bars are smaller than 




Table 2.39. DPPH scavenging assay results for bipy.a 
[bipy], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.1 1.65 ± 0.56 0.036 
1 -3.41 ± 0.15 < 0.001 
10 -0.55 ± 0.35 0.113 
50 -1.54 ± 0.80 0.079 
100 -3.74 ± 0.58 0.008 
1000 3.30 ± 1.65 0.074 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
Figure 2.29. Dose-response plot for bipy in the DPPH-scavenging assay. Error bars are smaller than the 




Table 2.40. DPPH scavenging assay results for dmise.a 
[dmise], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.01 0.00 ± 0.10 0.878 
0.1 0.99 ± 0.20 0.013 
1 5.39 ± 0.12 < 0.001 
10 17.38 ± 0.67 < 0.001 
50 36.74 ± 0.21 < 0.001 
100 49.62 ± 0.21 < 0.001 
250 51.20 ± 0.15 < 0.001 
500 59.35 ± 0.15 < 0.001 
1000 75.15 ± 0.12 < 0.001 
2000 94.51 ± 0.06 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure 2.30. Dose-response plot for dmise in the DPPH-scavenging assay. Error bars are smaller than the 




Table 2.41. DPPH scavenging assay results for ebis.a 
[ebis], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.01 9.07 ± 0.15 < 0.001 
0.1 45.74 ± 0.01 < 0.001 
1 98.61 ± 0.25 < 0.001 
10 100 ± 0.35 < 0.001 
25 99.26 ± 0.01 < 0.001 
50 100 ± 0.38 < 0.001 
100 100 ± 0.01 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure 2.31. Dose-response plot for ebis in the DPPH-scavenging assay. Error bars are smaller than the 





Table 2.42. DPPH scavenging assay results for Trolox.a 
[Trolox], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.001 0.00 ± 0.17 0.928 
0.1 0.44 ± 0.06 0.006 
1 8.25 ± 0.17 < 0.001 
5 31.24 ± 0.15 < 0.001 
10 72.05 ± 0.15 < 0.001 
50 100 ± 0.01 < 0.001 
100 100 ± 0.01 < 0.001 
150 100± 0.01 < 0.001 




Figure 2.32. Dose-response plot for Trolox in the DPPH-scavenging assay. Error bars are smaller than the 





Table 2.43. DPPH scavenging assay results for Edaravone.a 
[Edaravone], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.001 -4.72 ± 0.1 < 0.001 
0.1 13.19 ± 0.20 < 0.001 
1 23.65 ± 0.15 < 0.001 
5 60.51 ± 0.15 < 0.001 
10 90.10 ± 0.20 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure 2.33. Dose-response plot for Edaravone in the DPPH-scavenging assay. Error bars are smaller than 





Table 2.44. DPPH scavenging assay results for ebselen.a 
[Ebselen], μM % Scavenged p Value 
DPPH 0 ± - 
Trolox (50 µM) 100 ± 0 - 
0.1 11.66 ± 0.31 < 0.001 
1 10.34 ± 0.15 < 0.001 
10 5.28 ± 0.70 0.006 
50 5.39 ± 0.45 0.002 
100 3.74 ± 0.06 < 0.001 
500 4.84 ± 0.25 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Figure 2.34. Dose-response plot for ebselen in the DPPH-scavenging assay. Error bars are smaller than the 





Figure 2.35. EPR spectra of Cu2+ (300 µM), ascorbic acid (375 µM), H2O2 (2.5 mM) and DMPO (30 mM) 





Figure 2.36. EPR spectra of Cu2+ (300 µM), ascorbic acid (375 µM), H2O2 (2.5 mM), DMPO (30 mM), 





Figure 2.37. EPR spectra of Fe2+ (300 µM), H2O2 (2.5 mM), and DMPO (30 mM) at the indicated time 
points. 
 
Figure 2.38. EPR spectra of Fe2+ (300 µM), H2O2 (2.5 mM), DMPO (30 mM), and ethanol (1.7 M) at the 




Figure 2.39. EPR spectra of Fe2+ (300 µM), H2O2 (2.5 mM), DMPO (30 mM), and ethanol (875 mM) at 
the indicated time points. 
 
 
Figure 2.40. EPR spectra of Fe2+ (300 µM), H2O2 (2.5 mM), DMPO (30 mM), and ethanol (425 mM) at 




(1) Azzi, A. Biochem. Biophys. Res. Commun. 2007, 362, 230–232. 
(2) Imlay, J. A.; Linn, S. Science 1988, 240, 1302–1309. 
(3) Battin, E. E.; Zimmerman, M. T.; Ramoutar, R. R.; Quarles, C. E.; Brumaghim, J. L. 
Metallomics 2011, 3, 503–512. 
(4) Garcia, C. R.; Angele-Martinez, C.; Wilkes, J. A.; Wang, H. C.; Battin, E. E.; 
Brumaghim, J. L. Dalton Trans. 2012, 41, 6458–6467. 
(5) Begonja, A. J.; Teichmann, L.; Geiger, J.; Gambaryan, S.; Walter, U. Blood Cells 
Mol. Dis. 2006, 36, 166–170. 
(6) Halliwell, B.; Gutteridge, J. M.C. Mol. Aspects Med. 1985, 8, 89–193. 
(7) Cross, C. E.; Halliwell, B.; Borish, E. T.; Pryor, W. A.; Ames, B. N.; Saul, R. L.; 
McCord, J. M.; Harman, D. Ann. Intern. Med. 1987, 107, 526–545. 
(8) Aust, S. D.; Morehouse, L. A.; Thomas, C. E. J. Free Radic. Biol. Med. 1985, 1, 3–
25. 
(9) Oswald, M. C. W.; Garnham, N.; Sweeney, S. T.; Landgraf, M. FEBS Lett. 2018, 
592, 679–691. 
(10) Akhtar, M. J.; Ahamed, M.; Alhadlaq, H. A.; Alshamsan, A. Biochim. Biophys. Acta 
2017, 1861, 802–813. 
(11) Dixon, S. J.; Stockwell, B. R. Nature Chem. Biol. 2014, 10, 9–17. 
(12) Saeidnia, S.; Abdollahi, M. Toxicol. Appl. Pharmacol. 2013, 273, 442–455. 
(13) Heneka, M. T.; O'Banion, M. K. J. Neuroimmunol. 2007, 184, 69–91. 
 109 
 
(14) Fetoni, A. R.; Paciello, F.; Rolesi, R.; Paludetti, G.; Troiani, D. Free Radic. Biol. 
Med. 2019, 135, 46–59. 
(15) Moody, C. S.; Hassan, H. M. Proc. Natl. Acad. Sci. USA 1982, 79, 2855–2859. 
(16) Weitzman, S. A.; Weitberg, A. B.; Clark, E. P.; Stossel, T. P. Science 1985, 227, 
1231–1233. 
(17) Brawn, M. K.; Fridovich, I. J. Biol. Chem. 1985, 260, 922–925. 
(18) Bhabak, K. P.; Mugesh, G. Chem. Eur. J. 2010, 16, 1175–1185. 
(19) Lee, S. H.; Blair, I. A. Trends Cardiovasc. Med. 2001, 11, 148–155. 
(20) Jeremy, J. Y.; Yim, A. P.; Wan, S.; Angelini, G. D. J. Card. Surg. 2002, 17, 324–
327. 
(21) Hureau, C.; Faller, P. Biochimie 2009, 91, 1212–1217. 
(22) Puppo, A.; Halliwell, B. Free Radic. Res. Commun. 1988, 4, 415–422. 
(23) Halliwell, B.; Aruoma, O. I. FEBS Lett. 1991, 281, 9–19. 
(24) Aruoma, O. I.; Halliwell, B.; Gajewski, E.; Dizdaroglu, M. Biochem. J. 1991, 273, 
601–604. 
(25) Halliwell, B. Free Radic. Biol. Med. 1989, 7, 645–651. 
(26) Nassi-Calò, L.; Mello-Filho, C.; Meneghini, R. Carcinogenesis 1989, 10, 1055–
1057. 
(27) Aruoma, O. I.; Halliwell, B.; Hoey, B. M.; Butler, J. Biochem. J. 1988, 256, 251–
255. 
(28) Gutteridge, J. M.C.; Halliwell, B. 1 Bail. Cl. Hae. 1989, 2, 195–256. 
(29) Storz, G.; Imlay, J. A. Curr. Opin. Microbiol. 1999, 2, 188–194. 
 110 
 
(30) Park, S.; Imlay, J. A. J. Bacteriol. 2003, 185, 1942–1950. 
(31) Sorg, O. C. R. Biol. 2004, 327, 649–662. 
(32) Fridovich, I. J. Biol. Chem. 1989, 264, 7761–7764. 
(33) Duthie, G. G. Proc. Nutr. Soc. 1999, 58, 1015–1024. 
(34) Kedare, S. B.; Singh, R. P. J. Food Sci. Technol. 2011, 48, 412–422. 
(35) Mishra, K.; Ojha, H.; Chaudhury, N. K. Food Chem. 2012, 130, 1036–1043. 
(36) Schaich, K. M.; Tian, X.; Xie, J. J. Funct. Foods 2015, 18, 782–796. 
(37) Frankel, E. N.; Meyer, A. S. J. Sci. Food Agric. 2000, 80, 1925–1941. 
(38) Aruoma, O. I. Mut. Res. 2003, 523-524, 9–20. 
(39) Pérez-Jiménez, J.; Saura-Calixto, F. Food Res. Int. 2006, 39, 791–800. 
(40) Pinchuk, I.; Shoval, H.; Dotan, Y.; Lichtenberg, D. Chem. Phys. Lipids 2012, 165, 
638–647. 
(41) Benzie, I. F.F.; Devaki, M. In Measurement of antioxidant activity and capacity: 
Recent trends and applications. Wiley: Hoboken, NJ, USA, 2018; pp 77–106. 
(42) Özyürek, M.; Güçlü, K.; Tütem, E.; Başkan, K. S.; Erçağ, E.; Esin Çelik, S.; Baki, 
S.; Yıldız, L.; Karaman, Ş.; Apak, R. Anal. Methods 2011, 3, 2439. 
(43) López-Alarcón, C.; Denicola, A. Anal. Chim. Acta 2013, 763, 1–10. 
(44) Martín, M. Á.; Fernández-Millán, E.; Ramos, S.; Bravo, L.; Goya, L. Mol. Nutr. 
Food Res. 2014, 58, 447–456. 
(45) Dajas, F.; Rivera, F.; Blasina, F.; Arredondo, F.; Echeverry, C.; Lafon, L.; Morquio, 
A.; Heinzen, H.; Heizen, H. Neurotox. Res. 2003, 5, 425–432. 
(46) Singh, S.; Singh, R. P. Food Rev. Int. 2008, 24, 392–415. 
 111 
 
(47) Nascimento da Silva, L. C.; Bezerra Filho, C. M.; Paula, R. A. de; Silva E Silva, C. 
S.; Oliveira de Souza, L. I.; Silva, M. V. d.; Correia, M. T. D. S.; Figueiredo, R. C. B. Q. 
de. Free Radic. Res. 2016, 50, 801–812. 
(48) Carocho, M.; Ferreira, I. C. F. R. Food Chem. Tox. 2013, 51, 15–25. 
(49) Cao, G.; Alessio, H. M.; Cutler, R. G. Free Radic. Biol. Med. 1993, 14, 303–311. 
(50) Huang, D.; Ou, B.; Hampsch-Woodill, M.; Flanagan, J. A.; Deemer, E. K. J. Agric. 
Food Chem. 2002, 50, 1815–1821. 
(51) Huang, D.; Ou, B.; Prior, R. L. J. Agric. Food Chem. 2005, 53, 1841–1856. 
(52) Ou, B.; Hampsch-Woodill, M.; Prior, R. L. J. Agric. Food Chem. 2001, 49, 4619–
4626. 
(53) Bank, G.; Schauss, A. Nutraceuticals World 2004, 68–71. 
(54) Ou, B.; Hampsch-Woodill, M.; Flanagan, J.; Deemer, E. K.; Prior, R. L.; Huang, D. 
J. Agric. Food Chem. 2002, 50, 2772–2777. 
(55) Cao, G.; Verdon, C. P.; Wu, A. H.; Wang, H.; Prior, R. L. Clin. Chem. 1995, 41, 
1738–1744. 
(56) Cunningham, E. J. Acad. Nutr. Diet. 2013, 113, 740. 
(57) Fraga, C. G.; Oteiza, P. I.; Galleano, M. Biochim. Biophys. Acta 2014, 1840, 931–
934. 
(58) Chen, H.-Y. ACS Omega 2019, 4, 14105–14113. 
(59) Ryter, S. W.; Kim, H. P.; Hoetzel, A.; Park, J. W.; Nakahira, K.; Wang, X.; Choi, 
A. M. K. Antiox. Redox Signal. 2007, 9, 49–89. 
 112 
 
(60) Kroemer, G.; Dallaporta, B.; Resche-Rigon, M. Annu. Rev. Physiol. 1998, 60, 619–
642. 
(61) Halliwell, B. Am. J. Clin. Nutr. 2000, 72, 1082–1087. 
(62) Arif, R.; Nayab, P. S.; Akrema; Abid, M.; Yadava, U.; Rahisuddin. J. Anal. Sci. 
Technol. 2019, 10, 1024. 
(63) Battin, E. E.; Perron, N. R.; Brumaghim, J. L. Inorg. Chem. 2006, 45, 499–501. 
(64) Soumya, K.; Haridas, K. R.; James, J.; Sameer Kumar, V. B.; Edatt, L.; Sudheesh, 
S. J. Taibah Univ. Sci. 2019, 13, 755–763. 
(65) Xu, J.-G.; Hu, Q.-P.; Liu, Y. J. Agric. Food Chem. 2012, 60, 11625–11630. 
(66) Hu, Q.-P.; Cao, X.-M.; Hao, D.-L.; Zhang, L.-L. Sci. Rep. 2017, 7, 45231. 
(67) Johnson, G. R. A.; Nazhat, N. B.; Saadalla-Nazhat, R. A. J. Chem. Soc., Chem. 
Commun. 1985, 407. 
(68) Jung, Y.-J.; Surh, Y.-J. Free Radic. Biol. Med. 2001, 30, 1407–1417. 
(69) Roussyn, I.; Briviba, K.; Masumoto, H.; Sies, H. Arch. Biochem. Biophys. 1996, 
330, 216–218. 
(70) Imlay, J. A.; Chin, S. M.; Linn, S. Science 1988, 240, 640–642. 
(71) Imlay, J. A.; Linn, S. Science 1988, 240, 1302–1309. 
(72) Mello-Filho, A. C.; Meneghini, R. Mut. Res. 1991, 251, 109–113. 
(73) Mello Filho, A. C.; Hoffmann, M. E.; Meneghini, R. Biochem. J. 1984, 218, 273–
275. 
(74) Keyer, K.; Imlay, J. A. Proc. Natl. Acad. Sci. USA 1996, 93, 13635–13640. 
 113 
 
(75) Touati, D.; Jacques, M.; Tardat, B.; Bouchard, L.; Despied, S. J. Bacteriol. 1995, 
177, 2305–2314. 
(76) Perron, N. R.; Brumaghim, J. L. Cell Biochem. Biophys. 2009, 53, 75–100. 
(77) Touati, D. Iron and oxidative stress in bacteria. Arch. Biochem. Biophys. 2000, 373, 
1–6. 
(78) Blokhina, O.; Virolainen, E.; Fagerstedt, K. V. Ann. Bot. 2003, 91, 179–194. 
(79) Valko, M.; Morris, H.; Cronin, M. Curr. Med. Chem. 2005, 12, 1161–1208. 
(80) Tashiro, M.; Tursun, P.; Konishi, M. Biophys. J. 2005, 89, 3235–3247. 
(81) Stöckel, J.; Safar, J.; Wallace, A. C.; Cohen, F. E.; Prusiner, S. B. Biochemistry 
1998, 37, 7185–7193. 
(82) Angelé-Martínez, C.; Goodman, C.; Brumaghim, J. Metallomics 2014, 6, 1358–
1381. 
(83) Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G. Chem. Rev. 2006, 106, 
1995–2044. 
(84) Hopt, A.; Korte, S.; Fink, H.; Panne, U.; Niessner, R.; Jahn, R.; Kretzschmar, H.; 
Herms, J. J. Neurosci. Meth. 2003, 128, 159–172. 
(85) Liu, C. J. Inorg. Biochem. 1999, 75, 233–240. 
(86) Chikira, M.; Ng, C. H.; Palaniandavar, M. Int. J. Mol. Sci. 2015, 16, 22754–22780. 
(87) Galindo-Murillo, R.; García-Ramos, J. C.; Ruiz-Azuara, L.; Cheatham, T. E.; 
Cortés-Guzmán, F. Nucleic Acids Res. 2015, 43, 5364–5376. 
(88) Halliwell, B. Free Radic. Biol. Med. 2002, 32, 968–974. 
(89) Woodmansee, A. N.; Imlay, J. A. Methods Enzymol. 2002, 349, 3–9. 
 114 
 
(90) Linn, S. J. Biol. Chem. 2015, 290, 8748–8757. 
(91) Luo, Y.; Han, Z.; Chin, S. M.; Linn, S. Proc. Natl. Acad. Sci. USA 1994, 91, 12438–
12442. 
(92) Henle, E. S.; Han, Z.; Tang, N.; Rai, P.; Luo, Y.; Linn, S. J. Biol. Chem. 1999, 274, 
962–971. 
(93) Henle, E. S.; Linn, S. J. Biol. Chem. 1997, 272, 19095–19098. 
(94) Ogusucu, R.; Rettori, D.; Netto, L. E. S.; Augusto, O. J. Biol. Chem. 2009, 284, 
5546–5556. 
(95) Augusto, O. Free Radic. Biol. Med. 1993, 15, 329–336. 
(96) Nakao, L. S.; Augusto, O. Chem. Res. Toxicol. 1998, 11, 888–894. 
(97) Nakao, L. S.; Fonseca, E.; Augusto, O. Chem. Res. Toxicol. 2002, 15, 1248–1253. 
(98) Perron, N. R.; Wang, H. C.; Deguire, S. N.; Jenkins, M.; Lawson, M.; Brumaghim, 
J. L. Dalton Trans. 2010, 39, 9982–9987. 
(99) Battin, E. E.; Zimmerman, M. T.; Ramoutar, R. R.; Quarles, C. E.; Brumaghim, J. 
L. Metallomics 2011, 3, 503–512. 
(100) Abbas, M.; Gaertner, A. A. E.; McMillen, C. D.; Brumaghim, J. L. Dalton trans. 
In preparation. 
(101) Briviba, K.; Roussyn, I.; Sharov, V. S.; Sies, H. Biochem. J. 1996, 319, 13–15. 
(102) Morgan, B.; Lahav, O. Chemosphere 2007, 68, 2080–2084. 
(103) Floyd, R. A.; Lewis, C. A. Biochemistry 1983, 22, 2645–2649. 
(104) Halliwell, B.; Gutteridge, J. M.C. FEBS Lett. 1992, 307, 108–112. 
(105) Steiner, M. G.; Babbs, C. F. Arch. Biochem. Biophys. 1990, 278, 478–481. 
 115 
 
(106) Burkitt, M. J.; Mason, R. P. Proc. Natl. Acad. Sci. USA 1991, 88, 8440–8444. 
(107) Kadiiska, M. B.; Burkitt, M. J.; Xiang, Q. H.; Mason, R. P. J. Clin. Invest. 1995, 
96, 1653–1657. 
(108) Schraufstätter, I.; Hyslop, P. A.; Jackson, J. H.; Cochrane, C. G. J. Clin. Invest. 
1988, 82, 1040–1050. 
(109) Olsen, M. J. J. Tox. Environ. Health 1988, 23, 407–423. 
(110) Jonas, S. K.; Riley, P. A.; Willson, R. L. Biochem. J. 1989, 264, 651–655. 
(111) Sagripanti, J. L.; Kraemer, K. H. J. Biol. Chem. 1989, 264, 1729–1734. 
(112) Fujimoto, S.; Adachi, Y.; Ishimitsu, S.; Ohara, A. Chem. Pharm. Bull. 1986, 34, 
4848–4851. 
(113) Rowley, D. A.; Halliwell, B. Arch. Biochem. Biophys. 1983, 225, 279–284. 
(114) Reed, C. J.; Douglas, K. T. Biochem. Biophys. Res. Commun. 1989, 162, 1111–
1117. 
(115) Masarwa, M.; Cohen, H.; Meyerstein, D.; Hickman, D. L.; Bakac, A.; Espenson, J. 
H. J. Am. Chem. Soc. 1988, 110, 4293–4297. 
(116) Goldstein, S.; Meyerstein, D. Acc. Chem. Res. 1999, 32, 547–550. 
(117) Ingraham, L. L. Arch. Biochem. Biophys. 1959, 81, 309–318. 
(118) Yamamoto, K.; Kawanishi, S. J. Biol. Chem. 1989, 264, 15435–15440. 
(119) Sutton, H. C.; Winterbourn, C. C. Free Radic. Biol. Med. 1989, 6, 53–60. 
(120) Johnson, G. R. A.; Nazhat, N. B.; Saadalla-Nazhat, R. A. J. Chem. Soc., Faraday 
Trans. 1 1988, 84, 501. 
(121) Sigman, D. S. Acc. Chem. Res. 1986, 19, 180–186. 
 116 
 
(122) Rodriguez, H.; Drouin, R.; Holmquist, G. P.; O'Connor, T. R.; Boiteux, S.; Laval, 
J.; Doroshow, J. H.; Akman, S. A. J. Biol. Chem. 1995, 270, 17633–17640. 
(123) Dizdaroglu, M.; Rao, G.; Halliwell, B.; Gajewski, E. Arch. Biochem. Biophys. 
1991, 285, 317–324. 
(124) Stoewe, R.; Prütz, W. A. Free Radic. Biol. Med. 1987, 3, 97–105. 
(125) Taniguchi, H.; Madden, K. P. Radiat. Res. 2000, 153, 447–453. 
(126) Haire, D. L.; Kotake, Y.; Janzen, E. G. Can. J. Chem. 1988, 66, 1901–1911. 
(127) Kotake, Y.; Kuwata, K.; Janzen, E. G. Electron spin resonance spectra of 
diastereomeric nitroxyls produced by spin trapping hydroxylalkyl radicals. J. Phys. 
Chem. 1979, 83, 3024–3029. 
(128) Kirino, Y.; Ohkuma, T.; Kwan, T. Spin Chem. Pharm. Bull. 1981, 29, 29–34. 
(129) Hedrick, W. R.; Webb, M. D.; Zimbrick, J. D. Int. J. Rad. Biol. Rel. Stud. Phys. 
Chem. Med. 1982, 41, 435–442. 
(130) Wei, J.; Liang, Y.; Hu, Y.; Kong, B.; Zhang, J.; Gu, Q.; Tong, Y.; Wang, X.; 
Jiang, S. P.; Wang, H. Angew. Chem. Int. Ed. 2016, 55, 12470–12474. 
(131) Rice-Evans, C. A.; Miller, N. J.; Paganga, G. Free Radic. Biol. Med. 1996, 20, 
933–956. 
(132) El Gharras, H. Int. J. Food Sci. Technol. 2009, 44, 2512–2518. 
(133) Sánchez-Moreno, C.; Larrauri, J. A.; Saura-Calixto, F. J. Sci. Food Agric. 1998, 
76, 270–276. 
(134) Sanchez-Moreno, C. Food Sci Technol. Int. 2002, 8, 121–137. 
 117 
 
(135) Perron, N. R. Effects of Polyphenol Compounds on Iron- and Copper-mediated 
DNA damage: Mechanism and Predictive Models. Dissertation, Clemson Univeristy, 
Clemson, 2008. 
(136) Imlay, J. A.; Linn, S. J. Bact. 1987, 169, 2967–2976. 
(137) Duthie, G. G. Pr. Nutr. Soc. 1999, 58, 1015–1024. 
(138) Stadelman, B. S.; Kimani, M. M.; Bayse, C. A.; McMillen, C. D.; Brumaghim, J. 
L. Dalton Trans. 2016, 45, 4697–4711. 
(139) Kimani, M. M.; Watts, D.; Graham, L. A.; Rabinovich, D.; Yap, G. P. A.; 
Brumaghim, J. L. Dalton Trans. 2015, 44, 16313–16324. 
(140) Kimani, M. M.; Bayse, C. A.; Stadelman, B. S.; Brumaghim, J. L. Inorg. Chem. 
2013, 52, 11685–11687. 
(141) Fábián, I. Inorg. Chem. 1989, 28, 3805–3807. 
(142) Inskeep, R. G. J. Inorg. Nucl. Chem. 1962, 24, 763–776. 
(143) Zimmerman, M. T. Determining DNA damage prevention mechanisms for 
multifunctional selenium and sulfur antioxidants and the DNA-damaging capabilities of 
clotrimazole and pseudophedrine-derived metal complexes. Dissertation, Clemson, 2014. 
(144) Cabani, S.; Moretti, G.; Scrocco, E. 17. J. Chem. Soc. 1962, 0, 88–93. 
(145) Sun, M. S.; Brewer, D. G. Can. J. Chem. 1967, 45, 2729–2743. 
(146) Abraham, A.; Nefussy, B.; Fainmesser, Y.; Ebrahimi, Y.; Karni, A.; Drory, V. E. 
Amyotroph. Lat. Scl. & Fr. Deg. 2019, 20, 260–263. 
(147) Yoshino, H. Expert Rev. Neurother.s 2019, 19, 185–193. 
 118 
 
(148) Homma, T.; Kobayashi, S.; Sato, H.; Fujii, J. Exp. Cell Res. 2019, 384, 111592-
111611. 
(149) Watanabe, K.; Tanaka, M.; Yuki, S.; Hirai, M.; Yamamoto, Y. J. Clin. Biochem. 
Nutr. 2018, 62, 20–38. 
(150) Cruz, M. P. Pharm. Ther. 2018, 43, 25–28. 
(151) Oberley, L. W.; Buettner, G. R. Cancer Res. 1979, 39, 1141–1149. 
(152) Mruk, D. D.; Silvestrini, B.; Mo, M.-y.; Cheng, C.Y. Contraception 2002, 65, 
305–311. 
(153) Tokuda, E.; Furukawa, Y. Int. J. Mol. Sci. 2016, 17, 636-650. 
(154) Oliveira, R.; Geraldo, D.; Bento, F. Talanta 2014, 129, 320–327. 
(155) Alberto, M. E.; Russo, N.; Grand, A.; Galano, A. Phys. Chem. Chem. Phys. 2013, 
15, 4642–4650. 
(156) Mitarai, A.; Ouchi, A.; Mukai, K.; Tokunaga, A.; Mukai, K.; Abe, K. J. Agric.  
Food Chem. 2008, 56, 84–91. 
(157) Friaa, O.; Brault, D. Org. Biomol. Chem. 2006, 4, 2417–2423. 
(158) Wang, L.-F.; Zhang, H.-Y. Bioorg. Med. Chem. Lett. 2003, 13, 3789–3792. 
(159) Tokumaru, O.; Shuto, Y.; Ogata, K.; Kamibayashi, M.; Bacal, K.; Takei, H.; 
Yokoi, I.; Kitano, T. J. Surg. Res. 2018, 228, 147–153. 
(160) Minnelli, C.; Laudadio, E.; Galeazzi, R.; Rusciano, D.; Armeni, T.; Stipa, P.; 
Cantarini, M.; Mobbili, G. Antioxidants 2019, 8, 258-262. 
(161) Pardridge, W. M. Drug Discov. Today 2007, 12, 54–61. 
(162) Jamieson, J. J.; Searson, P. C.; Gerecht, S. J. Biol. Eng. 2017, 11, 37. 
 119 
 
(163) Piętka-Ottlik, M.; Wójtowicz-Młochowska, H.; Kołodziejczyk, K.; Piasecki, E.; 
Młochowski, J. Chem. Pharm. Bull. 2008, 56, 1423–1427. 
(164) Santi, C.; Tidei, C.; Scalera, C.; Piroddi, M.; Galli, F. Curr. Chem. Biol. 2013, 7, 
25–36. 
(165) Zade, S. S.; Panda, S.; Tripathi, S. K.; Singh, H. B.; Wolmershäuser, G. Eur. J. 
Org. Chem. 2004, 2004, 3857–3864. 
(166) Azad, G. K.; Tomar, R. S. Mol. Biol. Rep. 2014, 41, 4865–4879. 
(167) Álvarez-Pérez, M.; Ali, W.; Marć, M. A.; Handzlik, J.; Domínguez-Álvarez, E. 
Molecules  2018, 23, 628-647. 
(168) Steinbrenner, H.; Brigelius-Floh, R. Aktue.l Ernahrungsmed. 2015, 40, 368–378. 
(169) Yamaguchi, T.; Sano, K.; Takakura, K.; Saito, I.; Shinohara, Y.; Asano, T.; 
Yasuhara, H. Stroke 1998, 29, 12–17. 
(170) Kil, J.; Lobarinas, E.; Spankovich, C.; Griffiths, S. K.; Antonelli, P. J.; Lynch, E. 
D.; Le Prell, C. G. Lancet 2017, 390, 969–979. 
(171) Parnham, M. J. Adv. Exp. Med. Biol. 1990, 264, 193–197. 
(172) Sies, H.; Masumoto, H. In Advances in Pharmacology. Elsevier, 1996. pp 229–
246. 
(173) Maiorino, M.; Roveri, A.; Coassin, M.; Ursini, F. Biochem. Pharmacol. 1988, 37, 
2267–2271. 
(174) Masumoto, H.; Sies, H. Chem. Res. Toxicol. 1996, 9, 262–267. 
(175) Fujisawa, S.; Kadoma, Y. Anticancer Res. 2005, 25, 3989–3994. 
 120 
 
(176) Adams, G. E.; Boag, J. W.; Michael, B. D. Trans. Faraday Soc. 1965, 61, 1417–
1424. 
(177) Woodmansee, A. N.; Imlay, J. A. In Superoxide dismutase. Academic Press: San 
Diego, London, 2002. pp 3–9. 
(178) Gordhan, H. M.; Patrick, S. L.; Swasy, M. I.; Hackler, A. L.; Anayee, M.; Golden, 
J. E.; Morris, J. C.; Whitehead, D. C. Bioorg. Med. Lett. 2016, 27, 537–541. 
(179) Cannan, R. K.; Kibrick, A. J. Am. Chem. Soc. 1938, 60, 2314–2320. 
(180) Bala, T.; Prasad, B. L. V.; Sastry, M.; Kahaly, M. U.; Waghmare, U. V. J. Phys. 
Chem. A 2007, 111, 6183–6190. 
(181) Battin, E. E.; Brumaghim, J. L. J. Inorg. Biochem. 2008, 102, 2036–2042. 
(182) Perkowski, D. A.; Perkowski, M. Data and probability connection. Pearson 







FLUCONAZOLE PRODUCES REACTIVE OXYGEN SPECIES IN THE PRESENCE 
OF COPPER AND IRON TO CAUSE DNA DAMAGE 
 
3.1 Introduction 
Cryptococcus neoformans is a basidiomycetous yeast that causes pneumonia and 
meningitis primarily in immunocompromised patients, and is responsible for 
approximately 620,000 deaths per year.1–3 Global prevalence of cryptococcal disease is 5–
10% in the Americas and Europe and exceeds 15% in South East Asia and Sub-Saharan 
Africa.4,5 Azoles are a class of five-membered heterocyclic compounds containing at least 
one nitrogen atom and drugs containing azoles are commonly used to treat various fungal 
infections. Complexes of three FDA-approved antifungal drugs were tested in the 
Brumaghim group6,7 for their ability to facilitate DNA damage in combination with 
transition metals. In this study, fluconazole (FLC; Figure 3.1), a triazole-containing drug 
that accumulates in the cerebrospinal fluid that has been used as an antifungal agent since 
1990,8,9 is evaluated for its ability to cause DNA damage with copper and iron. FLC and 
clotrimazole (CTZ)7 are being used to treat ectopic as well as systemic fungal infections, 
whereas tinidazole (TNZ) is only approved for topical treatments.6,10 
 FLC is used as an antifungal drug due to its metabolic stability, relatively high 
water-solubility, and good tolerability when used to treat cryptococcosis;11–14,14,15 however, 
due to the fungistatic rather than fungicidal effects of FLC, emergence of FLC resistance 




Figure 3.1. Structures of fluconazole (FLC) and deferoxamine (DFO)  
for FLC drug resistance to develop more effective therapies for cryptococcal meningitis.   
The mechanisms that attribute to the increasing C. neoformans azole drug 
resistance include lanosterol 14α demethylase (ERG11) gene mutation,18 gene 
duplication,19 and drug efflux pump Afr1 upregulation.20,21 In addition, a number of kinases 
involved in TOR signaling (Ypk1, Ipk1, Gsk3), related to vacuole transport (Vps15) and 
involved in the pathogenicity-related kinase cell cycle (Cdc7), are associated with FLC 
resistance.22 FLC inhibits (ERG11), a conserved enzyme that catalyzes the conversion of 
lanosterol to ergosterol.23 Fungal growth arrest upon exposure to FLC is attributed to the 
reduction of ergosterol in the plasma membrane combined with an accumulation of 
potentially toxic sterols.24  
In addition, depletion of ergosterol has been associated with the disruption of V-
ATPase function.25 Only a single copy of the ERG11 gene was mapped to C. neoformans 
chromosome #1 (Chr1).23 However, in FLC resistant strains, Chr1 was found to possess 
disomic duplication.19 Integrity of the endoplasmic reticulum is a major factor in the 
emergence of disomy of Chr1 and Chr4, leading to FLC resistance by overcoming the drug 
stress.26,27 Chr1 contains two genes that are important involved with drug resistance, AFR1, 
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the drug transporter, and ERG11, the target of FLC. Recent findings suggest that 
decoupling of cellular growth and nuclear division during FLC treatment leads to increased 
DNA content, which may be a conserved way to acquire azole resistance in fungal 
pathogens;28,29 however, the exact mechanisms underlying chromosomal changes in cells 
treated with FLC remain unknown.  
Chromosomal instability is associated with chronic oxidative stress mediated by 
elevated reactive oxygen species (ROS), and it is well established that ROS can damage 
DNA. For example, human-hamster hybrid GM10115 cells acquire 22% chromosomal 
instability after exposure to H2O2.
30 In the model organism Saccharomyces cerevisiae, 
mutant strains with impaired DNA repair and reduced ROS scavenging enzymes show 
increased frequency of chromosomal rearrangement upon H2O2 challenge.
31 One ROS, 
hydroxyl radical, is generated by the oxidation of metal ions in vivo and in vitro (Reaction 
1).32 
 Fe2+/Cu+  +  H2O2  → Fe3+/Cu2+  +  •OH  + OH-  (1) 
Metallothioneins (MTs) are cysteine-rich, metal-chelating proteins that help to 
maintain physiological ROS concentrations.33,34 Two copper-detoxifying MTs were 
identified in the C. neoformans proteome: CMT1 (13.4 kDa) and CMT2 (20.1 kDa), both 
of which are upregulated in the presence of copper.35 Metal-chelating domains in C. 
neoformans MTs provide high capacity MT-Cu+ binding, which is critical for 
counteracting the first line of copper-based immunity of the host.36,37 Impaired MT proteins 
result in ROS accumulation and cell cycle arrest in mice embryonic fibroblast cells.38 Thus, 
accumulated evidence suggests that FLC leads to an increase of ROS in C. neoformans, 
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and such a response may lead to chromosomal instability. However, no direct study has 
addressed this possibility. 
Peng et al.39 have determined that FLC induces accumulation of intracellular ROS, 
which correlates with plasma membrane damage in C. neoformans, and caused 
transcription changes of oxidative-stress-related genes encoding superoxide dismutase 
(SOD1), catalase (CAT3), and thioredoxin reductase (TRR1). FLC also increases DNA 
damage in vitro, suggesting that FLC treatment leads to increase of ROS concurrently with 
plasma membrane damage. FLC also triggers adverse transcription of genes encoding 
primary antioxidant defense genes: copper/zinc superoxide dismutase (SOD1)40 and 
catalase (CAT3).39 Consistent with FLC affecting DNA integrity, FLC treatment of C. 
neoformans leads to transcription changes of genes associated with DNA repair and 
chromosome segregation (RAD54 and SCC1).39 These findings suggest that FLC treatment 
results in increase of ROS in C. neoformans and this effect may lead to chromosomal 
instability.41 To evaluate the importance of metal coordination of FLC to iron, 
deferoxamine (DFO), a hexadentate iron chelator produced by soil bacteria to obtain iron 
from their environment,42,43 was tested for its ability to cause or prevent DNA damage 
cause by FLC and iron. Iron chelators have been shown to be effective in killing fungi44,44 
but it has not been fully determined whether iron depletion or another mechanism causes 
the observed fungal killing. 
This work was carried out in collaboration with Prof. Lukasz Kozubowski, 
Department of Genetics and Biochemistry at Clemson University, but this Chapter 
highlights only the in vitro DNA damage assay results performed by the author and does 
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not include the work performed by the collaborators. The majority of this work was 
published in PLOS One (doi: 10.1371/journal.pone.0208471)39 reproduced with 
permission of the publisher (Appendix A), but this Chapter also includes additional studies 
of the effects of ascorbic acid treatment as well as an investigation into the effect of DFO 
addition on FLC’s ability to damage DNA.  
 
3.2 Results and Discussion 
Metal Coordination of FLC and Change to Metal Redox Potential. Since results 
reported by Peng et al.39 suggest an increase of ROS in FLC-treated cells, we hypothesized 
that treatment with FLC leads to chromosomal instability through the mechanism that 
involves ROS. Previous studies by Betanzos-Lara et al.7 and Castro-Ramirez et al.6 have 
indicated that antimicrobial drugs bind metals to potentiate DNA damage. Our hypothesis 
is that most azole containing antifungal drugs coordinate to redox-active transition metals, 
iron and /or copper to change the redox potential resulting in enhanced DNA damage 
abilities and potentially reduced development of drug resistance. 
Most crystal structures of FLC with transition metals have been obtaining using 
hydrothermal growth conditions and therefore may not be biologically relevant. 
Coordination of FLC to copper and iron in aqueous solution was confirmed using MALDI-
TOF mass spectrometry (Table 3.3 and Figure 3.6) and is consistent with the findings of 
Ali et al.45 who synthesized FLC complexes with Cu2+, Fe2+, Cd2+, Co2+, Ni2+, and Mn2+ 
verified the structures of these complexes by further characterization with infrared 
spectroscopy, elemental analysis, UV-vis and NMR spectroscopy. In our mass 
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spectrometry studies, two equivalents of FLC bound per metal ion (Fe2+ and Cu2+). Even 
when metal:FLC ratios were increased to 1:4 or 1:6, only complexes with a 1:2 ratio of 
metal to FLC were observed (Table 3.2 and Figure 3.5). Although Nagaj et al.46 observed 
pH/pD-dependent metal-FLC complexes with a variety of metal:FLC ratios using NMR 
spectroscopy, we chose a ratio of 1:2 metal:FLC for our subsequent electrochemical and 
DNA damage studies since this was the only complex ratio we observed. 
Cyclic voltammetry (CV) experiments were performed on FLC in the presence of 
metal ions to evaluate how FLC binding alters the redox activity of copper and iron. All 
experiments were performed in aqueous solutions at physiologically relevant pH with 
potassium nitrate as supporting electrolyte. FLC alone does not exhibit electrochemical 
activity. Upon addition of FLC to copper, the Cu+/0 and Cu2+/+ redox potentials shift to 
more positive potentials relative to aqueous CuSO4 (E1/2 values of 250 vs. 11 mV, 
respectively), indicating that FLC binding stabilizes hydroxyl-radical-generating Cu+ over 
Cu2+. Similar stabilization of Fe2+ over Fe3+ is observed upon iron-FLC binding (Fe3+/2+ 
E1/2 values shift from 65 mV for aqueous FeSO4 to 98 mV for FeSO4 with FLC). In both 
cases, the redox potentials of the FLC-metal complexes are well within the potential 
window for biological hydroxyl radical generation (-320 to 460 mV).47  
FLC Coordination to Metals Causes DNA Damage in Vitro. The ability of FLC to 
promote DNA damage in the presence of iron and copper was investigated using gel 
electrophoresis studies under physiologically relevant conditions. DNA damage caused by 
increasing concentrations of FLC and iron (in a 2:1 ratio) is shown in Figure 3.2; complete 
data tables for these studies are provided in Tables 3.4 - 3.19. DNA damage is defined as 
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percentage of shift between the fluorescent band corresponding to intact (circular) DNA 
and the band corresponding to the nicked (damaged) DNA. 
Lane 2 in Figures 3.2A and B shows that hydrogen peroxide alone does not cause 
DNA damage. Similarly, FLC in the presence or absence of hydrogen peroxide does not 
cause DNA damage (Figure 3.2A, lanes 3 and 4). Quantification of the band intensities in 
lane 5 (Figure 3.2A) shows that Fe2+ (FeSO4, 2 μM) and hydrogen peroxide cause ~90% 
DNA damage. Increasing concentrations of FLC and Fe2+ in the presence of hydrogen 
peroxide cause DNA damage in a dose-dependent manner (Figure 3.2A, lanes 6–13; Table 
3.1). Addition of FLC (2 μM) and Fe2+ (1 μM) with hydrogen peroxide causes ~90% DNA 




Figure 3.2. Gel electrophoresis images showing FLC-metal-mediated DNA damage for MW: 1 kb molecular 
weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 and A) lane 3: p + FLC (50 μM) + H2O2; lane 4: 
p + FLC (50 μM); lane 5: p + FeSO4 (2 μM) + H2O2; lanes 6-13: p + H2O2 + FLC (0.01, 0.1, 0.5, 1, 2, 4, 10, 
50 μM, respectively) and FeSO4 (0.005, 0.05, 0.25, 0.5, 1, 2, 5, and 25 μM, respectively) or B) lane 3: p + 
H2O2 + FLC (25 μM); lane 4: p + FLC (25 μM); lane 5: p + H2O2 + CuSO4 (6 μM) + ascorbate (7.5 μM); 
lane 6: p + H2O2 + CuSO4 (12.5 μM); lanes 7-12: p + H2O2 + FLC (0.1, 1, 5, 10, 18, 25 μM, respectively) + 




Similar DNA damage assays were conducted to evaluate the effects of FLC with Cu2+ on 
DNA damage. 
The plasmid DNA band intensities from these studies were quantified to obtain 
EC50 plots (Figure 3.3), showing the Fe
2+ or Cu+ concentrations needed to cause 50% DNA 
damage in the presence of FLC and hydrogen peroxide. An EC50 value of 0.46 ± 0.01 μM 
(p < 0.001) was determined for Fe2+ and FLC with H2O2. The EC50 plots in Figure 3.3A 
illustrate that addition of FLC shifts the iron-mediated DNA damage curve so that lower 
concentrations of iron in combination with FLC cause the same damage. Statistical 
analyses indicate that this enhancement of iron-mediated DNA damage in the presence of 
FLC is significant (Figure 3.3A, Table 3.19). 
In similar studies with Cu2+ and FLC, DNA damage is observed in the presence of 
hydrogen peroxide upon increasing concentrations of FLC and Cu2+ concentrations ranging 
from 5 to 12.5 μM (Figure 3.2, lanes 7–12 and Fig 3.11B), suggesting that the observed 
DNA damage results from copper-FLC binding. A maximum of 40% DNA damage is 
 
Figure 3.3. Dose-response curves of DNA damage by A) Fe2+, H2O2 with and without FLC and B) Cu2+, 




Table 3.1. EC50 table of iron or copper with and without FLC and the effect of ascorbate (AA). 
DNA Assay Conditions EC50 FLC [μM Cu] EC50 [μM Cu] 
Cu2+ No damage (0.05-300 μM) No damage (0.05-300 μM) 
Cu2+ + H2O2 40% DNA damage @12.5 μM No damage (0.05-12.5 μM) 
Cu2+ + AA 17.74 ± 0.03 25.61 ± 0.05 
Cu2+ + AA + H2O2 4.62 ± 0.01 2.45 ± 0.01 
 EC50 FLC [μM Fe] EC50 [μM Fe] 
Fe2+ No damage (0.05-300 μM) No damage (0.05-300 μM) 
Fe2+ + H2O2 0.46 ± 0.01 1.04 ± 0.01 
Fe2+ + AA 180.8 ± 0.3 187.7 ± 0.4 
Fe2+ + AA + H2O2 0.68 ± 0.01 0.76 ± 0.01 
 
observed with 25 μM FLC and 12.5 μM Cu2+ (Figure 4.2B, lane 12), whereas Cu2+ at the 
same concentration without FLC addition does not cause any DNA damage. Since FLC 
alone does not damage DNA, these results highlight the importance of metal binding for 
FLC-mediated DNA damage. These plasmid damage assay results indicate that FLC 
binding to iron or copper significantly increases the metal’s ability to generate ROS 
generation and DNA damage (Table 3.1). 
To evaluate whether addition of ascorbic acid changes the effectiveness of FLC in 
causing DNA damage in the presence of Cu2+ or Fe2+, 1.25 equiv. of ascorbic acid was 
added per metal ion. In the Fe2+ system, added ascorbate with and without FLC addition 
results in EC50 values of 187.8 ± 0.4 μM and 180.8 ± 0.3 μM, respectively. When Cu2+ is 
reduced to DNA-damaging Cu+ by ascorbate addition prior to hydrogen peroxide, DNA 
damage is observed (Figure 4.2B, lane 5), and the EC50 value under these conditions is 2.45 
± 0.01 μM. 
 In general, FLC increases copper and irons ability to cause DNA damage. The most 
significant effect is observed when the copper and ascorbate or iron and H2O2 are combined 
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with FLC. FLC halves the EC50 for iron-mediated DNA damage and, in the case of copper, 
changes the stabilizes the more reactive Cu+ resulting in DNA damage.  
FLC-Iron-mediated DNA Damage with DFO Treatment. To evaluate whether FLC 
has similar DNA damaging effects if iron is chelated, one equivalent of the hexadentate 
chelator deferoxamine (DFO), a siderophore produced by soil bacteria and FDA-approved 
drug to treat iron overload,48,49 was added to the Fe2+ solution (prepared with FeSO4) prior 
to addition of DNA. DFO has a low dissociation constant with iron (Kd = 10
-31 M),50 so it 
will completely coordinates Fe2+ under the gel conditions. Upon DFO addition, an EC50 of 
7.84 μM ± 0.03 is measured for iron-mediated DNA damage in the presence of hydrogen 
peroxide (Figure 4.13F). For similar DNA damage studies with DFO, constant 
concentrations of 9 μM each for Fe2+ and DFO were chosen because this concentration 
range close to the EC50 for iron-coordinated DFO in the presence of hydrogen peroxide, 
allowing both increased and decreased DNA damage to be readily quantified. FLC in 
various concentrations was added with Fe2+/DFO under these conditions at 1/3:1, 1:1, 3:1 
and 9:1 ratios of FLC to Fe2+/DFO. No change in DNA damage upon addition of FLC 
relative to the Fe:DFO control lanes is observed (Figure 3.4), indicating that direct FLC-
iron coordination is responsible for its enhancement of iron-mediated DNA damage. In 
addition, these results strengthen the observation that FLC-metal coordination is essential 






Figure 3.4. Percent DNA damage caused by Fe2+ (2 µM) + H2O2 and Fe2+ (9 µM) + DFO (9 µM) + H2O2 
with and without FLC addition (3 µM, 9 µM, 27 µM, and 81 µM, respectively). 
 
3.3 Conclusion 
 Electrochemical studies demonstrate that FLC-metal binding favors Cu+ and Fe2+ 
over Cu2+ and Fe3+, respectively, and mass spectrometry studies indicate FLC-metal 
coordination ratios of only 2:1. Plasmid DNA damage studies show that FLC causes no 
DNA damage by itself or in combination with H2O2 or ascorbate. However, FLC enhancs 
the ability of copper and iron to cause DNA damage, halving the EC50 for iron-mediated 
DNA damage. These experiments highlight the impact of metals for FLC mediated DNA 
damage. Research to date has primarily focused on the impact FLC has on the cell 
membrane of C. neoformans, but these studies show that FLC mechanism of action is more 
complex and could be modulated through the addition of different drugs resulting in drug 
synergism. Since the FLC resistance of C. neoformans is increasing, the use of FLC-metal 
complexes would be worth exploring to enhance DNA damage to the pathogen and reduce 
the development of resistant strains. 
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3.4 Experimental and Methods 
Materials. Water was deionized (diH2O) using a Nano Pure DIamond Ultrapure 
H2O system (Barnstead International). CuSO4 and H2O2 were purchased from Fisher. 3-
(N-morpholino)propanesulfonic acid (MOPS), were attained from Sigma Aldrich. 2-(N-
morpholino)ethanesulfonic acid (MES) was obtained from BDH. FeSO4 was purchased 
from Acros. Ascorbic acid, 99% fluconazole, and NaCl were obtained from Alfa Aesar. 
Mass spectrometry. Matrix assisted laser desorption/ionization time of flight 
(MALDI-TOF) mass spectrometry experiments were performed using a Bruker Microflex 
mass spectrometer with trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenyldiene (250.34 
m/z) as the matrix. Samples with 1:1 and 1:4 Cu2+: FLC ratios were prepared by combining 
aqueous solutions of CuSO4 (100 µL; 300 µM) and fluconazole (100 µL; 300 or 1200 µM, 
respectively). Samples with 1:1 and 1:6 Fe2+: FLC ratios were made by combining aqueous 
solutions of FeSO4 (100 µL; 300 µM) and fluconazole (100 µL; 300 or 1800 µM, 
respectively). 
Electrochemical studies of FLC and FLC-metal complexes. Cyclic voltammetry 
(CV) was conducted with a CH Electrochemical Analyzer (CH Instruments, Inc.) at a 
sweep rate of 100 mV/s using a glassy carbon working electrode, a Pt counter electrode, 
and a Ag/AgCl (+0.197 V vs. NHE).51 All experiments were externally referenced to 
potassium ferricyanide (0.361 V vs. NHE).51 Studies were conducted in degassed MOPS 
buffer (10 mM, pH 7.0) for FLC and copper studies or MES buffer (10 mM, pH 6.0) for 
iron studies, with KNO3 (100 mM) as a supporting electrolyte. For iron binding studies, a 
solution of 1:2 iron-FLC ratio was made by adding aqueous solutions of FeSO4 (3 mL; 900 
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µM) and FLC (3 mL; 1800 µM), then diluting with the MES buffer (3 mL; 30 mM). For 
the copper study, a 1:2 solution was made by adding CuSO4 (3 mL; 300 µM) to FLC (3 
mL; 900 µM), then diluting with the MOPS buffer (3 mL; 30 mM). All samples were 
deaerated for 10 minutes with N2 before each experiment. Samples were cycled between  
-0.6 and 1.0 V for copper and -1.0 and 1.0 V for iron complexes. 
Plasmid DNA transfection, amplification, and purification. Plasmid DNA (pBSSK) 
was purified from DH1 E. coli competent cells using a ZyppyTM Plasmid Miniprep Kit 
(400 count, Zymo Research). Tris-EDTA buffer (pH 8.01) was used to elude the plasmid 
from the spin columns. Plasmid was dialyzed against 130 mM NaCl for 24 hours at 4°C to 
ensure all Tris-EDTA buffer and metal contaminates were removed, and plasmid 
concentration was determined by UV-vis spectroscopy at a wavelength of 260 nm. 
Absorbance ratios of A250/A260   0.95 and A260/A280  1.8 were determined for DNA used 
in all experiments. Plasmid purity was determined through digestion of plasmid (0.1 pmol) 
with Sac 1 and KpN1 in a mixture of NEB buffer and BSA (bovine serum albumin) at 37°C 
for 90 minutes. Digested plasmids were compared to an undigested plasmid sample and a 
1 kb molecular weight marker using gel electrophoresis. 
DNA damage gel electrophoresis experiments. Deionized water, MOPS buffer (10 
mM, pH 7.0), NaCl (130 mM), ethanol (100% metal free, 10 mM), as well as the indicated 
concentrations of CuSO4∙5H2O, AA (7.5 µM, to reduce Cu2+ to Cu+), and FLC were 
combined in an acid-washed (1 M HCl for ~ 1 h) microcentrifuge tube and allowed to stand 
for 5 min at room temperature. Plasmid (pBSSK, 0.1 pmol in 130 mmol NaCl) was then 
added to the reaction mixture and allowed to stand for 5 min at room temperature. H2O2 
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(50 µM) was added and allowed to react at room temperature for 30 min. EDTA (50 µM) 
was added after 30 min to quench the reaction. For the Fe2+ DNA damage experiments, the 
indicated FeSO4∙7H2O concentrations and MES (10 mM, pH 6.0) were used. All 
concentrations are final concentrations in a 10 µM volume. Samples were loaded into a 1% 
agarose gel in a TAE running buffer (50); damaged and undamaged plasmid was 
separated by electrophoresis (140 V for 60 min). Gels were stained using ethidium bromide 
and imaged using UV light. The amounts of nicked (damaged) and circular (undamaged) 
were analyzed using UViProMW (Jencons Scientific Inc., 2007). Intensity of circular 
plasmid was multiplied by 1.24, due to the lower binding affinity of ethidium bromide to 
supercoiled plasmid.52,53 Intensities of the nicked and supercoiled bands were normalized 
for each lane so that % nicked + % supercoiled = 100%. All percentages were corrected 
for residual nicked DNA prior to calculation. Results were obtained in triplicate for all 
experiments, and standard deviations are represented as error bars. The plots of percent 
DNA damage versus log concentration of copper or iron were fit to a variable-slope 
sigmoidal dose-response curve using SigmaPlot (v. 11.0, Systat Software, Inc.). 
EC50 Determination. Plots of percent DNA damage versus log concentration of 
FLC or the respective metal were fit to a variable slope sigmoidal dose-response curve 
using SigmaPlot, version 11 (Systat Software, Inc.). EC50 value errors were calculated from 
error propagation of the gel electrophoresis measurements. Statistical significance was 
determined by calculating p values at 95% confidence (p < 0.05 indicates significance) as 




3.5. Supporting Information 
 
Table 3.2. MALDI mass spectrometry data for FLC with Fe2+ and Cu2+ prepared in H2O. 
Metal m/z (Da) Metal:Ligand Ratio 
Copper 693.1 1:2 










Table 3.3. CV data for FLC with Fe2+ and Cu2+. 
Metal Epa (mV) Epc (mV) ΔE (mV) E1/2 (mV) 
FLC - - - - 
Copper -83a, 121b -796a, -100b 713a, 212b -440a, 11b 
Copper: FLC (1:2) -73a, 342b -124a, 157b 51a, 499b -99a, 250b 
Iron 263 -133 396 65 
Iron: FLC (1:2) 324 -128 452 98 
a Cu+/0 potential. b Cu2+/+ potential. 
  
  
Figure 3.6. Cyclic voltammograms for A) CuSO4 (100 μM), B) 1:2 Cu2+:FLC (100 μM:200 μM) in MOPS 
buffer (10 mM, pH 7.0), C) FeSO4 (300 μM), and D) 1:2 Fe2+:FLC (300 μM:600 μM) in MES buffer (10 
mM, pH 6.0). All contain KNO3 (10 mM) as a supporting electrolyte. All samples were cycled at a scan 






Figure 3.7: Cyclic voltammograms for FLC (300 μM) in MES buffer (10 mM, pH 6.0) with KNO3 (10 




Figure 3.8. Gel image of DNA damage by iron with and without H2O2 and FLC. For all gel images, MW: 1 
kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2. (50 μM); A) lane 3: p + FeSO4 (2 
μM) + H2O2; lanes 4-12: p + FeSO4 (0.05, 0.5, 5, 25, 37.5, 50, 75, 100, and 150 μM, respectively); B) lanes 
3-10: p + H2O2 + FeSO4, (0.005, 0.5, 0.25, 0.5, 1, 2, 5, and 12.5 μM, respectively); C) lane 3: p + FLC (200 
μM); lane 4: p + FeSO4 (2 μM) + H2O2; lanes 5-10: p + FLC (0.1, 1, 10, 50, 100, and 200 μM, respectively) 






Figure 3.9. Gel image of DNA damage by iron with and without H2O2 and FLC and ascorbate. For all gel 
images, MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2. (50 μM); A) lane 
3: p +ascorbate (375 μM); lane 4: p + FeSO4 (2 μM) + H2O2; lane 5-11: p + FeSO4 (2, 10, 25, 50, 100, 150, 
500 μM, respectively) + ascorbate (2.5, 12.5, 31.25, 62.5, 125, 187.5, and 375 μM, respectively); B) lane 3: 
p + FLC (600 μM); lane 4: p + H2O2 + FeSO4 (2 μM); lanes 5-11: p + FeSO4 (2, 10, 25, 50, 100, 150, and 
300 μM, respectively) + ascorbate (3.5, 12.5, 31.25, 62.5, 125, 187.5, and 375 μM, respectively) + FLC (4, 
20, 50, 100, 200, 300, and 600 μM, respectively); C) lane 3: p + H2O2 + FeSO4 (2 μM); lanes 4-12: p + FeSO4 
(0.005, 0.5, 0.25, 0.5, 0.75, 1, 1.5, 2 and 5 μM, respectively) + ascorbate (0.00625, 0.0625, 0.3125, 0.625, 
0.9375, 1.25, 1.875, 2.5 and 6.25 μM, respectively); D) lane 3: p + H2O2+ FLC (20 μM) + ascorbate (12.5 
μM); lane 4: p + H2O2 + FeSO4 (2 μM); lanes 5-13: p + H2O2 + FeSO4 (0.005, 0.5, 0.25, 0.5, 0.75, 1, 1.5, 2 
and 5 μM, respectively) + FLC (0.01, 0.1, 0.5, 1, 1.5, 2, 3, 4,and 10 μM, respectively) + ascorbate (0.00625, 





Figure 3.10. Gel image of DNA damage by copper FLC, H2O2 and, where indicated, ascorbate. For all gel 
images, MW: 1 kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 (50 μM); A) lanes 
3-15: p + H2O2 + CuSO4 (0.05, 0.5, 2, 3, 4, 5, 6, 7, 8 and 12.5 μM, respectively) + ascorbate (0.0625, 0.625, 
2.5, 3.75, 5, 6.25, 7.5, 8.75, 10 and 15.625 μM, respectively); B) lane 3: p + FLC (600 μM); lane 4: p + H2O2 
+ CuSO4 (6 μM) + ascorbate (7.5 μM); lane 5: p + CuSO4 (300 μM); lanes 6-11: p + FLC (0.1, 1, 10, 100, 
300, and 600 μM, respectively) + CuSO4 (0.05, 0.5, 5, 50, 150, and 300 μM, respectively); C) lane 3: p + 
FLC (600 μM); lane 4: p + H2O2 + CuSO4 (6 μM) + ascorbate (7.5 μM); lanes 5-12: p + CuSO4 (0.05, 0.5, 5, 
12.5, 25, 50, 150, and 300 μM, respectively) + ascorbate (0.0625, 0.625, 6.25, 15.625, 31.25, 62.5, 187.5, 
and 375 μM, respectively) + FLC (0.1, 1, 10, 25, 50, 100, 300, and 600 μM, respectively); D) lane 3: p + 
H2O2 + FLC (25 μM); lane 4: p + FLC (25 μM); lane 5: p + H2O2+ CuSO4 (6 μM) + ascorbate (7.5 μM); lane 
6: p + H2O2 + CuSO4 (12.5 μM); lanes 7-12: p + H2O2 + FLC (0.1, 1, 5, 10, 18, and 25 μM, respectively) + 
CuSO4 (0.05, 0.5, 2.5, 5, 9, and 12.5 μM, respectively); E) lane 3: p + H2O2 + FLC (600 μM); lane 4: p + 
FLC (600 μM); lane 5: p + H2O2 + FLC (600 μM) + ascorbate (375 μM); lane 6: p + FLC (600 μM) + 
ascorbate (375 μM); lane 7: p + H2O2 + CuSO4 (6 μM) + ascorbate (7.5 μM); lanes 8-15: p + H2O2 + CuSO4 
(0.05, 0.5, 5, 12.5, 25, 50, 150, and 300 μM, respectively) + ascorbate (0.0625, 0.625, 6.25, 15.625, 31.25, 





Figure 3.11. Gel image of DNA damage by copper or iron FLC, H2O2, and DFO. For all gel images, MW: 1 
kb molecular weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2. (50 μM); A) lane 3:p + H2O2 + 
DFO (50 μM); lane 4: p + DFO (50 μM); lane 5: p + FeSO4 (50 μM) + DFO (50 μM); lane 6: p + H2O2 + 
FeSO4 (2 μM); lanes 7-8: p + H2O2 +FeSO4 (0.1, 1, 2, 5, 7.5, 10, 25, and 50 μM, respectively) + DFO (0.1, 
1, 2, 5, 7.5, 10, 25, and 50 μM, respectively, respectively); B) lane 3: p + FeSO4 (9 μM); lane 4: p + H2O2 + 
FLC (9 μM); lane 5: p + H2O2+ FeSO4 (9 μM) + DFO (9 μM); lane 6: p + FeSO4 (9 μM) + DFO (9 μM); lane 
7: p + H2O2 + FeSO4 (2 μM); lanes 8-10: p + H2O2 + FeSO4 (9 μM) + DFO (9 μM) + FLC (3 μM); lanes 11-
13: p + H2O2 + FeSO4 (9 μM) + DFO (9 μM) + FLC (9 μM); lanes 14-16: p + H2O2 + FeSO4 (9 μM) + DFO 







Figure 3.12. Dose-response curves for DNA damage by A) Cu2+ and FLC, B) Cu2+, FLC, and H2O2, and C) 





Figure 3.13. Dose-response curves for DNA damage by A) Fe2+; B) Fe2+ and FLC; C) Fe2+ and ascorbate 





Table 3.4. Gel electrophoresis results for FLC DNA damage assays with Cu2+ and H2O2.a 





% Damage p Value 
1: plasmid DNA (p) 0 99.87 ± 0.19 0.13 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + FLC + H2O2 25 100 ± 0 0 - - 
4: p + FLC 25 100 ± 0 0 - - 
5: p + Cu2+ (6 µM) + AA (7.5 µM) 
+ H2O2 
0 4.42 ± 0.05 95.58 - - 
6: p + Cu2+ (12.5 µM) + H2O2 0 100 ±0 0 -1 ± 0 < 0.001 
7: p + Cu2+ (0.05 μM) + FLC + 
H2O2 
0.5 99.91 ± 0.12 0.09 -0.91 ± 0 < 0.001 
8: p + Cu2+ (0.5 μM) + FLC + 
H2O2 
1 100 ± 0 0 -1 ± 0 < 0.001 
9: p + Cu2+ (2.5 μM) + FLC + 
H2O2 
5 100 ± 0 0 -1 ± 0 < 0.001 
10: p + Cu2+ (5 μM) + FLC + H2O2 10 96.68 ± 2.54 3.32 2.32 ± 2.54 0.254 
11: p + Cu2+ (9 μM) + FLC + H2O2 18 81.57 ± 2.49 18.43 17.43 ±2.49 0.007 
12: p + Cu2+ (12.5 μM) + FLC + 
H2O2 
25 63.33 ± 5.6 36.67 35.67 ± 5.6 0.008 
aData are reported as the average of three trials with calculated standard deviations shown. 








% Damage  p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + FLC + H2O2 600 100 ± 0 0 - - 
4: p + FLC 600 100 ± 0 0 - - 
5: p + Cu2+ (6 µM) + AA (7.5 µM) + 
H2O2 
0 18.40 ± 3.29 81.60 - - 
6: p + Cu2+ (0.05 µM) + AA (0.0625 
µM) + FLC + H2O2 
0.1 99.97 ± 0.03 0.03 -0.97 ± 0.03 < 0.001 
7: p + Cu2+ (0.5 μM) + AA (0.625 µM) 
+ FLC + H2O2 
1 100 ± 0 0 -1 ± 0 < 0.001 
8: p + Cu2+ (5 μM) + AA (6.25 µM) + 
FLC + H2O2 
10 71.44 ± 3.11 28.56 27.56 ± 3.11 0.004 
9: p + Cu2+ (12.5 μM) + AA (15.625 
µM) + FLC + H2O2 
25 0.12 ± 0.17 99.88 98.88 ± 0.17 < 0.001 
10: p + Cu2+ (25 μM) + AA (31.25 µM) 
+ FLC + H2O2 
50 0 ± 0 100 99.00 ± 0 < 0.001 
11: p + Cu2+ (50 μM) + AA (62.5 µM) + 
FLC + H2O2 
100 0.24 ± 0.34 99.76 98.76 ±0.34 < 0.001 
12: p + Cu2+ (150 μM) + AA (187.5 
µM) + FLC + H2O2 
300 0.65 ± 0.92 99.35 98.35 ±0.92 < 0.001 
13: p + Cu2+ (300 μM) + AA (375 µM) 
+ FLC + H2O2 
600 0 ± 0 100.00 99.00 ± 0 < 0.001 












% Damage  p Value 
1: plasmid DNA (p) 0 100 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0.00 - - 
3: p + FLC + H2O2 600 99.97 ± 0.03 0.03 - - 
4: p + Cu2+ (6 µM) + AA (7.5 µM) 0 18.40 ± 3.29 81.60 - - 
5: p + Cu2+ (0.05 µM) + AA (0.0625 
µM) + FLC 
0.1 100 ± 0 0.00 -1 ± 0 < 0.001 
6: p + Cu2+ (0.5 µM) + AA (0.625 µM) + 
FLC 
1 99.93 ± 0.13 0.07 -0.97 ± 0.13 0.006 
7: p + Cu2+ (5 μM) + AA (6.25 µM) + 
FLC 
10 100 ± 0 0.00 -1 ± 0 < 0.001 
8: p + Cu2+ (12.5 μM) + AA (15.625 µM) 
+ FLC 
25 93.10 ± 5.99 6.90 5.90 ± 5.99 0.230 
9: p + Cu2+ (25 μM) + AA (31.25 µM) + 
FLC 
50 7.36 ± 5.29 92.64 91.64 ± 5.29 0.001 
10: p + Cu2+ (75 μM) + AA (91.75 µM) 
+ FLC 
150 0.40 ± 0.70 99.60 98.60 ± 0.70 < 0.001 
11: p + Cu2+ (150 μM) + AA (187.5 µM) 
+ FLC 
300 0 ± 0 100.00 99.00 ± 0 < 0.001 
12: p + Cu2+ (300 μM) + AA (375 µM) + 
FLC 
600 0 ± 0 100.00 99.00 ± 0 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 







% Damage  p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + FLC 600 100 ± 0 0 - - 
4: p + Cu2+ (6 µM) + AA (7.5 µM) + 
H2O2 
0 18.40 ± 3.29 81.60 - - 
5: p + Cu2+ (300 μM) 0 100 ± 0 0 -1 ± 0 < 0.001 
6: p + Cu2+ (0.05 μM) + FLC 0.1 100 ± 0 0 -1 ± 0 < 0.001 
7: p + Cu2+ (0.5 μM) + FLC 1 100 ± 0 0 -1 ± 0 < 0.001 
8: p + Cu2+ (5 μM) + FLC 10 100 ± 0 0 -1 ± 0 < 0.001 
9: p + Cu2+ (50 μM) + FLC 100 100 ± 0 0 -1 ± 0 < 0.001 
10: p + Cu2+ (150 μM) + FLC 300 100 ± 0 0 -1 ± 0 < 0.001 
11: p + Cu2+ (300 μM) + FLC 600 100 ± 0 0 -1 ± 0 < 0.001 












% Damage p Value 
1: plasmid DNA (p) 0 99.94 ± 0.09 0.06 – – 
2: p + H2O2 0 99.85 ± 0.27 0.15 – – 
3: p + Cu2+ + AA (7.5 μM) + H2O2 6 12.44 ± 3.47 87.56 - – 
4: p + Cu2+ + AA (1.25 μM) 1 100 ± 0 0 -1.15 ± 0.27 < 0.001 
5: p + Cu2+ + AA (7.5 μM) 6 97.03 ± 1.18 2.97 1.82 ± 1.09 0.102 
6: p + Cu2+ + AA (11.25 μM) 9 96.57 ± 0.57 3.43 2.28 ± 0.70 0.030 
7: p + Cu2+ + AA (18.75 μM) 15 93.10 ± 1.45 6.90 5.74 ± 1.63 0.026 
8: p + Cu2+ + AA (31.25 μM) 25 46.72 ± 3.87 53.28 52.13 ± 4.14 0.002 
9: p + Cu2+ + AA (43.75 μM) 35 28.03 ± 0.62 71.97 70.82 ± 0.86 < 0.001 
10: p + Cu2+ + AA (62.5 μM) 50 15.39 ± 7.00 84.61 83.45 ± 6.82 0.002 
11: p + Cu2+ + AA (93.75 μM) 75 2.50 ± 2.71 97.50 96.34 ± 2.50 < 0.001 
12: p + Cu2+ + AA (125 μM) 100 0.00 ± 0 100.00 98.85 ± 0.27 < 0.001 
13: p + Cu2+ + AA (625 μM) 500 0.14 ± 0.24 99.86 98.71 ± 0.51 < 0.001 
14: p + Cu2+ + AA (1250 μM) 1000 0.49 ± 0.69 99.51 98.36 ± 0.64 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage  p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ±0 0 - - 
3: p + Cu2+ + AA (0.0625 µM) + H2O2 0.05 100 ± 0 0 ± 0 0 ± 0  
4: p + Cu2+ + AA (0.625 µM) + H2O2 0.5 100 ± 0 0 ± 0 0 ±0  
5: p + Cu2+ + AA (2.5 µM) + H2O2 2 60.86 ± 2.73 39.14 38.14 ± 2.73 0.002 
6: p + Cu2+ + AA (3.75 µM) + H2O2 3 35.39± 7.79 64.61 63.61 ± 7.79 0.005 
7: p + Cu2+ + AA (5 µM) + H2O2 4 22.99 ±5.44 77.01 76.01 ± 5.44 0.002 
8: p + Cu2+ + AA (6.25 µM) + H2O2 5 9.86 ± 3.96 90.14 89.14 ± 3.96 < 0.001 
9: p + Cu2+ + AA (7.5 µM) + H2O2 6 7.42 ± 2.17 92.58 92.58 ± 2.17 < 0.001 
10: p + Cu2+ + AA (8.75µM) + H2O2 7 2.28 ± 3.52 97.72 96.72 ± 3.52 < 0.001 
11: p + Cu2+ + AA (10 µM) + H2O2 8 0.00 ± 0 100.00 99.0 ± 0 < 0.001 
12: p + Cu2+ + AA (15.625 µM) + 
H2O2 
12.5 
0.00 ± 0 100.00 
100 ± 0 
< 0.001 











% Damage p Value 
1: plasmid DNA (p) 0 100 ±0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + FLC + H2O2 50 100 ± 0 0 - - 
4: p + FLC 50 100 ± 0 0 - - 
5: p + Fe2+ (2 μM) + H2O2 0 6.35 ±5.53 93.65 - - 
6: p + Fe2+ (0.005 μM) + FLC + H2O2 0.01 100 ± 0 0 -1 ± 0 < 0.001 
7: p + Fe2+ (0.05 μM) + FLC + H2O2 0.1 90.20 ± 0.10 9.8 8.8 ± 0.01 < 0.001 
8: p + Fe2+ (0.25 μM) + FLC + H2O2 0.5 60.46 ± 0.58 39.54 38.54 ± 0.58 < 0.001 
9: p + Fe2+ (0.5 μM) + FLC + H2O2 1 61.65 ±1.22 38.35 37.35 ± 1.22 < 0.001 
10: p + Fe2+ (1 μM) + FLC + H2O2 2 11.95 ± 5.69 88.05 87.05 ± 5.69 0.001 
11: p + Fe2+ (2.5 μM) + FLC + H2O2 5 3.03 ± 4.28 96.97 95.97 ± 4.28 < 0.001 
12: p + Fe2+ (5 μM) + FLC + H2O2 10 3.79 ± 0.76 96.21 95.21 ± 0.76 < 0.001 
13: p + Fe2+ (25 μM) + FLC + H2O2 50 4.43 ± 2.02 95.57 94.57 ± 2.02 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 







% Damage  p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + Fe2+ + H2O2 0.005 100 ± 0 0 -1 ± 0 < 0.001 
4: p + Fe2+ + H2O2 0.05 100 ± 0 0 -1 ± 0 < 0.001 
5: p + Fe2+ + H2O2 0.25 100 ± 0 0 -1 ± 0 < 0.001 
6: p + Fe2+ + H2O2 0.5 100 ± 0 0 -1 ± 0 < 0.001 
7: p + Fe2+ + H2O2 1 53.49 ± 5.0 46.51 45.51 ± 5.0 0.004 
8: p + Fe2+ + H2O2 2 9.51 ± 5.88 90.49 89.49 ± 5.88 0.001 
9: p + Fe2+ + H2O2 5 0.73 ± 1.03 99.27 98.27 ± 1.03 < 0.001 
10: p + Fe2+ + H2O2 12.5 1.51 ± 2.14 98.49 97.49 ± 2.14 < 0.001 











% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + FLC + H2O2 200 100 ± 0 0 - - 
4: p + Fe2+ (2 μM) + H2O2 0 16.35 ± 5.53 83.65 - - 
5: p + Fe2+ (0.05 μM) + FLC 0.1 100 ± 0 0 -1 ± 0 < 0.001 
6: p + Fe2+ (0.5 μM) + FLC 1 100 ±0 0 -1 ± 0 < 0.001 
7: p + Fe2+ (5 μM) + FLC 10 100 ±0 0 -1 ± 0 < 0.001 
8: p + Fe2+ (25 μM) + FLC 50 100 ±0 0 -1 ± 0 < 0.001 
9: p + Fe2+ (50 μM) + FLC 100 100 ±0 0 -1 ± 0 < 0.001 
10: p + Fe2+ (100 μM) + FLC 200 100 ±0 0 -1 ± 0 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage p Value 
1: plasmid DNA (p) 0 100 ± 0 0 - - 
2: p + H2O2 (50 µM) 0 100 ± 0 0 - - 
3: p + Fe2+ + H2O2 0 6.35 ± 5.53 93.65 - - 
4: p + Fe2+ 0.005 100 ±0 0 -1 ± 0 < 0.001 
5: p + Fe2+ 0.5 100 ± 0 0 -1 ± 0 < 0.001 
6: p + Fe2+ 5 100 ± 0 0 -1 ± 0 < 0.001 
7: p + Fe2+ 25 100 ± 0 0 -1 ± 0 < 0.001 
8: p + Fe2+ 37.5 100 ± 0 0 -1 ± 0 < 0.001 
9: p + Fe2+ 50 100 ± 0 0 -1 ± 0 < 0.001 
10: p + Fe2+ 75 100 ± 0 0 -1 ± 0 < 0.001 
11: p + Fe2+ 100 100 ± 0 0 -1 ± 0 < 0.001 
12: p + Fe2+ 150 100 ± 0 0 -1 ± 0 < 0.001 












% Damage  
p 
Value 
1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.77 ± 0.21 0.23 - - 
3: p + AA (375 µM)  97.36 ± 4.57 2.64 - - 
4: p + Fe2+ + H2O2 2 13.62 ± 4.56 86.38 - - 
5: p + Fe2+ + AA (2.5 µM) 2 100.00 ± 0 0.00 -0.23 ± 0 
< 
0.001 
6: p + Fe2+ + AA (12.5 µM) 10 99.97 ± 0.06 0.03 -0.20 ± 0.06 0.029 
7: p + Fe2+ + AA (31.25 µM) 25 99.93 ± 0.13 0.07 -0.16 ± 0.13 0.167 
8: p + Fe2+ + AA (62.5 µM) 50 99.95 ± 0.08 0.05 -0.18 ± 0.08 0.060 
9: p + Fe2+ + AA (125 µM) 100 91.94 ± 2.96 8.06 7.83 ± 2.96 0.045 
10: p + Fe2+ + AA (187.5 µM) 150 68.66 ± 2.77 31.34 31.11 ± 2.77 0.003 
11: p + Fe2+ + AA (375 µM) 300 26.24 ± 5.73 73.76 73.53 ± 5.73 0.002 
aData are reported as the average of three trials with calculated standard deviations shown. 
 








% Damage  
p 
Value 
1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 98.49 ± 2.07 1.51 - - 
3: p + FLC + AA (12.5 µM) + H2O2 20 98.46 ± 2.66 1.54 - - 
4: p + Fe2+ (µM) + H2O2 0 10.17 ± 8.90 89.83 - - 
5: p + FLC + Fe2+ (0.005 µM) + AA 
(0.00625 µM) + H2O2 
0.01 99.89 ± 0.26 0.11 -1.40 ± 0.26 0.011 
6: p + FLC + Fe2+ (0.05 µM) + AA 
(0.0625 µM) + H2O2 
0.1 99.89 ± 0.23 0.11 0.11 ± 0.23 0.495 
7: p + FLC + Fe2+ (0.25 µM) + AA 
(0.3125 µM) + H2O2 
0.5 55.41 ± 4.75 44.59 43.08 ± 4.75 0.004 
8: p + FLC + Fe2+ (0.5 µM) + AA 
(0.625 µM) + H2O2 
1 53.56 ± 4.75 46.44 44.93 ± 4.75 0.004 
9: p + FLC + Fe2+ (0.75 µM) + AA 
(0.9375 µM) + H2O2 
1.5 34.53 ± 8.93 65.47 63.96 ± 8.93 0.006 
10: p + FLC + Fe2+ (1 µM) + AA (1.25 
µM) + H2O2 
2 6.46 ± 6.69 93.54 92.03 ± 6.69 0.002 
11: p + FLC + Fe2+ (1.5 µM) + AA 
(1.875 µM) + H2O2 
3 1.53 ± 3.27 98.47 96.96 ±3.27 
< 
0.001 
12: p + FLC + Fe2+ (2 µM) + AA (2.5 
µM) + H2O2 
4 0.29 ± 0.51 99.71 98.20 ± 0.51 
< 
0.001 
13: p + FLC + Fe2+ (5 µM) + AA (6.25 
µM) + H2O2 
10 0.01 ± 0.01 99.99 98.48 ± 0.01 
< 
0.001 













% Damage  p Value 
1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.95 ± 0.09 0.05 - - 
3: p + FLC 600 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) 0 6.72 ± 3.60 93.28 - - 
5: p + Fe2+ (2 µM) + AA (1.5 µM) + FLC 4 97.05 ± 4.96 2.95 2.90 ± 4.96 0.418 
6: p + Fe2+ (10 µM) + AA (12.5 µM) + 
FLC 
20 
97.15 ± 4.76 2.85 2.80 ± 4.76 
0.415 
7: p + Fe2+ (25 µM) + AA (31.25 µM) + 
FLC 
50 
96.80 ± 4.93 3.20 3.15 ± 4.93 
0.384 
8: p + Fe2+ (50 µM) + AA (62.5 µM) + 
FLC 
100 
95.27 ± 3.27 4.73 4.68 ± 3.27 
0.131 
9: p + Fe2+ (100 µM) + AA (125 µM) + 
FLC 
200 
81.35 ± 4.15 18.65 18.60 ± 4.15 
0.016 
10: p + Fe2+ (150 µM) + AA (187.5 µM) + 
FLC 
300 
59.31 ± 3.03 40.69 40.64 ± 3.03 
0.002 
11: p + Fe2+ (300 µM) + AA (375 µM) + 
FLC 
600 
37.11 ± 1.00 62.89 62.84 ±1.00 
< 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 









% Damage  p Value 
1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.39 ± 1.05 0.61 - - 
3: p + Fe2+ + H2O2 2 4.59 ± 2.49 95.41 - - 
3: p + Fe2+ + AA (0.00625 µM) + H2O2 0.005 98.58 ± 1.92 1.42 0.81 ± 1.92 0.541 
3: p + Fe2+ + AA (0.0625 µM) + H2O2 0.05 98.01 ± 3.44  1.99 1.38 ± 3.44 0.559 
3: p + Fe2+ + AA (0.625 µM) + H2O2 0.5 76.07 ± 4.20 23.93 23.33 ± 4.20 0.011 
3: p + Fe2+ + AA (0.9375 µM) + H2O2 0.75 58.97 ± 4.46 41.03 40.42 ± 4.46 0.004 
3: p + Fe2+ + AA (1.25 µM) + H2O2 1 19.71 ± 4.64 80.29 79.69 ± 4.64 0.001 
3: p + Fe2+ + AA (1.875 µM) + H2O2 1.5 12.92 ± 5.21 87.08 86.47 ± 5.21 0.001 
3: p + Fe2+ + AA (2.5 µM) + H2O2 2 2.34 ± 2.34 97.66 97.05 ± 2.34 < 0.001 
3: p + Fe2+ + AA (5 µM) + H2O2 5 0.03 ± 0.06 99.97 99.36 ± 0.06 < 0.001 
3: p + Fe2+ + AA (10 µM) + H2O2 10 0.33 ±0.57 99.67 99.07 ± 0.57 < 0.001 












% Damage  p Value 
1: plasmid DNA (p) 0 99.95 ± 0.08 0.08 - - 
2: p + H2O2 (50 µM) 0 98.55 ± 1.25 01.45 - - 
3: p + DFO + H2O2 50 98.87 ± 1.34 1.13 - - 
4: p + DFO 50 93.62 ± 2.65 6.38 - - 
5: p + Fe2+ (50 µM) + DFO 50 92.34 ± 2.23 7.66 - - 
6: p + Fe2+ (2 µM) + H2O2 0 12.43 ± 6.92 87.57 - - 
7: p + Fe2+ (0.1 µM) + H2O2 + DFO 0.1 97.54 ± 1.62 2.46 1.01 ± 1.62 0.393 
8: p + Fe2+ (1 µM) + H2O2 + DFO 1 93.23 ± 5.81 6.77 5.32 ± 5.81 0.254 
9: p + Fe2+ (2 µM) + H2O2 + DFO 2 61.33 ± 8.42 38.67 37.22 ± 8.42 0.166 
10: p + Fe2+ (5 µM) + H2O2 + DFO 5 62.31 ± 9.05 37.69 36.52 ± 9.05 0.199 
11: p + Fe2+ (7.5 µM) + H2O2 + DFO 7.5 38.41 ± 6.28 61.59 60.15 ± 6.28 0.004 
12: p + Fe2+ (10 µM) + H2O2 + DFO 10 31.94 ± 9.72 68.06 66.61 ± 9.72 0.007 
13: p + Fe2+ (25 µM) + H2O2 + DFO 25 16.65 ± 4.69 83.35 81.90 ± 4.69 0.001 
14: p + Fe2+ (50 µM) + H2O2 + DFO 50 1.40 ± 2.43 98.60 97.15 ± 2.43 < 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
 
Table 3.19. Statistical analysis of Fe2+ and Fe2+ FLC DNA damage through one-tailed t-test analysis. 
[Fe2+], µM % DNA Damage Fe2+ % DNA Damage Fe2+ + FLC p Value 
0.005 -1 ± 0 -1 ± 0 < 0.001 
0.05 -1 ± 0 8.8 ± 0.01 < 0.001 
0.25 -1 ± 0 38.54 ± 0.58 < 0.001 
0.5 -1 ± 0 37.35 ± 1.22 < 0.001 
1 45.51 ± 5.00 87.05 ± 5.69 0.006 
2 89.49 ± 1.03 95.97 ± 4.28 0.120 
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INVESTIGATION OF PROCYANIDIN-RICH CONDENSED TANNINS FOR 




 Condensed tannins occur in a variety of common fruits and vegetables1 and are 
noted for a variety of effects on human health,2–4 often attributed to their antioxidant 
activity.5–8 Cranberry (Vaccinium macrocarpon) consumption is associated with many 
health benefits,9 including prevention of urinary tract infections.10,11 V. macrocarpon 
extract has been reported to have anti-virulence,12 anti-bacterial,13 and anti-microbal8,14 
activities as well as antioxidant and anticancer activities in vitro and in vivo.11,15–18 
Cranberry extract consumption may also protect against diet-induced obesity,19,20 and 
cranberry juice exhibits cardioprotective effects due to its antioxidant abilities; however, 
the cause of these effects must be further investigated to exploit these applications.21 
 Many of the health benefits of cranberry consumption are attributed to polyphenol 
compounds in V. macrocarpon. These polyphenols protect liver cells from oxidative stress 
through observed modulation of glutathione concentration, prevention of reactive oxygen 
species generation and lipid peroxidation, antioxidant enzyme activity, and cell signaling 
pathways.22 Condensed tannins (CTs), also known as proanthocyanidins (PCs), are a group 
of plant secondary metabolite polyphenols that are comprised of oligomers and polymers 
of flavan-3-ol subunits.23–26 In V. macrocarpon, these tannins are comprised of a group of 




Figure 4.1. In box: Structures of catechol and gallol groups and their metal coordination modes. Outside 
box: an example condensed tannin structure showing A-type and B-type linkages, selected polyphenol 
structures, and the structure of 2,2-diphenyl-1-picrylhydrazyl (DPPH). 
 
constitutive unit with trace amounts of (+)-catechin and (epi)gallocatechin (EGCG).21,25,26 
Proanthrocyanin concentrations in cranberries are observed from 13.6 to 419 mg/100 g 
depending on fruit size, ripeness, variety and other factors, making it a potentially 
significant dietary source of proanthrocyanins.27,27  
Polyphenol concentrations of 80 μg/mL in human blood plasma after consumption 
of 1800 mL cranberry juice are reported,22,27,28 but the number of studies evaluating the 
bioavailability of proanthrocyanins is limited, since the interest in their health benefits is 
recent and purification of sufficient amounts for testing has been a significant challenge.8 
The distribution of the subunits catechin, EC, EGC, and EGCG (Figure 5.1) in CTs 
can vary depending on the source of the CTs. Additionally, these subunits can be connected 
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via a number of interflavan-3-ol linkages but the most commonly isolated CTs contain 
three types of bond connectivity. Two of these types have single bonds from either the C-
4 carbon to the C-8 carbon (4,8-B-type interflavan-3-ol linkage; Figure 5.1) or the C-4 
carbon to the C-6 carbon (4,6-B-type interflavan-3-ol linkage; Figure 5.1) of adjacent 
flavan-3-ol subunits. One additional common type of interflavan-3-ol linkage involves 
formation of two single bonds between adjacent flavan-3-ol subunits, involving both C-C 
and C-O bonds and is referred to as an A-type interflavan-3-ol linkage (Figure 4.1). 
Condensed tannins possess catechol or gallol substituents (Figure 4.1; inside box) 
on the B-ring of the constituent flavan-3-ol subunits. These phenolic moieties have been 
shown to prevent oxidative DNA damage caused by the Fenton reaction (Reaction 1).29,30 
Overproduction of hydroxyl radical can result in oxidative damage and other biomolecules 
and is an underlying cause of neurodegenerative diseases, cancer, and many other 
conditions.31 In vitro and in cells, polyphenols can prevent iron-mediated DNA damage 
from hydroxyl radical by coordinating Fe2+.29,30,32–34 Polyphenol binding to Fe2+ promotes 
autooxidation to non-hydroxyl-generating Fe3+ in the presence of O2.
30  
 Fe2+/Cu+  +  H2O2  → Fe3+/Cu2+  +  •OH  + OH-  (1) 
In this study, we investigated the antioxidant capabilities of a series of procyanidin-
rich CTs with different structural features for their ability to inhibit copper and iron-
mediated DNA damage, including purified CTs from V. macrocarpon (cranberry), 
Humulus lupulus (hops), Vitis vinifera (grapeseed) and Tilia inflorescentia (lime tree) 
flowers. The activity of these CTs was also compared to the activity of six commercially 
available polyphenolic compounds (Figure 4.1): epigallocatechin (EGC), 
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(-)-epigallocatechin-3-gallate (EGCG), gallic acid (GA), epicatechin (EC), epicatechin 
gallate (ECG), and tannic acid (TA). No study has investigated the effect of the different 
CT linkages and degree of galloylation and the resulting 3-dimensional structural changes, 
but Brumaghim et al.29,30,35,36 highlighted the importance of metal interaction for the 
antioxidant activity of proanthocyanidins.  This is the first study to investigate CTs with 
structural differences and their ability to prevent metal-mediated DNA damage. 
CTs from cranberry (V. macrocarpon), hops (H. lupulus), grapeseed (V. vinifera 
seed), and lime tree (T. inflorescentia flowers) were extracted and purified by Dr. Wayne 
Zeller, Research Chemist at the United States Department of Agriculture, U.S. Dairy 
Forage Research Center in Madison, Wisconsin.  This research was supported by National 
Science Foundation grants CHE 1213912 and 1807709. 
 
4.2 Results and Discussion 
Compositional Analysis of Purified Condensed Tannins. The aim of this project is to 
overcome the difficulty of purifying CTs with specific structural characteristics, therefore 
enabling the investigation in their ability to prevent metal-mediated DNA damage in vitro 
in comparison to their subunits. Zeller et al.37,38 have previously shown that volume 
integration ratios of appropriate cross-peak signals in 1H-13C HSQC NMR spectra provide 
a strong correlation with thiolysis data in determination of procyanidin/prodelphinidin 
(PC/PD) and cis/trans ratios, mean degree of polymerization (mDP), percent galloylation, 
and A-type interflavan linkages (Table 4.1). The mDP for the purified CTs were similar as 
were the PC/PD and cis/trans ratios. V. vinifera seed CTs were included in this study to  
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examine the effect of C-3 galloylation. A-type linkages were prevalent in the V. 
macrocarpon CTs but were also present, to a small degree (~3%), in the CTs purified from 
H. lupulus. 
CTs from cranberry (V. macrocarpon), hops (H. lupulus), grapeseed (V. vinifera 
seed), and lime tree (T. inflorescentia flowers) were chosen for their similar mean degree 
of polymerization and similar average molecular weights, on average 4.2-6.5 flavan-3-ol 
subunits on average (Table 4.1). The mean degree of polymerization can affect antioxidant 
activity as highlighted by Gaulejac et al.,39 who reported an up to 2-fold increase in 
antioxidant activity as measured by scavenging of superoxide anion radical by 
proanthocyanidins from grape extracts with mDP of 1 to 4.  
Jerez et al.40 also observed an increase in the ability to scavenge 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radicals (Figure 4.1) up to by proanthocyanidins with mDP of 6-7 
from barks. V. macrocarpon condensed CTs contain mostly A-type linkages (C2-C7 and 
O7-C2; Figure 4.1),21 whereas T. inflorescentia has primarily B-type linkages (C4-C8 or 
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C4-C6; Figure 4.1).41 In addition, H. lupulus CTs have a relatively high number of trans 
flavan-3-ol subunits containing a higher catechin concentration than epicatechin. V. 
vinifera seed CTs has a high percentage of galloylation at C3 subunits such as EGCG 
(Figure 4.1). 
Metal-mediated DNA Damage Prevention by CTs. Plasmid DNA gel 
electrophoresis assays were conducted to determine the ability of predominantly 
proanthocyanidin (PC) CTs from V. macrocarpon, H. luupulus, V. vinifera and T. 
inflorescentia, varying in distinct structural features, to prevent copper- or iron-mediated 
DNA damage. Both Fe2+ and Cu+ can produce DNA-damaging hydroxyl radical (Reaction 
1),29,42–44 and the polyphenol substituents in CTs are known to bind both iron and 
copper.29,34,45–47 This DNA assay evaluates the ability of antioxidants to prevent metal-
mediated DNA damage under biological relevant conditions. The naturally supercoiled 
(undamaged) and damaged (nicked) plasmid DNA can be separated using gel 
electrophoresis, therefore allowing a quantitative analysis of antioxidant activity. 
In the DNA assay gel images (Figure 4.2A and 4.2B), lane 3 shows that V. 
macrocarpon CTs do not cause DNA damage in the presence of H2O2, but Cu
+ and H2O2 
cause over 90% damage (Figure 4.2A, lane 4). The same amount of DNA damage occurs 
with Fe2+ and H2O2 (Figure 4.2B, lane 4). Increasing V. macrocarpon CT concentrations 
up to 5 or 200 mg/mL (Figures 4.2A and 4.2B, lanes 5-12) prevent this iron- or copper-




Figure 4.2. Agarose gel electrophoresis images of DNA treated with various concentrations of V. 
macrocarpon CTs with A) Cu2+ (6 µM) and ascorbate (7.5 µM) or B) Fe2+ (2 µM) and H2O2. Damaged 
(nicked) plasmid DNA (p) is the top band and undamaged (supercoiled) DNA is in the bottom band. Lanes 
are MW: 1 kb DNA ladder; 1: p; 2: p + H2O2 (50 µM); A) 3: p + H2O2 + V. macrocarpon CTs (200 mg/L); 
4: p + H2O2 + Cu2+ (6 µM) + ascorbate (7.5 µM); 5-14: p + H2O2 + Cu2+ (6 µM) + ascorbate + V. macrocarpon 
CTs (0.1, 1, 5, 15, 25, 50, 100, and 200 mg/L respectively). B) 3: p + H2O2 + V. macrocarpon CTs (5 mg/L); 
4: p + H2O2 + Fe2+ (2 µM); 5-13: p + H2O2 + Fe2+ (2 µM) + V. macrocarpon CTs (0.001, 0.01, 0.1, 0.5, 1, 
2.5, and 5 mg/L respectively).  
 
performed for CTs from V. vinifera seed, H. lupulus, and T. inflorescentia (data provided 
in Figures 4.4 and 4.5 and Tables 4.4 to 4.9). 
From analysis of the intensities of the gel bands, best-fit dose-response curves for 
copper- and iron-mediated DNA damage prevention were obtained for V. macrocarpon, V. 
vinifera seed, H. lupulus, and T. inflorescentia CTs (Figure 4.3). From these plots, the 
concentrations of each of the CTs required to inhibit 50% of DNA damage (IC50 values) 
were quantified (Table 4.2). V. macrocarpon CTs has IC50 values of 162.6 ± 0.3 and 0.75 
± 0.01 mg/L for copper- and iron- mediated DNA damage prevention, respectively. 
 Compared to V. macrocarpon CTs, V. vinifera seed and H. lupulus CTs exhibit 
much less inhibition of copper-mediated DNA damage, with 27 and 28% inhibition at 200 
mg/L, respectively (Table 4.2), insufficient DNA damage prevention to determine an IC50 




Figure 4.3. Dose-response curves for copper- and iron-mediated DNA damage prevention by A) V. 
macrocarpon CTs, B) V. vinifera seed CTs, C) H. lupulus CTs (the data point at 0.01 mg/L was excluded 
from the iron-mediated DNA damage fit due to its negative value), and D) T. inflorescentia CTs (the data 
points at 0.1 and 0.5 mg/L were excluded from the iron-mediated DNA damage due to their negative values). 
 
tested concentration of 50 mg/L. At concentrations greater than 50 mg/L, T. inflorescentia 
CTs alone and with copper interacted with the DNA so that the DNA no longer moved out 
of the wells of the agarose gel (Figure 4.4C). 
 Condensed tannins are polymers of the polyphenol subunits EGCG, EC, gallic 
acid (GA) and epigallogatechin (EGC; Figure 4.1). EGCG is a catechin formed from 
condensation of gallic acid with an epigallocatechin ester. It is the most abundant green 
tea flavan-3-ol and is found in many dietary supplements due to its potential beneficial 
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Table 4.2. IC50 values for metal-mediated DNA damage prevention by CTs of the indicated foods. 
Compound IC50 Cu+ [mg/L] IC50 Fe2+ [mg/L] IC50 Fe2+ [M] a) Ref. 
V. macrocarpon CTs IC50 162.5 ± 0.3 IC50 0.75 ± 0.01 0.40  
H. lupulus 27% Damage inhibition at 200 mg/L Prooxidant 0.001-1 mg/L 
Antioxidant 1-50 mg/L 
IC50 3.60 ± 0.01 
2.3  
V. vinifera seed CTs 28% Damage inhibition at 200 mg/L IC50 4.96 ± 0.01 3.4  
T. inflorescentia CTs No DNA damage inhibition 0.1-50 mg/L Prooxidant 0.001-1 mg/L 
Antioxidant 1-50 mg/L 
IC50 4.41 ± 0.01 
2.8  
Tannic acid (TA) IC50 9 ± 1 IC50 0.51 ± 0.01 0.30 [48] 
Epigallocatechin (EGC) Prooxidant 0.12–306 mg/L IC50 3.00 ± 0.31 9.8 [36] 
Gallic acid (GA) Prooxidant 0.68–1.70 mg/L 
Antioxidant 16 % at 85.06 mg/L 
IC50 2.38 ± 0.17 14 [36,35] 
Epicatechin (EC) Prooxidant 0.06–145 mg/L IC50 17.16 ± 0.29 59 [36,35] 
Epicatechin gallate (EGCG) Prooxidant 0.04–1.77 mg/L 
Antioxidant 4.42–442 mg/L 
IC50 23.5 ± 0.9 
IC50 1.02 ± 0.44 1.1 [36,35] 




effects on human health.49 EC is an antioxidant flavonoid, occurring especially in woody 
plants as both (+)-catechin and (-)-epicatechin. In human plasma, EGCG, and EC are found 
at concentrations of 5-150 ng/mL.50,51  
 Tannic acid (TA; Figure 4.1) is a commercially available tannin with multiple 
phenolic groups.52 It is used as an aroma compound in soft drinks and juices and as a 
clarifying agent, color stabilizer, and taste enhancer in the wine industry.49 TA 
concentrations in red wine have been shown to increase from 250.5 to 524.4 mg/mL upon 
aging, correlating with increased DPPH radical scavenging activity.53 TA is a 
representative of the hydrolysable tannins group of polyphenols, consisting of sets of gallic 
acid esters protruding from a glucose core molecule, and inhibits growth of many fungi, 
yeast, bacteria, and viruses.30,52 TA is also an antioxidant, and its antioxidant behavior may 
be linked to its anti-carcinogenic and anti-mutagenic properties.30,52,54  
Under copper-mediated DNA damage conditions, GA, EGC, and EC show 
prooxidant activity. ECG prevention of copper-mediated DNA damage shows prooxidant 
activity at low concentrations but shows antioxidant activity at concentrations greater than 
4.42 mg/L with an IC50 of 23.5 mg/L. Interestingly, the CTs of V. vinifera seed and T. 
inflorescentia show no prooxidant activity in the tested concentration range with copper 
even though its constituent monomers do. 
Under iron-mediated DNA damage conditions, V. vinifera seed CTs showed only 
antioxidant activity at all concentrations examined. Its IC50 value is higher than the IC50 of 
its monomers EGC, GA, and EGCG but lower than EC. The IC50 value for T. inflorescentia 
CT prevention of iron-mediated DNA damage is 4.41 mg/L. Similar to H. lupulus CTs, T. 
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inflorescentia CTs exhibit prooxidant activity with iron at low concentrations (0.1 and 1 
mg/L). Such concentration-dependent prooxidant/antioxidant activity has not been 
previously observed for polyphenol inhibition of iron-mediated DNA damage, except 
when chelated iron is used as the iron source.35,36 
V. vinifera seed, H. lupulus, and T. inflorescentia prevented iron-mediated DNA 
damage with IC50 values of 4.96, 3.60, and 4.41 mg/L, respectively. Although these IC50 
values are substantially lower than their corresponding IC50 values for prevention of 
copper-mediated damage (Table 4.2), they are 5-6 fold higher than that of V. macrocarpon 
CTs. The IC50 values for DNA damage inhibition by H. lupulus CTs falls between those of 
its constituent monomers: 3-fold higher than EGCG, but 5-fold lower than EC. Under these 
conditions, we observed slight prooxidant activity at 0.1 mg/L concentration (p = 0.017), 
similar to the prooxidant results observed for EC and ECGC. 
V. macrocarpon and T. inflorescentia CTs have different interflavan linkages 
(Table 4.1); V. macrocarpon CTs have a more rigid structure due to the two interflavan A-
type linkages55 compared to T. inflorescentia’s B-type linkages. The significantly lower 
IC50 values for V. macrocarpon may suggest that CTs with A-type linkages are more 
effective antioxidants than those with more B-type linkages, although more extensive 
testing of a variety of CT samples are needed to fully explore this relationship. It is likely 
that these different linkage patterns affect CT structure and metal coordination, leading to 
observed antioxidant behaviors. 
Mackenzie et al.56 showed through Monte Carlo simulation that in a dimer of EC 
subunits connected by B-linkages, subunits are stacked through formation of internal 
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hydrogen bonds. Based on this work, Verstraeten et al.57 argued that a dimer with EC or 
catechin monomers connected by A-type linkages should not be able to fold over 
themselves due to the two covalent bonds and may not be able stack, and should therefore 
exhibit a more elongated structure than condensed polyphenols with B-type linkages. This 
could result in A-type linkages having a greater number of accessible metal coordination 
sites. The presence of these accessible binding sites, may, in turn, result in greater 
antioxidant efficacy, since polyphenol-iron binding typically results in antioxidant rather 
than prooxidant effects.29,58,59 Thus, the greater percentage of A-type linkages found in V. 
macrocarpon CTs may correlate with greater efficacy in preventing both iron- and copper-
mediated DNA damage, although additional studies are needed to elucidate the structures 
of condensed polyphenols as well as their metal binding properties to confirm this result.  
Dong et al.41 tested A- and B-type dimers of either EC, EGC, or EGCG for their 
ability to scavenge DPPH (Figure 5.1) and observed the opposite trend as discussed in this 
Chapter of A-type linkages being better antioxidants than B-type linkages. DPPH is a long-
lived, sterically-hindered, nitrogen-based radical with significantly different properties60,61 
compared to the short-lived, more reactive hydroxyl and superoxide radicals.62 In addition, 
the steric bulk of the phenyl rings in DPPH may hinder reactivity at the radical site but still 
allow H-atom donors to donate their H-atom to form DPPH−H.61 Additionally, Gaulejac 
et al.39 reported that B-type linked dimers of either two (+)-catechin or one (+)-catechin 
and one (-)-epicatechin are more effective at scavenging superoxide radical anion, a 
variance from the results presented here could be due to the different origin and reactivity 
these radical species. Although superoxide radical can react with iron, resulting in hydroxyl 
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radical formation,63 metal coordination could play a more significant role in the antioxidant 
activity in our assay since the CTs could affect the redox potential of the metals as seen by 
some CTs having prooxidant activity at low concentrations (Table 5.1). It is likely that 
chemical differences between the radicals, such as size, stability, and charge, also alter the 
antioxidant abilities of CTs in addition to the type of linkages present between the 
polyphenol subunits.  
V. macrocarpon CTs have a higher EC fraction than H. lupulus CTs (Table 4.1); H. 
lupulus CTs have more catechin subunits. Catechin and EC are isomers since that they 
differ in the stereochemical position of the phenolic OH group on the C-ring (Figure 4.1), 
resulting in EC and catechin having R- and S-confirmations at this site, respectively. From 
the DNA damage studies, CTs with a higher epicatechin content are 2- and 7-fold more 
effective in preventing copper- and iron-mediated DNA damage compared to catechin CTs, 
respectively (Table 4.2). This difference in activity between EC and catechin was also 
observed by Gaulejac et al.39 who reported that EC as monomer was almost 2-fold more 
effective at scavenging the superoxide anion radical, and Vivas et al.64 who reported that 
epicatechin monomers are more quickly oxidized during potentiometric titrations.39,64 
V. macrocarpon CTs are 7-fold more effective at preventing iron- and 2-fold more 
effective for copper-mediated DNA damage than CTs from V. Vinifera seed. This 
difference may result from V. vinifera seed CTs having a higher percentage of galloylation 
compared to V. macrocarpon CTs. Gaulejac et al.39 report that galloyl groups in CTs have 
increased intramolecular π-π or σ-π interactions compared to CTs without galloylation, 
potentially increasing CT astringency and constraining proanthrocyanidin conformations 
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within these compounds. These intramolecular interactions result in a very compact 
molecule, with some of the molecule being protected from external influences,39 potentially 
shielding the inner functional groups from metal interactions. 
Interestingly, all monomer polyphenols in Table 4.2 show prooxidant activity at 
low concentrations only for copper-mediated DNA damage but not for iron-mediated DNA 
damage; however, the condensed CTs exhibit the opposite trend. Prooxidant activity is 
observed for CTs with more B-type linkages or higher catechin content. Polyphenol 
prooxidant activity can arise from polyphenol compounds that can be readily oxidized after 
coordinating Cu2+ or Fe3+, and reducing these ions to hydroxyl-radical-generating Cu+ or 
Fe2+.29,59  
Although metal coordination ability has not been well studied with regard to 
differences in CT structures, a study of grapeseed proanthocyanins showed that they 
strongly sequester metals with stoichometric ratios of 2:1 and 4:1 for Fe2+- and Cu2+-
proanthocyanin complexes, respectively.65 Yoneda et al.66 tested the relative stability of an 
aluminum-proanthocyanin complex, concluding that the catechol functionality of the B-
ring is important for metal coordination. They also determined that at CT concentrations 
above 400 μM, increasing degree of polymerization generally increases the relative 
stability of the aluminum complex, but at lower concentrations, no significant difference 
in complex stability is observed. Powell et al.51 and Yoneda et al. 52 describe the importance 
of the three-dimensional structure of CTs for metal binding, due to the potential new 
coordination sites that can arise from spatially adjacent functional groups, but little work 
has investigated the impact of various conformations on the number, availability, and 
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location of metal coordination sites. These scattered results highlight the need to 
independently understand the effects of different CT linkages, galloylation percentages, 
monomer compositions, and polymer lengths on metal coordination to better predict 
antioxidant activity of CTs from various sources. 
 
5.3 Conclusions 
V. macrocarpon CTs are the most effective at inhibiting both copper- and iron-
mediated DNA damage compared to H. lupulus, V. vinifera seed, and T. inflorescentia CTs. 
Although H. lupulus, V. vinifera seed, and T. inflorescentia CTs prevent little-to-no copper-
mediated DNA damage, they prevent significantly more iron-mediated DNA damage at 
low micromolar concentrations. Only H. lupulus and T. inflorescentia CTs promote iron-
mediated DNA damage at very low (0.1 and 1 mg/L) concentrations in addition to 
antioxidant activity at higher concentrations, the first report of this dual activity with iron.  
This is the first study to investigate the ability of CTs with several different 
structural characteristics for prevention metal-mediated DNA damage. CTs with A-type 
linkages, such as in V. macrocarpon may more effectively inhibit copper- and iron-
mediated DNA damage than CTs with B-type linkages. In addition, higher percentages of 
catechin compared to epicatechin subunits and higher percentages of galloylation may also 
reduce CT antioxidant activity. Although these results require further study to establish 
trends among a variety of CTs, these results demonstrate the significant effects of CT 




4.4 Experimental Methods 
Materials. Water was deionized (diH2O) using a Nano Pure DIamond Ultrapure 
H2O system (Barnstead International). CuSO4 and H2O2 were purchased from Fisher. 3-
(N-morpholino)propanesulfonic acid (MOPS), was purchased from Sigma Aldrich, 2-(N-
morpholino)ethanesulfonic acid (MES) was purchased from BDH, FeSO4 was purchased 
from Acros and ascorbic acid and NaCl were purchased from Alfa Aesar. The condensed 
CTs were provided by Dr. Wayne Zeller at the USDA (Madison, WI). 
Isolation and Purification of Condensed Tannins. Condensed tannins were purified 
from H. lupulus (hops), V. vinifera (grapeseed) and T. inflorescentia flowers using methods 
previously described.33 V. macrocarpon (cranberry) CTs were obtained through 
purification of commercially available fresh frozen cranberries obtained from a local 
grocer. Thawed cranberries were placed in a blender, diluted and homogenized. The 
homogenate was vacuum filtered with a Buchner funnel equipped with a filter paper. The 
resulting press cake was lyophilized and ground in a cyclone mill (UDY Corporation, For 
Collins, CO) to ≤ 1 mm. Portions of the ground cranberry press cake were extracted with 
acetone/water (7:3, 5 ml/g of cake), and the combined extracts were concentrated under 
reduced pressure and lyophilized. The lyophilized cranberry CT extract was subjected to 
the batch method of purification using Sephadex LH-20 as previously described using the 
methanol/water (1:1) washes followed by consecutive elution of the CT-laden Sephadex 
LH-20 gel with acetone/water mixtures of (3:7), (1:1) and (7:3) v/v.  Fractions eluting with 
7:3 acetone/water portion were combined and lyophilized. Lyophilized powders were 
examined by 1H-13C HSQC NMR spectroscopy. The fractions containing high CT content 
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were pooled and the lipid impurities present in these fractions were removed by 
centrifugation of their aqueous suspensions. dissolved in water (at 4 mg/mL), 
centrifugation at 10,000 X g for 20 min. The supernatant was decanted and lyophilized to 
provide the target V. macrocarpon CT preparation. Structural composition (PC/PD and 
cis/trans ratios, determination of mean degrees of polymerization, mDP) of CTs isolated 
were determined through a combination of thiolytic degradation and analysis of their 
respective 1H-13C HSQC NMR spectra.37,38 The percent A-type linkage present in the 
cranberry CT was estimated through relative integration of the H/C-4 cross-peak arising 
from A-type linked subunit to sum of the normal internal and terminal B-type linked 
subunits cross-peaks. 
NMR Analysis. 1H, 13C and 1H-13C HSQC NMR spectra were recorded at 27 °C on 
a BrukerBiospin DMX-500 (1H 500.13 MHz, 13C 125.76 MHz) instrument equipped with 
TopSpin 3.5 software and a cryogenically cooled 5-mm TXI 1H/13C/15N gradient probe 
in inverse geometry. Spectra were recorded in DMSO-d6 and were referenced to the 
residual signals of DMSO-d6 (2.49 ppm for 1H and 39.5 ppm for 13C spectra). 13C NMR 
spectra were obtained using 1K scans (acquisition time 56 min). For 1H−13C HSQC 
experiments, spectra were obtained using between 200 and 620 scans (depending on 
sample size and instrument availability) obtained using the standard Bruker pulse program 
(hsqcetgpsisp.2) with the following parameters: Acquisition: TD 1024 (F2), 256 (F1); 
SW 16.0 ppm (F2), 165 ppm (F1); O1 2350.61 Hz; O2 9431.83 Hz; D1 = 1.50 s; CNST2 
= 145. Acquisition time: F2 channel, 64 ms, F1 channel 6.17 ms. Processing: SI =1024 
(F2, F1), WDW = QSINE, LB = 1.00 Hz (F2), 0.30 Hz (F1); PH_mod = pk; baseline 
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correction ABSG =5 (F2, F1), BCFW = 1.00 ppm, BC mod = quad (F2), no (F1); linear 
prediction = no (F2), LPfr (F1). Sample sizes used for these spectra ranged from 5-10 mg 
providing NMR sample solutions with concentrations of 10-20 mg/mL. 
Plasmid Transfection, Amplification, and Purification: 2.5-3 μL (1 pmol) of 
plasmid DNA (pBSSK) was purified from DH1 E. coli competent cells using ZyppyTM 
Plasmid Miniprep Kit (400 count, Zymo Research). Tris-EDTA buffer (pH 8.01) was used 
to elude the plasmid from the spin columns. Plasmid was dialyzed against 130 mM NaCl 
for 24 hours at 4°C to ensure all Tris-EDTA buffer and metal contaminates were removed. 
Plasmid concentration was determined by UV-vis spectroscopy at a wavelength of 260 nm. 
Organic and protein contents were also determined using UV-vis spectroscopy from ratios 
of A250/A260 ≤ 0.95 and A260/A280≥ 1.8 respectively. Plasmid purity was determined through 
digestion of plasmid with Sac 1 and KpN1 in a mixture of NEB buffer and BSA (bovine 
serum albumin) was conducted at 37°C for 90 min. Comparison to an undigested plasmid 
sample and a 1 kb molecular-weight marker was conducted by gel electrophoresis. 
Plasmid DNA damage inhibition assays. Gel electrophoresis samples were prepared 
in deionized H2O, MOPS buffer (10 mM, pH 7) for copper or MES buffer (10 mM, pH 6) 
for iron, NaCl (130 mM), 100% ethanol (10 mM), ascorbate (7.25 µM) and CuSO4 (6 µM) 
or FeSO4 (2 µM) and indicated concentrations of the CTs were combined in a 
microcentrifuge tube and allowed to stand for 5 min at room temperature. Since Cu+ is 
unstable in aqueous solution, ascorbic acid was added to reduce Cu2+ to Cu+ before the 
addition of H2O2 in these studies. Plasmid (pBSSK; 0.1 pmol in 130 mmol NaCl solution) 
was then added to the reaction mixture and allowed to stand for 5 min at room temperature. 
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Hydrogen peroxide (50 μM) was added to the indicated lanes and allowed to react at room 
temperature for 30 min, then EDTA (50 μM) was added to quench the reaction and loading 
dye (2 μL) was added. All given concentrations are final concentrations in a 12 μL volume. 
Samples were loaded into a 1% agarose gel in TAE running buffer; and damaged and 
undamaged plasmid DNA was separated by electrophoresis (140 V for 30 min). Gels were 
then stained using ethidium bromide and washed with diH2O before being imaged under 
UV light. The amounts of nicked (damaged) and circular (undamaged) DNA were 
quantified using UViProMW (Jencons Scientific Inc.). The intensity of the circular plasmid 
band was multiplied by 1.24, due to the different binding abilities of ethidium bromide to 
supercoiled and nicked plasmid DNA.67,68 Intensities of the nicked and supercoiled bands 
were normalized for each lane so that % nicked + % supercoiled = 100%. All percentages 
were corrected for residual nicked DNA prior to calculation. Results were obtained in 
triplicate for all experiments, and standard deviations are represented as error bars. 
Calculation of percent DNA damage inhibition. The formula 1-[%N-%B]*100 was 
used to calculate percent DNA damage inhibition; %N = percent of nicked DNA in lanes 
4, and %B = the percent of nicked DNA in the Cu2+/H2O2 or Fe
2+/H2O2 control lanes. 
Percentages were corrected for residual nicked DNA (lane 2) prior to calculations. Results 
were obtained from an average of three trials, with indicated standard deviations. 
IC50 Determination. Plots of percent inhibition of DNA damage versus log 
concentration of CTs were fit to a variable slope sigmoidal dose-response curve using 
SigmaPlot, version 11 (Systat Software, Inc.). DNA damage inhibition were omitted 
(concentrations 0.1 mg/L for H. lupulus CTs and 0.5 and 1 mg/L for T. inflorescentia CTs). 
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IC50 value errors were calculated from error propagation of the gel electrophoresis 
measurements. Statistical significance was determined by calculating p values at 95% 
confidence (p < 0.05 indicates significance) as described by Perkowski et al.69 Data from 
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Figure 4.4. Agarose gel electrophoresis images of copper-mediated DNA damage prevention with Vitis 
vinifera seed, Humulus lupulus, or Tilia inflorescentia condensed tannins. Lanes are: MW: 1 kb molecular 
weight marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 (50 µM); A) lane 3: p + 200 mg/L V. vinifera 
seed + H2O2, lane 4: p + Cu2+ (6 µM) + ascorbate (7.5 µM) + H2O2; lanes 5-13: p + Cu2+ + ascorbate + 
H2O2 + 0.1, 1, 5, 10, 15, 25, 50, 100, and 200 mg/L V. vinifera seed, respectively; B) lane 3: p + 200 mg/L 
H. lupulus + H2O2, lane 4: p + Cu2+ (6 µM) + ascorbate (7.5 µM) + H2O2; lanes 5-13: p + Cu2+ + ascorbate 
+ H2O2 + 0.1, 1, 5, 10, 15, 25, 50, 100, and 200 mg/L H. lupulus, respectively; C) lane 3: p + 200 mg/L T. 
inflorescentia + H2O2, lane 4: p + Cu2+ (6 µM) + ascorbate (7.5 µM) + H2O2; lanes 5-13: p + Cu2+ + 




Figure 4.5. Agarose gel electrophoresis images of iron-mediated DNA damage prevention with Vitis vinifera 
seed, Humulus lupulus, or Tilia inflorescentia condensed tannins. Lanes are: MW: 1kb molecular weight 
marker; lane 1: plasmid DNA (p); lane 2: p + H2O2 (50 µM); A) lane 3: p + 200 mg/L V. vinifera seed + 
H2O2, lane 4: p + Fe2+ (2 µM) + H2O2; lane 5-14: p + Fe2+ + H2O2 + 0.001, 0.01, 0.1, 0.5, 1, 2.5, 5, 10, 25, 
and 50 mg/L V. vinifera seed, respectively); B) lane 3: p + 200 mg/L H. lupulus + H2O2, lane 4: p + Fe2+ (2 
µM) + H2O2; lane 5-14: p + Fe2+ + H2O2 + 0.001, 0.01, 0.1, 0.5, 1, 2.5, 5, 10, 25, and 50 mg/L H. lupulus, 
respectively; C) lane 3: p + 200 mg/L T. inflorescentia + H2O2, lane 4: p + Fe2+ (2 µM) + H2O2; lane 5-14: p 




Table 4.3. Gel electrophoresis results for Cu+ DNA damage prevention assays with Vaccinium. 











1: plasmid DNA (p) 0 100 ± 0 0 – – 
2: p + H2O2 (50 µM) 0 99.96 ± 0.07 0.04 – – 
3: p + V. macrocarpon + H2O2 0.1 99.99 ± 0.01 0.01 – – 
4: p + Cu2+ (6 µM) + 
ascorbate (7.5 µM) + H2O2 0 5.13 ± 0.59 94.87 0 – 
5: p + Cu2+ + ascorbate + 
H2O2 + V. macrocarpon 0.1 1.63 ± 0.15 98.37 -3.64 ± 0.15 < 0.001 
6: 1 0.13 ± 0.12 99.87 -5.26 ± 0.10 < 0.001 
7: 5 0.79 ± 0.24 99.21 -4.52 ± 0.26 0.001 
8: 15 6.31 ± 1.12 93.69 1.31 ± 1.12 0.180 
9: 25 13.71 ± 5.51 86.29 9.08 ± 5.48 0.103 
10: 50 20.99 ± 1.62 79.01 16.77 ± 1.59 0.003 
11: 100 32.31 ± 5.30 67.69 28.68 ± 5.31 0.011 
12: 200 60.73 ± 3.92 39.27 58.72 ± 3.82 0.001 
aData are reported as the average of three trials with calculated standard deviations shown. 
 
Table 4.4. Gel electrophoresis results for Fe2+ DNA damage prevention assays with Vaccinium 











1: plasmid DNA (p) 0 100 ± 0  0 – – 
2: p + H2O2 (50 µM) 0 100 ± 0  0 – – 
3: p + V. macrocarpon + H2O2 0.001 99.96 ± 0.07 0.04 – – 
4: p + Fe2+ (2 µM) + H2O2 0 5.69 ± 3.81 94.31 0 – 
5: p + Fe2+ + H2O2 + V. 
macrocarpon 0.001 8.27 ± 1.54 91.73 2.73 ± 1.56 0.938 
6: 0.01 1.95 ± 1.16 98.05 -3.95 ± 1.17 0.280 
7: 0.1 7.01 ± 2.01 92.99 1.42 ± 2.02 0.348 
8: 0.5 9.25 ± 1.31 90.75 3.76 ± 1.30 0.376 
9: 0.7 38.20 ± 0.70 61.80 34.47 ± 0.50 < 0.001 
10: 1 92.02 ±3.88 7.98 91.55 ± 3.90 < 0.001 
11: 2.5 97.90 ± 1.99 2.10 97.77 ± 1.99 < 0.001 
12: 5 99.99 ± 0.01 0.01 100 ± 0 < 0.001 


















1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.94 ± 0.05 0.06 - - 
3: p + V. vinifera seed + H2O2 200 100.00 ± 0 0.00 - - 
4: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 
0 5.26 ± 3.94 94.74 - - 
5: p + Cu2+ + ascorbate + H2O2 
+ V. Vinifera seed 
0.1 1.95 ± 2.21 98.05 -3.45 ± 2.23 0.116 
6: 1 1.18 ± 1.86 98.82 -4.26 ± 1.85 0.057 
7: 5 1.04 ± 1.81 98.96 -4.40 ± 1.79 0.051 
8: 10 0.27 ± 0.33 99.73 -5.21 ± 0.31 0.001 
9: 15 1.74 ± 2.95 98.26 -3.63 ± 2.97 0.168 
10: 25 1.75 ± 2.90 98.25 -3.63 ± 2.89 0.162 
11: 50 9.06 ± 5.95 90.94 4.08 ± 5.99 0.359 
12: 100 8.75 ± 1.48 91.25 3.73 1.53 0.052 
13: 200 32.00 ± 4.51 68.00 28.28 ± 4.55 0.009 
aData are reported as the average of three trials with calculated standard deviations shown. 
 













1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.99 ± 0.02 0.01 - - 
3: p + V. vinifera seed + H2O2 50 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 0 8.58 ± 4.81 91.42 - - 
5: p + Fe2+ + H2O2 + V. vinifera 
seed 
0.001 
5.91 ± 2.96 94.09 -2.87 ± 2.94 
0.233 
6: 0.01 10.00 ± 1.30 90.00 1.58 ± 1.30 0.170 
7: 0.1 6.75 ± 2.71 93.25 -2.00 ± 2.75 0.335 
8: 0.5 6.07 ± 5.18 93.93 -2.73 ± 5.18 0.458 
9: 1 1.39 ± 1.54 98.61 -7.87 ± 1.53 0.124 
10: 2.5 0.80 ± 0.45 99.20 -8.49 ± 0.44 >0.001 
11: 5 54.73 ± 3.63 45.27 50.47 ± 3.64 0.002 
12: 10 94.37 ± 2.49 5.63 93.86 ± 2.48 >0.001 
13: 25 100.00 ± 0 0.00 100.02 ± 0 >0.001 
14: 50 99.95 ± 0.09 0.05 99.95 ± 0.12 >0.001 

















1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 98.71 ± 2.23 1.29 - - 
3: p + H. lupulus + H2O2 200 100.00 ± 0 0.00 - - 
4: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 
0 
3.20 ± 3.22 96.80 
- - 
5: p + Cu2+ + ascorbate + H2O2 
+ H. lupulus 
0.1 
3.75 ± 2.33 96.25 -1.52 ± 2.33 
0.376 
6: 1 0.13 ± 0.17 99.87 -5.35 ± 0.15 >0.001 
7: 5 0.07 ± 0.12 99.93 -5.42 ± 0.12 >0.001 
8: 10 0.72 ± 1.25 99.28 -4.72 ± 1.27 0.023 
9: 15 0.36 ± 0.52 99.64 -5.10 ± 0.55 0.004 
10: 25 0.74 ± 1.15 99.26 -4.68 ± 1.16 0.020 
11: 50 3.43 ± 3.06 96.57 -1.87 ± 3.03 0.397 
12: 100 14.68 ± 6.11 85.32 10.02 ± 6.09 0.104 
13: 200 31.45 ± 5.26 68.55 27.69 ± 5.27 0.012 
aData are reported as the average of three trials with calculated standard deviations shown. 
 













1: plasmid DNA (p) 0 99.83 ± 0.29 0.17 - - 
2: p + H2O2 (50 µM) 0 99.95 ± 0.09 0.05 - - 
3: p + H. lupulus + H2O2 50 99.99 ± 0.02 0.01 - - 
4: p + Fe2+ (2 µM) + H2O2 0 25.20 ± 3.99 74.80 - - 
5: p + Fe2+ + H2O2 + H. lupulus 0.001 30.88 ± 4.53 69.12 7.74 ± 4.52 0.097 
6: 0.01 28.49 ± 2.41 71.51 4.53 ± 2.39 0.082 
7: 0.1 14.53 ± 3.29 85.47 -14.18 ± 3.27 0.017 
8: 0.5 20.49 ± 3.20 79.51 -6.16 ± 3.21 0.939 
9: 1 19.24 ± 2.04 80.76 -7.86 ± 2.06 0.022 
10: 2.5 50.65 ± 1.13 49.35 34.17 ± 1.11 >0.001 
11: 5 75.09 ± 1.37 24.91 66.79 ± 1.34 >0.001 
12: 10 91.71 ± 3.33 8.29 89.02 ± 3.38 >0.001 
13: 25 97.94 ± 3.43 2.06 97.40 ± 3.44 >0.001 
14: 50 99.89 ± 0.19 0.11 99.99 ± 0.17 >0.001 


















1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 100.00 ± 0 0.00 - - 
3: p + T. inflorescentia + H2O2 200 99.99 ± 0.02 0.01 - - 
4: p + Cu2+ (6 µM) + ascorbate 
(7.5 µM) + H2O2 
0 3.68 ± 2.47 96.32 - - 
5: p + Cu2+ + ascorbate + H2O2 
+ T. inflorescentia 
0.1 3.62 ± 0.10 96.38 -1.66 ± 0.06 >0.001 
6: 1 2.34 ± 1.72 97.66 -3.03 ± 1.71 0.092 
7: 5 0.50 ± 0.09 99.50 -4.96 ± 0.10 >0.001 
8: 10 0.46 ± 0.44 99.54 -5.00 ± 0.45 0.003 
9: 15 0.25 ± 0.19 99.75 -5.25 ± 0.21 >0.001 
10: 25 1.01 ± 1.07 98.99 -4.40 ± 1.07 0.019 
11: 50 11.16 ± 5.66 88.84 6.26 ± 5.66 0.195 
aData are reported as the average of three trials with calculated standard deviations shown. 
 














1: plasmid DNA (p) 0 100.00 ± 0 0.00 - - 
2: p + H2O2 (50 µM) 0 99.96 ± 0.06 0.04 - - 
3: p + T. inflorescentia + H2O2 50 100.00 ± 0 0.00 - - 
4: p + Fe2+ (2 µM) + H2O2 0 26.22 ± 1.84 73.78 - - 
5: p + Fe2+ + H2O2 + T. 
inflorescentia 
0.001 23.40 ± 1.21 76.60 -3.77 ± 1.22 0.033 
6: 0.01 22.47 ± 1.26 77.53 -5.03 ± 1.31 0.022 
7: 0.1 21.30 ± 4.38 78.70 -6.61 ± 4.36 0.120 
8: 0.5 14.56 ± 0.95 85.44 -15.74 ±0.95 0.001 
9: 1 14.12 ± 1.31 85.88 -16.33 ± 1.32 0.002 
10: 2.5 45.10 ± 1.99 54.90 25.64 ± 1.95 0.002 
11: 5 63.36 ± 3.28 36.64 50.40 ± 3.31 0.001 
12: 10 93.85 ± 4.53 6.15 92.15 ±4.95 >0.001 
13: 25 96.52 ± 4.83 3.48 95.36 ± 4.84 >0.001 
14: 50 100 ± 0 0 100.05 ± 0 >0.001 
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